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Abstract 
Flowmotion, the rhythmic oscillation of blood flow across a tissue, optimises nutrient delivery at rest 
and during states of increased metabolic demand. Five known factors influence flowmotion patterns 
across a tissue, each distinguishable by their rate of input; cardiac, respiratory, myogenic, neurogenic 
and endothelial components. In disease states such as type 2 diabetes (T2D), flowmotion is thought 
to be altered and may contribute to dysregulated metabolism. The aim of this thesis was to 
characterise flowmotion in healthy controls and T2D participants.  
Flowmotion was investigated in healthy controls and T2D participants at rest, and following 
endogenous insulin release in response to a 50g oral glucose challenge (OGC). The effect of a 
resistance training (RT) intervention in T2D participants was also assessed. Total blood flow to the 
forearm was measured using 2D-ultrasound and skeletal muscle perfusion was measured with 
contrast enhanced ultrasound (CEU). Microvascular blood flow in the skin and subcutaneous tissue 
(skin+SC) of the forearm was examined using a combined Laser Doppler Flowmetry (LDF) and tissue 
oxygenation probe. Spectral analysis (wavelet transformation) was performed on the data to 
characterise the individual contributions of the five factors known to influence flowmotion.  
Type 2 diabetics exhibited differences in total blood flow, skin+SC LDF flux and skin+SC flowmotion 
compared to healthy controls at rest. Flowmotion was altered in response to the OGC in healthy 
controls, without changes in total flow and skin+SC LDF flux. In contrast, flowmotion and skin+SC LDF 
flux were unaltered in response to OGC in T2D, while total blood flow to the forearm increased. In the 
T2D group, a 6-week RT intervention partially restored skin+SC flowmotion. 
In response to OGC skeletal muscle microvascular perfusion was reduced in healthy controls, but not 
in T2D participants. In contrast, skin+SC microvascular perfusion did not change in response to OGC in 
either group, indicating skin+SC flowmotion may not represent flowmotion in skeletal muscle. 
The CEU technique, used to determine skeletal muscle microvascular perfusion, was adapted to 
investigate flowmotion within skeletal muscle. In anaesthetised rats, skeletal muscle flowmotion 
patterns were measured with both the LDF and the newly adapted CEU techniques. An α-
adrenoceptor antagonist, which inhibits the neurogenic component of flowmotion, was used to 
compare the two techniques. Both the LDF and CEU methods detected the inhibition. In addition, the 
CEU method enable identification of different flowmotion patterns within specific fibre types. 
In conclusion, these studies demonstrate dysfunction in blood flow and flowmotion in T2D. They also 
highlight a difference in skin+SC and skeletal muscle microvascular blood flow in response to OGC. The 
newly adapted CEU technique will allow more informative assessment of flowmotion in skeletal 
muscle, facilitating future research into its role in regulation of muscle metabolism.  
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Chapter 1 - Introduction 
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Vascular delivery of nutrients and hormones is normally tightly coupled to the metabolic demands of 
the supplied cells, and has been investigated in tissues including the brain, heart, skin and skeletal 
muscle (1). In mammals, skeletal muscle makes up a high proportion of body mass (30-40% of body 
(2)) and has the potential to be highly metabolically active, which has major implications for the 
cardiovascular system. It is therefore critical that blood flow changes with skeletal muscle metabolic 
demand to efficiently couple nutrient delivery and waste removal with the function of the tissue (3). 
Blood flow is minimised when metabolic demand is low, in order to prevent excess circulatory demand 
(cardiac output), but must have the capacity to support the significant rise in oxygen consumption and 
nutrient utilisation for fuel production in the myocytes during exercise when the work load and 
thereby metabolism is greatly enhanced (4). Additionally, there are other stimuli which cause skeletal 
muscle metabolism and blood flow requirements to change, for example, when muscle is storing 
nutrients derived from diet (i.e. glucose) (5, 6). Meeting increased metabolism with sufficient blood 
flow to the working tissue occurs through both systemic and local mechanisms. 
 
The capillary recruitment theory indicates that at rest when nutrient demand is low, blood flow can 
be reduced by intermittently perfusing fewer of the available capillaries; however, to keep nutrient 
delivery adequate to all myocytes the sets of perfused capillaries must be continually varied. This is in 
part achieved through vasomotion, a function of the vasculature that involves the rhythmical 
oscillation of blood vessel diameter to allow or restrict blood flow through individual vessels (7, 8). 
The physiological consequence of vasomotion is flowmotion, which is the rhythmical oscillation and 
variation of flow through tissue (7, 9). Vasomotion and flowmotion have been observed in skeletal 
muscle during rest, and has been seen to change in response to insulin (10, 11). Vasomotion has also 
been seen in other tissues in the body such as the skin and subcutaneous tissue (skin+SC) (12). It is 
suspected that these processes are critical for the efficient matching of nutrient and oxygen delivery 
to demand. Demonstration of how vasomotion and flowmotion affect metabolism, and how they are 
in turn affected by alterations in metabolism or pathological processes has been difficult.  
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Flowmotion can be assessed by techniques that are commonly used to measure blood flow through 
regions of tissues whereby blood flow data are collected constantly over time, (e.g. Laser Doppler 
Flowmetry [LDF]). These techniques can be used to assess changes in skin+SC or skeletal muscle 
flowmotion in response to the infusion of insulin or other vasoactive molecules, and in disease states 
such as insulin resistance and type 2 diabetes (T2D). The purpose of the studies in this thesis was to 
develop methods for the assessment of flowmotion; to investigate normal patterns of blood flow in 
both human participants (skin+SC) and animal models (skeletal muscle), and to assess the changes 
that occur in T2D.  
 
1.1 Vascular structure 
 
The body’s vasculature is composed of three types of vessels; arteries, capillaries and veins. The 
arterial system consists of larger conducting arteries that move oxygenated blood from the heart to 
the tissues; these are comprised of an endothelial layer, layers of smooth muscle, and many elastic 
connective tissue fibres. The larger arteries branch into smaller arterioles which carry blood 
throughout organs into capillaries. Arterioles are known as resistance vessels and consist of an 
endothelial layer, connective tissue, and a thick layer of smooth muscle. Capillaries are comprised only 
of an endothelial layer, which aids their role in nutrient exchange at the cellular level as it allows for 
the diffusion of select nutrients out of the blood into the tissue and vice versa (13). The arrangement 
of arterioles in rodent cremaster, soleus, and extensor digitorum longus muscles has been described 
by Sweeney and Sarelius (14) and Williams and Segal (15). These studies show that blood enters the 
muscle through a feed artery classified as a 1st order arteriole, which then branches into smaller 
vessels (numbered in increasing order). 3rd order arterioles transverse the muscle tissue and 5th order 
arterioles lead into the capillaries. The capillaries are arranged in groups known as modules, which 
consist of approximately 15 capillaries that arise from each 5th order arteriole. A group of modules 
which arise from a 4th order arteriole is known as a capillary network (Figure 1) (16).  
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Figure 1.1: Skeletal muscle microvasculature. Adapted from Boron and Boulpaep 2003 (13). 
 
The prevailing theory indicates that blood flow to the whole muscle (often referred to as bulk or total 
flow) is controlled by constriction and dilation of the 1st-3rd order arterioles, whereas flow to the 
individual capillary networks is controlled by the 3rd-5th order arterioles (16). A number of animal and 
human studies indicate there is intermittent and heterogeneous movement of blood through the 
skeletal muscle tissue, differing in both spatial and temporal structure of flow (17-19). It appears that 
a rhythmic oscillation of arteriole diameter (vasomotion) occurs at regular intervals so that different 
capillary modules are perfused at different times (20, 21). It has been proposed that at any one time 
not all capillaries in the muscle tissue are perfused (14, 22) and that control of this blood flow is tightly 
linked to changes in metabolic demand and other stimuli such as increased work during exercise or 
after a meal (23). Further to this, it is proposed that within skeletal muscle two different capillary 
routes exist and changes in distribution between these two pathways may be a means to minimise 
blood nutrient utilisation during rest, while also maintaining the ability to meet increased demands 
when they arise (24).  
 
First alluded to by Pappenheimer in 1941 (25) using constant-pressure perfused canine gastrocnemius 
muscle and then later extensively investigated by Clark et. al. (3, 5, 23, 24) with the constant-flow 
perfused rat hindlimb is the idea that the skeletal muscle contains two different capillary networks, 
each with a different role within the tissue. It is proposed ‘nutritive’ and ‘non-nutritive’ capillary 
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networks run parallel to each other in skeletal muscle vasculature, with flow distribution within each 
changing based on metabolic demand. Structural studies of skeletal muscle vasculature support this 
concept of two separate blood flow routes running parallel to each other (26, 27). Clark et. al. (24) 
propose that the nutritive flow route consists of longer tortuous capillaries which wrap around muscle 
fibres, thereby providing a large surface area for nutrient exchange between myocytes and blood. The 
non-nutritive pathway, believed to consist of lower resistance, shorter and wider capillaries (28), is 
thought to act as a shunt through the skeletal muscle tissue. A proportion of the non-nutritive 
capillaries are thought to supply connective tissue such as septa and tendons (29), as well as 
adipocytes within the tissue (30). Clark and colleagues surmised that in vivo the non-nutritive flow 
route in skeletal muscle may act as a flow reserve which can be rapidly redistributed to the nutritive 
flow route in response to increased metabolic demand (24). The redistribution of blood into the two 
different flow routes in vivo is proposed to be an important component in the regulation of muscle 
nutrient utilisation. This allows conservation of nutrient and oxygen supply during rest, while 
maintaining the ability of muscle to meet increased demands in response to stimuli such as 
contraction (5, 24). It should be noted that the nutritive and non-nutritive capillary theory is not 
universally accepted, other theories indicating homogenous capillary structure and continuous 
perfusion of all capillaries do exist (31) and these theories have been subject to debate in the literature 
(32, 33). 
 
1.1.2 Capillary perfusion  
 
According to the capillary perfusion theory (which is postulated to accurately reflect true 
microvascular flow (32)), in skeletal muscle at rest, only a proportion of capillaries are believed to be 
perfused at any one time (14, 22), with a constant change in the regions perfused occurring via 
vasomotion (20, 21). During times of increased metabolic demand such as during exercise or after a 
meal, the number of capillaries perfused and the surface area available for nutrient exchange is 
6 
 
increased. However, the major alternative theory states that there is continuous perfusion of all 
capillaries at all time and that only the haematocrit becomes altered when demand is changed (31). 
The mechanisms through which this increase in perfusion occurs may vary depending upon the stimuli. 
Increased capillary perfusion occurs via dilation of terminal arterioles (4th-5th order), allowing blood 
flow through previously quiescent capillaries, a process known as microvascular recruitment (or 
capillary recruitment) (6, 34, 35). Greater distribution of flow into the capillaries can occur with or 
without the increase in total flow to the muscle, controlled by feeder (1st-3rd order) arterioles (16). 
Total blood flow is the bulk volume of blood moving through main arteries into the muscle tissue as a 
whole, as distinct from capillary perfusion, which refers to the distribution of the blood within the 
muscle capillaries. It is thought that because of the two different flow routes in muscle, capillary 
perfusion can change and increase without necessarily requiring a change in total blood flow (36). 
Coggins et. al. (37) looked at changes in total blood flow and microvascular perfusion in the forearm 
during a 4-hour infusion of physiological levels of insulin (0.05mU/kg/min). This showed an increase 
in microvascular perfusion which occurred without a significant increase in total flow to the forearm, 
thereby demonstrating that distribution of blood within skeletal muscle tissue can be altered without 
changing the total amount of blood delivered into the muscle.  
 
Experiments looking at the vascular control by insulin may have great importance in elucidating the 
true behaviour of blood flow through muscle. Commonly, the euglycemic hyperinsulinemic clamp, 
where constant insulin infusion is coupled with variable glucose infusion to stabilise blood glucose 
levels, is used to assess insulin action within the body. Studies involving infusion of insulin affect the 
whole body and allow assessment of partial changes in blood flow within muscle, unlike studies 
utilising contraction to assess blood flow behaviour which is a more isolated effect and generally 
results in large changes in blood flow. Utilising techniques which assess capillary perfusion, rather than 
bulk flow, in insulin studies may be an effective way of gaining greater understanding of how insulin 
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is able to alter blood flow distribution within the tissue, an action that has been linked to increased 
glucoses uptake in human (38, 39) and rat (36, 40, 41) studies. 
1.1.2.1 Techniques to measure capillary perfusion 
 
A number of techniques exist to measure the change in total flow as well as capillary perfusion. 
Changes in bulk blood flow have been investigated using thermodilution (42, 43), dye dilution (44), 
plethysmography (45, 46), positron emission tomography combined with [15O]H2O (47), and 2D-
ultrasound (48). However, these techniques only give an insight into the total amount of blood moving 
through the skeletal muscle tissue (total/bulk flow), via conducting and feed arteries, and not how 
that blood is distributed between capillaries. Importantly, there are a number of techniques which 
can be used to look at changes in microvascular perfusion alone (assessing the number of capillaries 
which are perfusion at any one time), independent of changes in bulk blood flow (48).  
 
A commonly used technique to measure microvascular flow is laser Doppler Flowmetry (LDF). LDF is a 
measure sensitive to both the velocity and number of red blood cells (RBC) within the vasculature, 
with the resulting LDF signal (measured as flux) being proportional to the tissue perfusion (49). LDF 
probes can be placed onto the skin or into tissue and consist of fibre optic cables that direct a laser 
light (700-800nm) into the tissue. As the RBC move through vessels in the illuminated section of tissue 
they interact with the laser to create a scatter pattern with a frequency change according to the 
Doppler effect. Sensitive photo detectors in the collecting optic fibre of the LDF probe then measure 
the scattered light and frequency shift (50-52). The resulting signal gives an indication of the number 
and speed of RBCs in the tissue that is being illuminated by the laser. However, the use of LDF to assess 
capillary perfusion is limited by a number of factors. LDF is only able measure blood flow in the specific 
region of tissue illuminated by the laser, and as such cannot be used to determine whole tissue blood 
flow (49). The flow measured in the area illuminated may differ to that of other regions of the tissue. 
For example, through experimental observation Clark et. al. (24) propose that if the LDF probe is 
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placed in a section of the non-nutritive flow route, the flow rates indicated by LDF measurements will 
differ from the flow-rates in another region of muscle where the nutritive pathway predominates. 
Additionally, in the assessment of skeletal muscle flow, the inability of the LDF laser to penetrate 
beyond the skin and subcutaneous tissue (skin+SC) has limited its use in assessing blood flow within 
deeper tissues such as skeletal muscle. The problems with the power of the laser can be overcome by 
removing skin and other superficial tissues and placing the probe directly on the muscle, or more 
recently, using high power LDF probes that can potentially penetrate into the muscle when placed on 
the skin. Previous studies have generally focused upon the change in the averaged LDF signal value 
during interventions (53, 54). The average measure gives an overall indication of microvascular blood 
flow status of the tissue sampled and if blood flow may have become altered during disease, but not 
an in-depth assessment of underlying changes in blood flow function that may be occurring. To give a 
greater insight into the control of microvascular blood flow patterns and to identify what specific 
changes in microvascular blood flow behaviour may be occurring during diseases such as T2D, 
mathematical modelling can be applied to the LDF data to analyse different aspects of the signal. 
These include spectral analysis such as Fourier analysis or wavelet transformation which determine 
different frequencies in the signal (55-57) and complexity measures which assess the randomness of 
the LDF flux (58, 59). 
 
Interestingly, recent advances in technology have produced combined LDF flux and tissue oxygenation 
probes (LDF + OXY probe), which can measure LDF flux, oxygen saturation (O2 Sat) and total 
haemoglobin (tHb) concurrently at the same site. However, the different light sources for each 
measurement type may have different penetration into the tissue, as such these different measures 
are detecting blood flow in different volumes of tissue (60, 61). The oxygenation of tissue (O2 Sat) and 
total number of RCB (tHb) can be measured and analysed in the same manner as LDF flux to give a 
more holistic assessment of microvascular perfusion. O2 Sat and tHb measures are taken with white 
light spectroscopy, where oxygenated and deoxygenated haemoglobin absorb light at different 
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wavelengths, which is then detected by photosensors in the probe and recorded (62). Kuliga et. al. 
(63) validated the novel combined LDF flux and white light reflectance spectroscopy sensor probe. LDF 
+ OXY measurement of forearm microvascular blood flow in healthy participants were assessed. The 
result showed that resting skin+SC O2 Sat is independently associated with blood flow and skin 
temperature, with the relationship between blood flow and O2 Sat best described by a one-phase 
association curve fit with a plateau in O2 Sat of 84%. The study concluded that the tissue oxygenation 
measures are able to detect similar skin+SC microvascular blood flow as LDF flux, but through 
measurement of different parameters. The use of the combined LDF + OXY probe gives a platform for 
a more in-depth investigation of microvascular blood flow under different metabolic and disease 
conditions.  
 
1-MX metabolism is a biochemical technique used to determine the microvascular perfusion in rat 
skeletal muscle (48). It has an advantage over LDF as it can assess whole tissue microvascular 
perfusion. This technique relies upon the presence of the enzyme xanthine oxidase (XO) on the surface 
of all capillaries in skeletal muscle tissue. XO can metabolise 1-MX into one product, 1-methylurate (1-
MU). The difference between the amount of 1-MX infused into the rat skeletal muscle and the amount 
of 1-MU in the venous blood, measured by high performance liquid chromatography, gives an 
indication of microvascular perfusion. The 1-MX metabolism technique essentially looks at the total 
surface area of microvasculature within the muscle through which the blood passes. With greater 
microvascular perfusion, the blood is exposed to a greater surface area of the microvascular 
endothelium, and thereby greater metabolism of 1-MX occurs (48). Studies of 1-MX metabolism in the 
constant-flow perfusion hindlimb, where the perfusion rate was altered to give more or less total flow 
into the muscle, have shown that 1-MX metabolism is not significantly changed with changes in muscle 
flow rate, verifying that this technique is a measure of flow redistribution alone (5). There are, 
however, limitations to this technique, as it is an indirect measure of microvascular perfusion, and it 
also cannot be used in humans as the clearance of 1-MX across human skeletal muscle beds is 
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insufficient for the assay, due to inadequate levels of XO (64). Additionally, 1-MX metabolism cannot 
look at changes in microvascular perfusion in real time, only giving an average value for a time period 
(usually 60mins) (48). The 1-MX technique is therefore unsuitable for the assessment of flowmotion, 
which requires continuously collected data for spectral analysis.  
 
Contrast enhanced ultrasound (CEU) is another means of measuring microvasculature blood flow. It 
has an advantage over 1-MX metabolism as it can monitor real time changes in microvascular 
responses in the tissue of both rats (40) and humans (65), however it is a more invasive measure as 
compared to surface LDF. CEU allows visualisation and quantification of blood flow through a specific 
tissue region of interest (ROI). Ultrasound uses sound waves to visualise regions of the body. Within a 
specific ROI, contrast agents (which are infused into circulation) can be visualised as each sound wave 
emitted from the transducer results in an acoustic signal produced by the contrast agent (66). Gas 
filled phospholipid bubbles, known as microbubbles, are commonly used as contrast agents in animal 
and human experiments. The phospholipid microbubbles are introduced into the vasculature via 
constant venous infusion and travel in the blood. They are on average 4μm in diameter, constraining 
them to the vasculature and allowing them to travel in a similar manner to RBC (67). The acoustic 
intensity (AI) of microbubbles that are within the microvasculature can be detected. The AI signal is 
proportional to the concentration of microbubbles within the ROI, therefore when the arterial 
concentration of microbubbles is constant the AI is related to the blood volume. By imaging a muscle 
and measuring its AI signal, an indication of blood volume can be determined. CEU is able to track 
changes in blood volume in real time, and can be used to detect differences in microvascular perfusion 
with different treatments. Vincent et. al. (41) showed total blood flow (measured with an ultrasonic 
flow probe placed around the femoral artery) and microvascular blood volume (measured by CEU), 
were monitored during a euglycemic hyperinsulinemic clamp with physiological levels of insulin 
(3mU/kg/min) in an anaesthetised rat hindlimb. There was a rapid increase (55% 5-10min into insulin 
infusion) in microvascular volume observed via CEU, which occurred without any significant change to 
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the total blood flow to the hindlimb. The observed increase in microvascular blood volume indicates 
that microvascular perfusion has been increased by insulin, independently of change in total blood 
flow to the hindlimb.  
 
The minimally invasive nature of the LDF + OXY and CEU techniques is believed to more likely produce 
observations of true, non-artificial blood flow changes in muscle, thus eliminating any potential 
changes in blood flow that can be caused by experimental intervention. These techniques also allow 
the assessment of blood flow through the large load-bearing muscle which makes up the majority of 
skeletal muscle tissue in the body. An additional advantage is that blood flow analysis utilising these 
minimally invasive techniques can be performed in both animals (36, 48, 68) and humans (65), 
combined with measurements of total blood flow, allowing a more holistic assessment blood flow 
physiology. 
 
Table 1.1: Summary of microvascular blood flow techniques advantages and disadvantages.  
Technique Advantages Disadvantages 
LDF + OXY Real-time measurements 
Skin measures non-invasive and easy to perform 
RBC number and tissue oxygenation combined 
Animal and human applications 
LDF flux measures RBC number and velocity 
Small tissue section 
Invasive to measure deeper tissues 
1-MX Whole tissue measurement 
Assessment of microvascular surface exposure 
Measure of flow redistribution alone 
Cannot be used in humans 
Not real-time 
Indirect measure 
CEU Real-time measurements 
Animal and human applications 
Non-invasive to muscle  
Able to measure large load bearing muscles 
Large tissue sections  
Measure of microvascular blood volume alone 
Contrast agent required  
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Techniques to assess muscle blood flow directly do also exist, but are inherently more invasive. 
Intravital microscopy is a common method used to directly observe many different biological functions 
in vivo, including blood flow in skeletal muscle tissue (69-71). Using this technique, muscle in a live 
sedated animal is surgically exposed, and a high resolution microscope is used to directly observe 
blood flow patterns in the muscle. Intravital microscopy is generally used to assess blood flow in thin, 
more specialised muscle, as they are more easily accessed (31). This is as opposed to the less invasive 
techniques, which can also assess bulk load-bearing muscle (32). The technique is advantageous as it 
allows for direct assessment of blood flow in the muscle tissues, however, the highly intrusive nature 
of this method could potentially result in unnatural alteration of blood flow in the muscle, and thereby 
not give a true representation of normal blood flow and distribution through the tissue. Additionally, 
due to the surgery required, intravital microscopy cannot be used to assess human muscle blood flow. 
The only assessable vascular beds for intravital microscopy in humans are the nail fold 
microvasculature (12), retinal (72) and oral mucosa (73); studies of blood flow in these tissues are 
unlikely to reflect muscle flow, which is the primary tissue of interest when assessing metabolism and 
vascular dysfunction during disease. Each method used to assess in vivo muscle blood flow has 
inherent flaws, and as such the use of multiple and different techniques may be the best approach to 
the assessment of skeletal muscle blood flow.  
 
1.1.2.2 Alternative skeletal muscle blood flow hypotheses 
 
In 1917 Krogh (74) first proposed the idea of capillary perfusion from observations made in 
experiments where dye was passed through muscle microvasculature. Krogh noted that not all 
capillaries in the tissue gave passage to the dye and hypothesised that in the vasculature there is a 
reserve of unperfused capillaries, a concept that is still believed to hold true by many microvascular 
researchers (5, 6, 75). However, there are other theories as to how blood flow acts and changes in 
skeletal muscle. Primarily it is the work and opinions of Poole et. al. (31) who disagree with the concept 
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of capillary recruitment and through their study of blood flow at rest and during contraction suggest 
an alternative hypothesis. Poole et. al. propose that instead of only a proportion of capillaries being 
perfused any one time during rest, all capillaries within a tissue support plasma flow and almost all 
RBC flux, at all times. It is proposed that the haematocrit in capillaries is altered upon changes in 
metabolic demand within the muscle tissue (from 15% to 45%) (31). The manner in which the different 
components of blood interact with the vessel wall is theorised to allow for this change in haematocrit. 
During rest molecules on the vessel wall interact and hold up RBC but not the plasma and upon 
stimulation by increased metabolic demand (i.e. exercise) the RBC are released and haematocrit 
subsequently increases. Additionally they propose that ‘longitudinal recruitment’ occurs where the 
capillaries extend in length upon increased metabolic demand, to increase surface area on which 
exchange can take place (31). Poole et. al. based their hypothesis upon studies mostly done using 
intravital microscopy of thin more specialised muscle which is observed at ‘basal’ and then under 
electrical stimulation to induce contraction (76). The manner of these studies highlights potential 
issues with the resulting hypothesis that RBC concentration increases in capillaries during contraction, 
not whole blood flow. It is likely that the invasive nature of the techniques itself used by Poole et. al. 
may result in capillary recruitment and that ‘basal’ measurements of capillary RBC content may not 
be accurate. Questions are also raised about how haematocrit is able to dynamically change in a closed 
system. Additionally, Poole et. al. focus upon changes which result from contraction and mention little 
about the changes induced by insulin – such as increased glucose uptake (which travels in the plasma) 
resulting from an increased capillary flow (6) – or vasomotion within muscle vasculature (77), two key 
processes in the overall behaviour of blood flow in skeletal muscle.  
 
1.2 Vasomotion and flowmotion 
 
Vasomotion is the rhythmic oscillation of vasculature diameter (7, 8, 78) which occurs in many, if not 
all, tissues throughout the body (10). The consequence of vasomotion is oscillations of flow into or 
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within tissues; flowmotion (9). Vasomotion and the subsequent flowmotion which occurs are thought 
to be an important component in the distribution of blood flow within tissues such as muscle and 
skin+SC. Vasomotion was first described over 150 years ago by Jones (1852) (79), who observed 
rhythmical changes in vessel diameter in bat wings. Many in vivo and in vitro studies have since 
reported the presence of vasomotion (80). Studies of vasomotion and flowmotion have been 
conducted upon a number of different tissues including the testes (81), mesenteric vasculature (11), 
skin (82) and skeletal muscle (57), indicating a widespread occurrence throughout the body. 
Vasomotion is thought to be generated locally from within the vascular wall, not from systemic 
mediators such as heart beat, respiration or nervous system input; though synchronisation of 
vasomotion has been reported to occur through neurogenic input (83, 84). Studies by Colantuoni et. 
al. (85-88) using the hamster skin-fold window preparations show that the frequency of vasomotion 
is greater in smaller arteries, thus terminal arterioles have higher occurrence of vasomotion when 
compared to higher order arterioles. Additionally, experimental conditions may affect the study of 
vasomotion with varied reports of the presence of vasomotion in animals observed during rest, both 
with or without anaesthetic (10). Importantly, in human studies the presence of vasomotion and 
flowmotion has consistently been observed during and without anaesthesia (82, 89, 90). The study of 
vasomotion since its discovery in 1852, has been difficult due to the limited techniques with the 
appropriate sensitivity available to observe and measure vasomotion. There are two fundamental 
questions regarding vasomotion which are yet to be fully answered. 1) What are the cellular 
mechanisms that produce vasomotion and 2) what is the physiological role of vasomotion?  
 
The physiological consequence of vasomotion, flowmotion, is in contrast relatively easy to detect and 
has been assessed using techniques such as oxygen tension measures, local blood pressure measures, 
and LDF (81, 90-93). Importantly, flowmotion is not only controlled by vasomotion but is also 
influenced by the central factors; cardiac, respiratory and neurological activity. Five different 
oscillation frequencies (between 0.0095 and 1.6Hz) are present in human flowmotion measures (55). 
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These distinct frequencies correspond to the above factors (10, 11, 94) and have been identified in 
vivo using LDF (90, 91, 95-98), oxygen tension measures (99) and through direct observation (92, 100). 
Two of the oscillating bands occur at higher frequency and originate from cardiac (0.4-1.6Hz) and 
respiratory (0.15-0.4Hz) input (the range of these frequencies are increased in rats due to higher 
respiratory and heart rates). The other three factors are present at lower frequencies and through 
pharmaceutical intervention it has been established that the mechanistic backgrounds for each is 
intrinsic smooth muscle activity (myogenic, 0.06-0.15Hz), nervous system input (neurogenic, 0.02-
0.06Hz) and vascular endothelium (endothelial, 0.0095-0.02Hz) (55, 94). Studies in vitro looking at 
vasomotion in isolated small arteries suggests that the myogenic frequency of flowmotion at 0.06-
0.15Hz seen in vivo is due to vasomotion (11). It is also thought that the endothelium has a role in the 
control of vasomotion as vessels stripped of their endothelial layer show an inhibition of vasomotion 
that can be rescued by application of endothelial derived agents such as nitric oxide (NO) (10).  
 
1.2.1 In vivo measurement of flowmotion 
 
In the 1990’s Stefanovska et. al. (55, 56, 96) showed that the contribution of different frequency 
components of flowmotion could be revealed by mathematically transforming skin+SC LDF flux data 
with spectral analysis. The presence and relative input of each of the five factors influencing 
flowmotion can be determined by performing the mathematical transformation on raw LDF data. 
Spectral analysis applies a mathematical equation to the LDF data, which is expressed as perfusion 
units (PU) verses time, and transforms the data into average wavelet transformation (PU) verses 
frequency (Hz) (101, 102). LDF is unable to measure blood flow in absolute perfusion values, the PU 
measurements are therefore an arbitrary, relative measure of flux. It is therefore essential that LDF 
probes are correctly calibrated before measures are taken to enable comparison of results. A peak 
representing each of the five influencing factors is then able to be identified. Fast Fourier analysis and 
wavelet transformation are two forms of spectral analysis that can be used to analyse the LDF flux 
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data. Wavelet transformation is considered advantageous over fast Fourier analysis as it allows a more 
precise determination of the lower frequency components of a signal (103). As described by 
Stefanovska et al. (55), wavelet transformation also takes time into consideration, producing a 3D 
output with wavelet transformation, frequency and time considered (Figure 1.2A). The temporal 
information provided by performing a wavelet transformation indicates the variance of the signal and 
how often a modulating factor exerts its influence over blood flow. For example, the endothelial 
component which influences blood flow at a lower frequency has a great variation over time as the 
oscillating signal only occurs at 50-105 second intervals. The cardiac component however, exerts its 
influence at a much higher frequency, therefore there is less variation as the oscillations occur at 0.6-
2.5 seconds. In most biological circumstances, the wavelet transformation is averaged over time to 
give a 2D measure of wavelet transformation against frequency (Figure 1.2B), allowing easier handling 
and interpretation of the complex data. The averaging of wavelet transformation data over time for 
the interpretation of flowmotion patterns results in the loss of temporal information. In the context 
of the data described in this thesis, the temporal data is only of importance in the consideration of the 
time period on which the wavelet transformation is performed. To adequately measure the influence 
of the lower frequency components on flowmotion longer periods of time (20min or more) need to 
be used to overcome the variance in the signal and obtain an accurate reading of the endothelial 
influence on flowmotion.  
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Figure 1.2: Wavelet transformation of human skin LDF signal. Figure taken from Stefanovska et al. (55) 
(Figure 2) demonstrates the A) 3D output of wavelet transformation where average transformation (Z 
axis), frequency (X axis) and time (Y axis) are all taken into consideration. Data is averaged over time 
to give B) 2D average wavelet transformation against frequency for easier interpretation of data. 
 
By applying a normalisation calculation to the average wavelet transform values – achieved from 
wavelet transformation of LDF flux data – the relative contribution of each frequency to flowmotion 
can be established. A calculation to establish the relative contribution of each frequency allows the 
changes in flowmotion that are induced by interventions such as insulin infusion to be established.  
Wavelet transformation of LDF flux data provides an effective means of determining overall 
flowmotion patterns and the contribution of each frequency component within this. However, the use 
of LDF flux to assess flowmotion is limited in that it can only assess blood flow in one small section of 
a tissue. Flowmotion is the oscillation of flow across a whole tissue and it may be blood flow in 
different sections of the same tissue differ. LDF does not allow adequate investigation into the idea of 
varied flow distribution across a tissue. To overcome this limitation, the same analysis technique 
(wavelet transformation) could be applied to blood flow measurement techniques that assess flow 
A 
B 
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over larger regions of tissue (i.e. CEU), which can be performed on both animal models and human 
subjects. 
 
In order to understand and interpret changes in flowmotion observed by wavelet transformation; it is 
first important to understand the cellular mechanisms through which flowmotion is controlled.  
 
1.2.2 Cellular mechanism of vasomotion 
 
1.2.2.1 Myogenic input 
The myogenic input is often itself called vasomotion as it is the intrinsic contraction within the vessel 
smooth muscle per se. The cellular mechanisms in the smooth muscle which bring about vasomotion 
and the mediators which induce these mechanisms have been previously investigated, but are still not 
fully understood. The majority of investigations into the mechanism of vasomotion have been done 
with intravital microscopy and isolated larger arteries using various agonists and inhibitors of 
vasomotion (reviewed by Aalkjaer and Nilsson in (10, 11)). It is thought that two important processes 
induce vasomotion in arteries; firstly, generation of Ca2+-dependent oscillators within smooth muscle 
cells, which induces cellular depolarisation and secondly, synchronisation of that depolarisation 
between the smooth muscle cells (10). Oscillators within the smooth muscles cells are thought to be 
generated from cytosolic and membrane actions (80, 104). Vasomotion is thought to be initiated by 
release of cellular stores of Ca2+ (from sarcoplasmic reticulum) into the cytosol by cytosolic oscillators 
(105, 106). Vasomotion is only established when intercellular Ca2+ release is formed into synchronised 
waves (106-108). Prominent vasomotion researchers Aalkjaer and Nilsson hypothesise that the 
membrane oscillators induce the intracellular synchronisation (109-111). The waves of Ca2+  within the 
smooth muscle cells are believed to induce activation of many Ca2+-dependent membrane bound ion 
channels such as Cl- and K+ channels (112-115). Activation of these membrane channels is believed to 
induce the depolarisation of smooth muscle cells responsible for vasomotion activation (106). A study 
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by Bartlett et. al. (116) showed an abolishment of vasomotion in hamster cheek vasculature upon 
blockade of K+ channels, indicating the importance of membrane K+ channels in the activation of 
vasomotion through cellular depolarisation. It is proposed that in order for vasomotion to occur in a 
whole vessels, a synchronisation of the oscillating depolarisation between smooth muscle cells is 
required (10). The depolarisation initiated through generation of Ca2+ waves within cells can be 
propagated to the surrounding smooth muscle myocytes via gap junctions, forming an electrical signal 
(reviewed in (10)). Through the gap junction mediated synchronisation of cellular depolarisation, 
vasomotion in a vessel is believed to occur. Matchkov et. al. (117) used gap junction inhibitors on 
isolated rat mesenteric arteries to show a desynchronisation of membrane potential oscillations 
between vessel smooth muscle cells, which resulted in an inhibition of vasomotion. The 
desynchronisation of membrane potential oscillations was shown to occur without effecting Ca2+ 
waves within individual smooth muscle cells of the isolated arteries, indicating an inhibition in the 
synchronisation required to produce vasomotion, not the cellular mechanism involved. The 
observations by Matchkov et. al. (117) has been repeated in other studies which utilise gap junction 
inhibitors (117-120). These studies have formed the idea that gap junction mediated synchronisation 
of the Ca2+-dependant depolarisation is essential for induction of vasomotion in a vessel. While there 
are many studies outlining the possible mechanisms through which vasomotion occurs, the question 
of what induces these actions within the smooth muscle cells to bring about vessel vasomotion still 
remains and requires a great deal of further investigation. 
 
1.2.2.2 Neurogenic input 
Neurogenic input to flowmotion is primarily generated centrally in the brain, constantly outputting 
signal to cause vasoconstriction in the smooth muscle of vessel in order to maintain a balanced 
vascular tone (121). However, the effector of this process, noradrenaline (NA), acts locally at the tissue 
site to induce vasoconstriction. Using skin LDF measures, Kastrup et. al. (122)  demonstrated with 
denervation studies that the neurogenic component of flowmotion exerts its control at a frequency 
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of about 0.04Hz. Neurogenic input to the skin was removed after both local and ganglionic nerve block 
and after a sympathectomy. The control of vasoconstriction by the neurogenic input periodically 
modulates the vascular tone of vessels and thereby influences vasomotion patterns. NA is released by 
the axons of nerves, which then binds to and activates alpha1-adrenoceptors on the vessel smooth 
muscle to result in increased intracellular Ca2+. Increases in intracellular Ca2+ causes contraction of the 
myocytes and thereby vasoconstriction (123, 124). Under basal situations, neurogenic input to 
vascular smooth muscle is constant to produce a basal level of vasoconstriction in order to maintain 
normal blood pressure (121). However, neurogenic control can be more complicated and response to 
neurogenic input can vary at different vascular sites (26), likely due to the varied presence of alpha2-
adrenoceptors on vascular pre-synaptic neurons. Alpha2-adrenoceptors modulate alpha1-
adrenoceptors mediated vasodilation through the inhibition of NA release into the synapses, thereby 
inhibiting neurogenic mediated vasodilation (125). It is worth noting that NA can also be released from 
the adrenal gland into circulation as a stress response (126), which may then influence the neurogenic 
component of flowmotion.  
 
1.2.2.3 Endothelial input 
In addition to smooth muscle cell mechanisms, the endothelium is thought to be of great importance 
in the generation of vasomotion (11). Jackson et. al. (127) used α1-adrenergic agonists to stimulate 
vasomotion in isolated hamster aortas. This rhythmic activity was not simulated in vessels where the 
endothelium had been removed. Jackson et. al. (127) concluded that localised mechanisms within the 
endothelium were influencing and controlling the generation of vasomotion in the vessel smooth 
muscle. To establish the frequency at which the endothelial component of flowmotion exerts its 
effect, Kvernmo et. al. (128) performed wavelet transformation analysis of skin LDF measures during 
basal, endothelial-dependent (acetylcholine) and endothelial-independent (sodium nitroprusside) 
stimulation of vasodilation. During endothelial-dependent vasodilation there was a significant 
increase in the contribution of the frequency component at 0.01Hz, indicating that it is at this low 
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frequency that the endothelial input exerts control over flowmotion. Several different endothelium-
derived molecules have been suggested to be important for the activation of vasomotion. Restoration 
of vasomotion in hamster aorta stripped of the endothelial layer by sodium nitroprusside (SNP) and 
cyclic GMP (cGMP) has also been observed by Jackson et. al. (129). The ability of SNP and cGMP 
analogues to recovery oscillatory behaviour when vessel endothelium is removed suggests that the 
nitric oxide (NO) system (which is initiated in the endothelium) may play an important role in 
vasomotion generation. In another study by Gustafsson et. al. (130) isolated rat mesenteric arterioles 
and stripped the endothelial cells, resulting in an inhibition of vasomotion, which was then restored 
with the addition of the NO donor SNP and a cyclic GMP (cGMP) analogue. Additionally, high 
concentrations of cGMP introduced to smooth muscle in the absence of vessel endothelial cells has 
been shown to induce synchronisation of Ca2+ waves (106, 131). It appears that NO-mediated process 
are important in vasomotion, but other factors such as endothelium-derived hyperpolarising factor 
(EDHF) are thought to also play a role (132). Both NO and EDHF have been shown to modulate Ca2+ 
release in vascular smooth muscle cells (104). The release and synchronisation of Ca2+ is proposed to 
be the mechanism by which vasomotion is generated (10), thereby providing a mechanistic link for 
the endothelial modulation of flowmotion. The perceived importance of NO-mediated pathways in 
vasomotion is perhaps an important point in understanding the physiological role of vasomotion. 
Insulin induces NO production in vessel endothelium (133), and it has been shown that insulin induces 
vasomotion (57). It is thought that there is a link between insulin-mediated vasomotion and 
redistribution of blood flow within skeletal muscle tissue. In the current thesis, the relationship 
between insulin and flowmotion will be studied more extensively in an attempt to better understand 
the physiological role of vasomotion and flowmotion. 
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1.3 Insulin-mediated changes to skeletal muscle haemodynamics and their effect on metabolism 
  
1.3.1 Insulin-mediated changes in blood flow 
 
The vasoactivity of insulin was first described in 1939 when schizophrenic patients were treated with 
large doses of insulin (134). A bolus dose of 40-280U of insulin resulted in bulk increases in blood flow 
to the leg, forearm and hand. The ability of insulin to increase bulk blood flow to skeletal muscle has 
been reported in some subsequent studies (43, 45, 48, 135), but others studies have shown no change 
(136-139). Differences in the outcomes of total flow studies are not only attributed to the techniques 
used, but to the varied concentration of insulin employed in each case. At a relatively low dose 
(75mU/mL) Kelley et. al. (137) failed to see any increase in total blood flow to the leg. However, Laakso 
et. al. (43) using a euglycemic hyperinsulinemic clamp, found changes in total leg blood flow were 
related to insulin dose. The study used a ramped protocol in which insulin was infused at 
10mU/m2/min increasing to 600mU/m2/min and found total leg blood flow increased in a graded 
fashion relating to the insulin infusion. In addition to the changes in total flow, studies in humans (65) 
and rats (41, 48, 140) exploring insulin mediated distribution of blood within the skeletal muscle 
capillary beds have shown that insulin causes an increase in capillary perfusion. Insulin promotes 
capillary recruitment through the redistribution of blood flow amongst a greater number of capillaries, 
even at lower physiological doses, prior to any changes in whole-limb flow (36). Changes in 
microvascular perfusion, leading to enhanced glucose uptake occur primarily via insulin binding to the 
endothelial cells of the arterioles, as opposed to acting upon the smooth muscle cells that surround 
the vessel. Insulin signalling results in activation of several different pathways in the microvasculature 
to alter the tone of vessels, mediating both vasodilation and vasoconstriction, with the overall vascular 
tone achieved resulting from a balance of these two actions (Figure 1.3).   
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Insulin mediates vasodilation of arterioles by inhibiting vasoconstriction in vessel smooth muscle cells. 
Insulin-mediated vasodilation of the terminal arterioles is believed to induce microvascular 
recruitment (6). Binding of the insulin receptor on the endothelial cells leads to phosphorylation – 
therefore activation of – the endothelial form of the NO synthase (eNOS) via the phosphoinositide 3-
kinase (PI3K) pathway (140-142); resulting in NO production in the endothelial cells (Figure 1.3) (143). 
NO then diffuses into the surrounding smooth muscle, where it binds to and activates the enzyme 
guanylate cyclase (GC). Activation of GC leads to increased production of cGMP within the smooth 
muscle cells (144, 145) and allosteric activation of protein kinase G (PKG), which in turn causes 
vasodilation of the vascular smooth muscle cells. PKG inhibits the actions of vasoconstrictors by 
removing calcium from the cytosol and de-phosphorylating myosin light kinase (146-149), thus 
preventing contraction and producing relaxation. 
As can be seen in Figure 1.3, insulin binding to the receptor on endothelial cells also induces an 
endothelin-1 (ET-1) dependent vasoconstriction (150, 151). Activation of insulin receptors on an 
endothelial cell results in activation of the MAP-Kinase (MAPK) signalling pathway in addition the 
activation of the PI3K pathway (152). Activation of the MAPK pathway stimulates the release of the 
powerful vasoconstrictor ET-1 (153). The activation of ET-1 in addition to NO by insulin is important in 
the regulation of skeletal muscle vascular tone, ensuring a correct balance is maintained. In healthy 
individuals insulin stimulation results in controlled vasodilation (133).  
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Figure 1.3: Comparison of endothelial insulin-mediated vascular responses. Insulin induces two 
different pathways which effect vascular tone. The PI3K pathway leads to NO-mediated vasodilation. 
Activation of the MAPK pathway leads to ET-1 –mediated vasoconstriction. Overall vasculature tone 
results from the balances between the two pathways. Adapted from Kim et. al. (152). 
 
Additionally, insulin is known to activate the sympathetic nervous system (SNS) (reviewed in (154)). In 
healthy participants physiological concentrations of insulin have been shown to increase venous 
catecholamine levels and sympathetic nerve activity (155-157). Activation of the SNS generally leads 
to vasoconstriction, which is thought to oppose insulin-mediated NO vasodilation (158). There is 
however, evidence of varied responses to insulin by different vessels based on their position on the 
vascular tree (6, 159). With elevated SNS activity, distal arterioles have been shown to vasodilate in 
response to insulin, whereas proximal arterioles have been shown to vasoconstrict (160). However, 
other studies have shown that SNS activity is not involved in insulin-mediated vasodilation (161). It is 
clear that the vasoactive interaction between insulin and the SNS is complex and it maybe that 
different levels and regions of the vasculature controlled by the SNS respond separately to insulin, 
thereby potentially altering the overall outcome of insulin stimulation at different sights in the 
vasculature. 
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1.3.2 Insulin-mediated skeletal muscle glucose uptake 
 
Insulin promotes removal of glucose from the blood in order for it to be stored as glycogen within 
skeletal muscle (162). The importance of skeletal muscle as a target tissue can be seen after a meal, 
where 65-90% of the glucose ingested is stored as glycogen in the skeletal muscle myocytes (162-164). 
Bergman et. al. (165, 166) hypothesize that insulin delivery to the skeletal muscle interstitium is the 
rate-limiting step in insulin-stimulated glucose uptake by skeletal muscle. Actions of insulin on both 
the myocyte cells themselves and the surrounding vasculature are important in efficient uptake of 
glucose by the muscle.  
 
Binding of the insulin receptor on myocytes induces the PI3K signalling pathway to translocate vesicle 
bound glucose transporters (GLUT4) to the cell membrane where they become active (140, 141, 167), 
thereby allowing increased glucose uptake from the blood into cells. As discussed, in addition to the 
changes insulin induces within the myocyte cells, insulin is able to elicit vasodilation in the skeletal 
muscle microvasculature; a process that plays an important role in the overall ability of the tissue to 
take up glucose. Insulin stimulation induces balanced vasodilation the terminal arterioles, which leads 
to microvascular recruitment and therefore an enhanced flow of blood to the myocytes (36, 168, 169). 
It is thought that insulin stimulation increases blood flow into the nutritive pathway (5). With greater 
blood flow to the myocyte cells there is a greater surface area by which insulin and glucose are 
exposed in the skeletal muscle tissue. Greater exposure of insulin and glucose to myocytes enhances 
GLUT4 translocation by insulin and thereby allows greater uptake of the increased amounts of glucose 
exposed to the cells (reviewed in (6)). An in vivo rat hindlimb study by Vincent et. al. (40) where NO 
production was inhibited by L-arginine methyl ester (L-NAME) during a euglycemic hyperinsulinemic 
clamp (10mU/kg/min) showed a 40% reduction in glucose uptake induced by insulin in the skeletal 
muscle tissue. The 40% reduction in glucose uptake was attributed to the reduction in capillary 
perfusion and total blood flow that was observed. The decrease in glucose uptake with L-NAME 
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infusion was thought to be because the inhibition of NO-mediated vasodilation decreased blood flow 
to the myocytes and therefore less glucose and insulin exposure to the muscle cells, resulting in the 
reduced glucose uptake seen. Other studies inhibiting NO production during insulin infusion in animals 
(170) and humans (171) have also shown similar results, indicating the importance of insulin-mediated 
vasodilation upon normal glucose uptake into skeletal muscle. It is currently unknown whether 
flowmotion in skeletal muscle plays an important role in regulating the glucose uptake in this tissue. 
 
 
1.3.4 Insulin resistance and microvascular dysfunction 
 
Insulin resistance is a state where cells in the body become less sensitive to insulin. Insulin resistance 
over a prolonged time period is causative of T2D. There are a number of factors that lead to the 
development of insulin resistance, most relate to the weight status of the individual (172). Currently 
the most accepted theories indicate that inhibition of the PI3K insulin signalling pathways by aberrant 
lipid storage in muscle (133, 173, 174), and in later stages markers of low-grade inflammation (175-
177), result in cellular insulin resistance and therefore in a failure of glucose uptake by skeletal muscle 
cells (178). The resulting insulin resistance from inhibition of the insulin signalling pathway causes an 
attenuation in normal glucose metabolism in skeletal muscle (affecting both myocytes and the 
vasculature), and other insulin-dependent tissues such as liver and adipose cells. The result is a 
decrease in glucose disposal resulting in hyperglycaemia as less glucose is taken up into the skeletal 
muscle cells. Greater insulin concentrations are therefore required to achieve normal glucose uptake 
(179). In humans with T2D (180) and models of insulin resistance such as the obese Zucker rats (181), 
insulin resistance in skeletal muscle is associated with a failure of myocytes to take up glucose and an 
inability to adequately deliver glucose to the cells (182-184).  
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As insulin resistance is thought to result from an inhibition in the PI3K signalling pathway, it impacts 
not only on GLUT4 translocation in myocytes, but also upon insulin-mediated vasodilation in the 
arterioles, which is believed to result in microvascular dysfunction. A study by Cusi et. al. (185) 
performed euglycemic hyperinsulinemic clamps in healthy and type two diabetic patients. Muscle 
biopsies before, during and after the clamp where taken to determine activation levels of the PI3K and 
MAPK pathways. They found a significant decrease in the phosphorylation (therefore activation) of 
the PI3K pathway in T2D in response to insulin, without any change in activation of the MAPK pathway. 
In insulin resistance it is thought that the PI3K pathway is no longer able to induce adequate release 
of NO in the vasculature, but the MAPK pathway is unaffected and ET-1 production still occurs 
(reviewed in (152)). Indeed, some studies have found an increase in ET-1 in the vasculature and have 
proposed that markers of low grade inflammation, which occurs in later stages of insulin resistance, 
may be responsible for increased production (186, 187). The net result is an aberrant vasoconstriction 
of the microvasculature, which impedes blood flow to the myocytes and glucose uptake is 
consequently attenuated (75, 151, 152, 188). In anaesthetised rat studies where acute insulin 
resistance was induced by infusion of TNF-α (184) or free fatty acids (189), glucose uptake was reduced 
by 50% and 69% respectively, while NO-mediated vasodilation was impaired and capillary recruitment 
was shown to be attenuated. As previously described, the Vincent et. al. (40) study where NO 
production was blocked with L-NAME during an euglycemic hyperinsulinemic clamp (10mU/kg/min) 
reported a reduction in microvascular recruitment and a 40% reduction in glucose uptake. Even 
though the decrease in glucose uptake is varied in these studies, it is clear that normal vasculature 
function is important in the overall glucose uptake of skeletal muscle and this is attenuated in insulin 
resistance. Additionally, a reduced production and response to NO has been reported in insulin 
resistance (190) and T2D (191). In obese Zucker (192, 193) and high fat fed (194) rats, insulin-mediated 
microvascular recruitment has been shown to be impaired. Premilovac et. al. (194) studied high fat 
fed rats and compared their microvascular recruitment during a euglycemic hyperinsulinemic clamp 
with lean animals. Using the 1-MX technique Premilovac et. al. (194) showed 32% decrease in 1-MX 
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metabolism in the high fat animals as compared to the lean animals. The observed decrease in the 
insulin-mediated microvascular perfusion in the high fat feed animals was accompanied by a reduction 
in insulin-mediated skeletal muscle glucose uptake. There is significant evidence to suggest that 
microvascular dysfunction occurs in insulin resistance and T2D (reviewed in (133, 195)) and that it is 
involved in the attenuation of skeletal muscle glucose uptake seen in these conditions. In addition to 
insulin resistance causing vascular dysfunction in T2D other pathological changes in the disease also 
impact of vascular function. Capillary density and morphology become pathologically altered 
throughout the progression of T2D, leading to reduced capillary perfusion in key tissues such as 
skeletal muscle (196). A study by Barchetta et. al. (197) directly examining nailfold capillaries using 
videocapillaroscopy in healthy controls and participants with either type 1 or 2 diabetes mellitus, 
observed decreased capillary length, reduced and irregular capillary density and abnormal capillary 
morphology in the diabetic participants. Autonomic dysfunction is known to occur in T2D (198, 199), 
which results in increased neurogenic input to the vasculature and thereby an aberrant 
vasoconstrictive state, in addition to attenuation of insulin-mediated vasodilation. The result is a 
reduction in blood flow in key tissues such as skeletal muscle and thus an attenuation in skeletal 
muscle glucose uptake. Obesity and T2D are also commonly associated with increased cardiac output 
and respiratory rate due to pathological changes to the vasculature (200). Of particular interest in this 
thesis, is the observation of flowmotion dysfunction, altered contributions of the frequency 
components, in insulin resistance and T2D (reviewed in (10)). It is likely that in addition to the overall 
changes in vascular function seen in insulin resistance and T2D, changes to flowmotion may also be 
contributing to the metabolic dysfunction seen in these disease sates.  
 
The pathological changes that occur to the vasculature in T2D are extremely important in the 
progression of the disease over time and development of the adverse health outcomes associated 
with the disease such as retinopathy, neuropathy, nephropathy and increased risk of acute myocardial 
infarction and stroke (201). It is therefore important to minimise the progression of these 
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cardiovascular complications. While most of the anti-diabetic medications focus on increasing insulin 
production in the beta cells and insulin sensitivity in peripheral cells (202), improvements in 
cardiovascular function can be achieved through exercise intervention (203). Resistance training (RT) 
is one form of exercise that has been shown to improve several cardiovascular functions and risk 
factors including arterial stiffness (204), lipid profile (205), visceral adiposity (206), HbA1c control and 
insulin sensitivity (207). Importantly for the current studies, RT also improves endothelial function in 
both healthy (208, 209) and disease states (210, 211), in particular endothelial function has been 
shown to be improved with RT in T2D (212). The prevailing theory on how endothelial function is 
improved with RT is that with the continual enhanced shear stress placed on the endothelial cells 
during RT, NO-mediated vasodilation mechanisms are enhanced and the bioavailability of NO (213), 
through such mechanisms as upregulated eNOS expression (214) , is subsequently increased. The 
improvement of endothelial function with RT is of particular interest in the current thesis as little is 
known about the effect RT has upon microvascular flowmotion, and more particularly if it can be 
improved with training in type 2 diabetes. The improvement in endothelial function with RT in T2D 
may potentially also improve microvascular flowmotion. 
 
1.3.5 Flowmotion: Insulin-mediated changes and dysfunction in insulin resistance and T2D 
Alterations to flowmotion have been observed with the development of insulin resistance and T2D; 
shown in studies of acute vasoconstriction in in vivo rat skeletal muscle (57), as well as in skin+SC of 
obese (215, 216) and T2D (217, 218) populations. Investigation into flowmotion dysfunction in insulin 
resistance has primarily been determined with spectral analysis of skin+SC LDF measures and aberrant 
changes in a number of the different component frequencies have been observed. In a study by de 
Jongh et. al. (219) blood flow in the skin+SC was measured by LDF on healthy and obese female 
subjects, with and without the introduction of insulin through iontophoresis. Total LDF flux was 
assessed to determine blood flow and spectral analysis was performed on the LDF data to give a 
measure of flowmotion. Local administration of insulin to the skin+SC (iontophoresis) produced a 
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vasodilatory response in the healthy women, but not in the obese. In the basal state, flowmotion as a 
whole (the contribution of the total frequency spectrum) as well as the endothelial and neurogenic 
activity of flowmotion was lower in the obese subjects. The authors surmised that obesity involves an 
impaired microvascular vasodilatory effects and decrease in skin+SC microvasculature flowmotion. A 
study by Montero et. al. (216) comparing lean and severely obese adolescent participants, also using 
insulin iontophoresis and LDF flux measures, showed a reduction in insulin-induced myogenic activity 
in the obese individuals. The authors suggested dysfunction in the myogenic response to insulin may 
be an early step in the development of insulin resistance and T2D. Studies describing disruption of 
vascular smooth muscle Ca2+ release and signalling resulting from hyperglycaemia (220) and in an 
obese rat model (104) support the idea that the myogenic component of flowmotion (vasomotion) is 
disrupted in the development of T2D. Another study by Clough et. al. (215) measuring skin+SC 
flowmotion with LDF flux in participants with central obesity, showed an increased neurogenic input 
during a euglycemic hyperinsulinemic clamp as compared to previously reported healthy participants. 
Furthermore, an association study by de Boer et. al. (221) showed an inverse relationship between 
BMI and normalised neurogenic component of flowmotion. Additionally, the cardiac component of 
flowmotion was positively associated with BMI. These studies show a link between an obese state, 
which is known to be causative of insulin resistance, and changes in flowmotion patterns and 
contribution. The results are quite varied based on the technique and participant populations, 
highlighting the need for further study into the area to elucidate what changes in flowmotion may be 
occurring in different stages of disease progression.  
 
Flowmotion studies in patients with clinically diagnosed type 2 diabetics show similar dysfunction in 
flowmotion frequency components. Most studies in this area focus on patients with clinically 
diagnosed T2D at the later stages of disease progression when complications such as neuropathy and 
retinopathy have manifested. Studies by Sun et. al. (217, 218) investigating flowmotion dysfunction in 
T2D patients with various severity of neuropathy, show changes (decreased input) in the endothelial 
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and neurogenic components of flowmotion in the early stages of neuropathy development. The two 
studies indicate dysfunction in these frequency components may be causative of disease 
development. These studies measured skin+SC flowmotion with LDF flux on the foot of participants, 
but skin+SC LDF measures are not the only means to investigate changes in flowmotion that occur in 
T2D. A study by Bek et. al. (72) examined changes in retinal arteriole flowmotion over 180seconds by 
applying spectral analysis to video recordings of vasomotion activity in healthy controls and T2D with 
increasing severity of retinopathy. The study found a significant reduction in spontaneous high 
frequency oscillations (attributed to changes to cardiac function) and noted a reduction in overall 
frequencies with increasing severity of disease. Studying the changes in flowmotion at different stages 
of disease development, from insulin resistance through to severe microvascular disease state such 
as retinopathy, nephropathy and neuropathy, in a number of different tissue types may greatly 
enhance knowledge about how T2D develops and progresses over time.  
 
A key tissue in the development of T2D is skeletal muscle, but due to technique difficulties there are 
a limited number of studies on skeletal muscle flowmotion in insulin resistances states. A previous 
study by Newman et. al. (57) on flowmotion in anesthetised rat skeletal muscle during a 10mU/min/kg 
euglycemic hyperinsulinemic clamp found (using LDF wavelet transformation from an implanted 
probe) an increase in the myogenic component (vasomotion) of flowmotion. Newman et. al. (57) then 
induced an acute state of insulin resistance with the peripheral vasoconstrictor α-methylserotonin 
and found a reduction in insulin-mediated glucose uptake and blockade of the myogenic component 
of flowmotion. The authors suggested that insulin-mediated microvascular recruitment may in part 
involve action on the vasculature smooth muscle to increase vasomotion, thereby enhancing capillary 
perfusion and glucose uptake. A concept supported by the evidence for NO-dependent endothelial 
mediated control of vasomotion. 
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The numerous changes in overall flowmotion as well as input from the individual frequency 
components is widely reported in abhorrent disease states such as insulin resistance and T2D. These 
changes may contribute to the development of disease and advancement of adverse outcomes. 
However, the results are varied based upon the tissue type and technique used, highlighting a need 
to better define changes that occur over the progression of disease. Importantly, the actions of 
flowmotion in tissues such as skeletal muscle may play an important role in normal glucose 
metabolism and thus dysfunction could play a role in early disease progression. A study by de Boer et. 
al. (12) on healthy individuals concurrently measuring skin+SC microvascular flowmotion and capillary 
perfusion in the nailfold during a euglycemic hyperinsulinemia clamp, showed an increase in 
normalised neurogenic input was associated with increased capillary perfusion, with both increases 
also associated with enhanced glucose uptake. The study concluded that lower insulin-mediated 
capillary recruitment and glucose uptake was associated with a decreased in neurogenic input during 
infusion of physiological levels of insulin (1mU/kg/min clamp). This study thereby indicates the 
potential importance in insulin-mediated changes in flowmotion. However, as the study was 
performed in skin+SC and nailfold, thus the translation of these results to the more metabolically 
important tissue of skeletal muscle is yet to be investigated.  
 
1.4 Summary of study aims: characterisation of flowmotion 
As previously discussed, vasomotion and the other factors that influence flowmotion are thought to 
regulate blood flow distribution in skin+SC and skeletal muscle. Dysregulation of blood flow patterns 
is believed to contribute to the development T2D and the adverse health outcomes associated with 
this disease such as neuropathy, retinopathy and nephropathy. Further studies into the basic control 
of flowmotion, particularly by the lower frequency mediators (endothelial, neurogenic and myogenic), 
is still required to better understand its function. Developing understanding of insulin-mediated 
changes to flowmotion is of particular interest in this thesis. It is thought that insulin alters vasomotion 
in terminal arterioles to induce flow redistribution, between non-nutritive and nutritive flow routes. 
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A more in-depth understanding of how insulin mediates changes into microvascular distribution and 
how this may be altered in pathological states, such as insulin resistance and T2D, would give further 
insight into how changes in blood flow are able to regulate glucose metabolism in skeletal muscle.  
 
In the current study the techniques of LDF flux, tissue oxygenation and CEU were used to investigate 
flowmotion function both clinically, comparing healthy and type 2 diabetic participants, as well as in 
an in vivo anaesthetised rat model. The overarching hypothesis of this thesis is that flowmotion is 
important for normal metabolic activity in a tissue, and therefore as a corollary, that vascular 
dysfunction will lead to impaired flowmotion. In this thesis there are a number of sub-hypothesis and 
aims to address this overall idea of flowmotion.  
 
1.4.1 Clinical hypothesis and aims 
Cardiac, respiratory, autonomic and endothelial dysfunction often occur in people with T2D.  
Therefore, it is hypothesised that people with T2D will have identifiable changes in these components 
of flowmotion compared to healthy controls.  
 
Aim 1: To determine whether differences occur in skin+SC flowmotion at rest between healthy 
controls and type 2 diabetics. 
 
Insulin is a vasomodulator that acts on the endothelium and the sympathetic nervous system.  
Therefore, it is hypothesised that insulin modifies blood flow patterns by altering flowmotion, and this 
process is dysregulated during states of insulin resistance such as T2D.   
 
Aim 2: To determine whether skin+SC flowmotion increases in response to oral glucose 
challenge (OGC) in healthy controls and type 2 diabetics. 
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Resistance training (RT) can improve insulin sensitivity and glucoregulatory control in healthy and type 
2 diabetic individuals (222-224). Whether RT can alter flowmotion is unknown. It is hypothesised that 
a 6-week RT intervention will improve skin+SC flowmotion in people with T2D.  
 
Aim 3: To determine if a 6-week RT intervention in T2D group improves skin+SC flowmotion 
at rest or in response to an OGC. 
 
The majority of clinical studies investigating flowmotion changes in insulin resistance and T2D are 
performed using skin+SC flowmotion measures (for practical reasons). However, measuring skin blood 
flow may not be reflective of blood flow patterns in skeletal muscle.  It is hypothesised that skin+SC 
microvascular blood flow measures will reflect those of skeletal muscle blood flow.  
 
Aim 4: To determine whether skin+SC and skeletal muscle blood flow show the same response 
to an OGC. 
 
1.4.2 Animal studies hypothesis and aims 
Flowmotion in the skeletal muscle microvasculature plays a role in the regulation of glucose and 
insulin delivery to muscle myocytes and thus impacts upon muscle metabolism. However, techniques 
for measuring skeletal muscle flowmotion are limited. It is hypothesised that CEU can be used to 
detect changes in flowmotion in skeletal muscle. 
 
Aim 5: Adapt the CEU technique for the measurement of skeletal muscle flowmotion in an 
animal model.  
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Chapter 2 - General Methods 
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2.1 Clinical studies 
All studies were approved by the University of Tasmania ethics committee and comply with the 
Australian Code for the Responsible Conduct of Research 2013. Details of studies were outlined to 
each participant and informed consent was obtained before commencement of testing.  
 
2.1.1 Testing conditions 
All clinical studies were undertaken in the clinical rooms at the Menzies Institute for Medical Research. 
Rooms were maintained at an ambient temperature between 20 and 25°C. During testing participants 
lay semi-recumbent (at about 45°) on a bed, right arm was extended out from the body with ventral 
side of forearm facing upward. The arm was held in place with a table and pillow at approximately the 
same height as participant’s heart. Participants were asked to limit arm movement as much as possible 
throughout testing. 
 
2.1.2 Skin and subcutaneous tissue microvascular measures  
Skin+SC microvascular blood flow was measured with Moor Instruments (Devon, UK) CP1-1000 
combined high power LDF (fibre separation 0.5mm) and tissue oxygenation (fibre separation 1mm, 
which indicates the depth of penetration into tissue) probe, which measures skin+SC LDF flux, oxygen 
saturation (O2 Sat), total haemoglobin (tHb) and skin temperature (LDF + OXY probe). The LDF 
component of the probe emits a laser light at a 785 ± 10nm wavelength which penetrates into the 
tissue and interacts with red blood cells in the section of tissue illuminated by the laser. The scattered 
and reflected light is then collected by optic fibres on the probe which then provides a perfusion flux 
value, indicating the number and velocity of red blood cells (Doppler shift) in the section illuminated 
by the laser light. Modern high power LDF probes have enhanced penetration of light into the tissue 
and are therefore able to measure both skin and subcutaneous blood flow. A variation in volume of 
skin and subcutaneous tissue between different individuals could potentially influence the LDF + OXY 
measurements of microvascular blood flow as the different tissue type may have different capillary 
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densities and blood flow controls. Potentially, to account for this variation, measurements of 
subcutaneous tissue volume at the site of LDF + OXY blood flow measurements could be performed 
and data corrected for any variation between participants. LDF is unable to measure blood flow in 
absolute perfusion values. As such, the output is LDF flux over time given as perfusion units (PU), an 
arbitrary measure, as demonstrated in Figure 2.1. The tissue oxygenation component of the probe 
uses white light spectroscopy to determine tissues O2 Sat and tHb concentrations in real time at the 
same site as the LDF (tissues separation 1mm). O2 Sat output is in percentage (%) and tHb as arbitrary 
units (AU) over time (Figure 2.1). The compound signals of O2 Sat and tHb were chosen as blood flow 
measures over oxy and deoxy signals as they each provide additional information useful to the aims 
of this thesis. O2 Sat also provides a measure of the metabolism occurring within the tissue, while tHb 
is a measure of blood volume which can then be linked to the CEU measure also taken throughout this 
thesis. Data were continuously recorded at a sampling rate of 40Hz and interfaced with Moor 
Instruments software (moorVMS-PC V3.1, Moor Instruments, Devon, United Kingdom). A frequency 
of 40Hz which, samples data at every 0.025second, was chosen as it was the default setting of the 
Moor Instruments equipment and was adequate to sufficiently sample the higher frequency 
flowmotion components which occur at a rate of 0.6-2.5 seconds. 
 
Figure 2.1: Typical LDF output. High power LDF probes (as recorded by Moor instruments software) 
typical output of LDF + OXY probe LDF flux (perfusion units, upper panel), O2 Sat (percentage, upper 
middle panel), tHb (arbitrary units, lower middle panel) and temperature (degrees Celsius, lower 
panel). 
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On the forearm of each participant, the distance between cubital fossa and wrist joint was measured 
and midpoint marked. The LDF + OXY probe was placed on the forearm (volar surface) at the midway 
point avoiding any obvious veins on the skin, as demonstrated in Figure 2.2. Care must be taken while 
performing LDF measurements as the probes are sensitive to movement artifacts and should not be 
moved throughout testing. An additional limitation of LDF and tissue oxygenation measures in the 
skin+SC is the reproducibility of results over different days of testing as microvascular structure in the 
skin+SC varies significantly at different sites of the tissue. To minimize the impact of this on the data 
care was taken in the positioning of probes during testing, with probes placed at specific sites in the 
forearm and the avoidance of probe placement over large vessels. 
 
 
Figure 2.2: LDF probe placement of participant forearm. Distance between cubital fossa and wrist joint 
measured and midpoint marked. LDF + OXY probe placed at midpoint of forearm, avoiding any obvious 
veins in skin. 
 
 
2.1.3 Skeletal muscle microvascular perfusion 
CEU was used to determine the microvascular perfusion in forearm skeletal muscle. A linear-array L9-
3 ultrasound transducer was placed over the right deep flexor muscle of the forearm. The acoustic 
power of ultrasound, the mechanical index ([peak acoustic pressure] x [frequency]-1/2), was set to 0.10 
and gain settings optimised and held constant. The transducer was interfaced with an ultrasound 
system (iU22, Phillips Medical Systems, Andover, MA) on which CEU measures were taken. Contrast 
agent, gas filled phospholipid microbubbles (DEFINITY® Perflutren Lipid Microsphere, Lantheus 
LDF + OXY 
probe 
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Medical Imaging, MA, USA) were diluted (1.5mL added to 30mL saline) and continuously infused 
intravenously at 0.03mL/min/kg body weight throughout skeletal muscle blood volume 
measurements. Microbubbles are continually infused at the same rate to produce a constant 
concentration of the contrast agent in the blood, which is very important to accurately measure blood 
volume. Therefore, before each skeletal muscle CEU measure the consistency of blood microbubble 
concentration was established by measuring in triplicate, the AI in the brachial artery of participants. 
Microbubbles are echogenic and thus create acoustic signal by expanding and compressing in 
response to the ultrasound pressure waves. When microbubbles move into the imaged region they 
interact with the ultrasound output to create an acoustic intensity (AI) which can be recorded by the 
ultrasound system. As microbubbles concentration is constant in the blood, the AI signal created can 
be related to blood volume in the imaged region. The use of CEU to measure skeletal muscle 
microvascular perfusion is quite sensitive, but can be limited its reproducibility over different time 
points. The ultrasound probe needs to be placed in the same position when comparison of skeletal 
muscle microvascular perfusion is being made over different times points. To minimise the impact of 
this limitation on the current study highly trained individuals performed the CEU measures and used 
land marks such as veins to correctly position the ultrasound probe over the same section of muscle 
tissue for each measurement.  
 
Microvascular perfusion was determined by destroying microbubbles in the imaged region with a high 
energy ultrasound pulse (mechanical index set at 1.15) and then recording the replenishment of 
microbubbles into the skeletal muscle tissue over 45 seconds. CEU data were analysed using Qlab 
advanced quantification software (Philips Medical Systems, Eindhoven, The Netherlands). Refilling 
measures were taken in triplicate and then averaged, with the signal from the larger vessels and 
background subtracted (1 second). Microvascular refilling curve was created by plotting time 
(seconds) verses AI, giving an exponential rise to maximum plot (Figure 2.3). Microvascular volume (A) 
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and microvascular filling rate (β) where determined from the graph via SigmaPlot graphing software 
(Systat Software Inc., CA, USA) with the equation: 
 
Y = A(1-e-β(x(t)-bkg(t)))  
Where: 
 Y = Acoustic intensity  
 X = time (seconds)  
A = Acoustic intensity at the plateau position (an indicator of microvascular volume) 
 β = Rate constant which provides a measure of the microvascular filling rate  
 bkg = time of background image  
 
Microvascular blood flow is indicated by multiplying A and β values.  
 
 
 
 
 
 
 
 
 
Figure 2.3: Microvascular volume and filling rate calculation. Plot was constructed after high energy 
ultrasound pules destroyed microbubbles in imaged region at t=0. Microvascular volume is indicated 
by the plateau position (A), and the rate of microvascular refilling is indicated but the rate of increase 
(β). Microvascular perfusion is calculation by Axβ. 
 
2.1.4 Brachial artery blood flow 
Brachial artery blood flow measures were made using a high frequency L12-5 linear array ultrasound 
transducer (iU22 ultrasound, Philips Medical Systems, Andover, MA) placed ~ 10cm proximal to the 
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antecubital fold. The diameter of the brachial artery was measured to determine the distance 
between the upper and lower inner edge of arterial intima. Measurements of the brachial artery 
diameter were performed manually by trained technician in triplicate using 2-D imaging of the artery 
at one-time point during both rest and treatment. The manual nature of this measurement does 
introduce a margin for error, to minimise the impact of this all measurements were performed by 
the same individual. Pulse-wave Doppler was used to determine the velocity of blood flow in the 
brachial artery. Brachial artery blood flow (BBF) was then calculated from the diameter and velocity 
measures: 
BBF (mL/min) = π x (½ x diameter)2 x velocity x 60 
 Where diameter is in cm and velocity is in cm/sec. 
 
2.1.5 Blood pressure  
Resting systolic and diastolic brachial blood pressure (BP) measures were taken in triplicate with a 
Mobil-O-Graph monitor (I.E.M. Stolberg, Germany) while participants lay semi-recumbent on a bed. 
The Mobil-O-Graph monitor is a highly sensitive and reproducible method for measuring brachial 
blood pressure.  
  
2.1.6 Blood analysis 
Fasting blood was collected by a trained phlebotomist and blood chemistries (HbA1c, cholesterol, high 
density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), and triglycerides) 
determined at a nationally accredited pathology laboratory (Royal Hobart Hospital, TAS). Blood 
glucose measures taken throughout the protocol were determined using a bench top glucose analyser 
(YSI Model 2300 Stat plus, Yellow Springs Instruments, OH). Plasma insulin concentrations were 
determined by ELISA (Mercodia AB, Uppsala, Sweden). These blood analysis techniques are 
considered highly sensitive and reproducible when performed by trained individuals, as is the case in 
these studies.  
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2.1.7 Body composition  
To determine percentage body fat and percentage lean muscle mass participants underwent a whole-
body scan by dual-energy X-ray absorptiometry (DEXA; Hologic Delphi densitometer, Hologic, 
Waltham, USA). Each parameter was calculated as previously reported (225). DEXA is considered the 
gold standard measure of body composition.  
 
 
2.1.8 Analysis 
 
2.1.8.1 Microvascular blood flow averages 
All data are expressed in a scatter graph or as mean ± SE. For high power LDF + OXY probe 10 minute 
averages of skin+SC microvascular blood flow measures (LDF flux, O2 Sat and tHb) and skin 
temperature were determined using Moor Instruments software (moorVMS-PC V3.1, Devon, UK).  
 
2.1.8.2 Complexity 
Complexity analysis is a means of assessing the randomness of a recorded signal, the more random 
the collected data is (less regular reoccurring patterns within a signal) the higher the complexity value 
will be. It is hypothesised that in healthy individuals there is a high level of randomness in 
microvascular blood flow patterns and that with increasing severity of diseases such as T2D the 
randomness of blood flow patterns is reduced (226). Complexity analysis could therefore possibly be 
used to identify dysregulation of microvascular blood flow in T2D, when compared to healthy control 
data. MATLAB program (MathWorks, Natick, MA, USA) was used to perform Lempel-Ziv (LZ) 
complexity measurements (226, 227) on skin+SC microvascular blood flow measures. Briefly, the LZ 
complexity analysis technique determines the average value of a data set and then for each individual 
data point assigns a 0 if the data point is below or equal to the mean value, or a 1 if data point is above 
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mean value. The resulting output of numbers (e.g. 11000110101010…. etc.) is then analysed and 
reoccurring patterns in the signal determined. If there are large numbers of reoccurring patterns the 
resulting complexity value will be low, if there are only small numbers of reoccurring patterns within 
the signal the complexity value will be higher. Complexity determination is limited by the amount of 
random noise in the signal, depending upon the period of time analysed, the complexity value maxes 
out at a particular point. LZ complexity analysis was performed in MATLAB on 10 x 1min of high power 
LDF, O2 Sat and tHb (exported from Moor Instruments software). The complexity value of each of the 
10 x 1min data sections was averaged to give an overall complexity value for each blood flow measure. 
For 1min complexity analysis, the complexity value maxes out due to random noise in the signal at a 
value of 224.  
MATLAB script for complexity analysis: 
%%Enter data frequency and EPOH time 
a = 40; 
b = 60; 
c=a*b; 
  
%generate LZcomplex number for probe1 basal data1 and for EPOHs 
LZBP1a=lzcomplex(data1(1:c,2)); 
LZBP1b=lzcomplex(data1(c+1:2*c,2)); 
LZBP1c=lzcomplex(data1(2*c+1:3*c,2)); 
LZBP1d=lzcomplex(data1(3*c+1:4*c,2)); 
LZBP1e=lzcomplex(data1(4*c+1:5*c,2)); 
LZBP1f=lzcomplex(data1(5*c+1:6*c,2)); 
LZBP1g=lzcomplex(data1(6*c+1:7*c,2)); 
LZBP1h=lzcomplex(data1(7*c+1:8*c,2)); 
LZBP1i=lzcomplex(data1(8*c+1:9*c,2)); 
LZBP1j=lzcomplex(data1(9*c+1:10*c,2)); 
  
EPOH=[ 1; 2; 3; 4; 5; 6; 7; 8; 9; 10]; 
complexity=[LZBP1a;LZBP1b;LZBP1c;LZBP1d;LZBP1e;LZBP1f;LZBP1g;LZBP1h;LZBP1i; LZBP1j]; 
xls1=[EPOH,complexity]; 
[filename,pathname]=uiputfile('*.xls','give name to save file'); 
filenameinclpath=[pathname,filename]; 
s=xlswrite(filenameinclpath,xls1,'a1:b11'); 
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2.1.8.3 Flowmotion 
Wavelet transformation analysis was performed on all microvascular blood flow measures to assess 
skin+SC flowmotion patterns. LDF flux, O2 Sat and tHb measures were exported from Moor 
instruments software. MATLAB program (MathWorks, Natick, MA, USA) was used to perform wavelet 
transformation. Prior to wavelet transformation, average value of data set was determined and then 
subtracted from each data point as a means of controlling for data variation and optimising the 
wavelet transformation analysis by removing edge effects. 8:1 cmor morlet wavelet was used in 
wavelet transformation analysis of clinical data. 
 
Plotting wavelet transformation of blood flow data against frequency provides a picture of overall 
flowmotion pattern occurring in tissue. However, to determine any differences in frequency 
component contribution between treatments and disease states the data must be quantified. 
Previously in the literature the contribution of each frequency component has been quantified by 
determining the mean wavelet transformation value over each frequency range, which is then 
normalised by dividing the mean of the entire frequency range assessed (55).  Initially this technique 
was employed to the current data set, but proved to be problematic the as some of the sensitivity of 
the wavelet transformation analysis was lost through the averaging across the whole frequency 
region. The difference is baseline values between participants was an additional concern. It is the 
peaks in the wavelet transformation analysis that are of particular interest in this thesis as it is believed 
that the sum of these provided information about the contribution of each different frequency 
component to flowmotion. To better measure the contribution of each component to flowmotion and 
overcome the impact of varied baseline values, the area under the curve (AUC) of all the peaks in a 
frequency range was determined and summed together. Separate to the contribution of each 
component to flowmotion, the most prominent frequency at which each component exerted 
influence over flowmotion was also of interest. This was measured by determining the frequency at 
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which the highest peak in each region (i.e. the most prominent signal) occurred at. AUC of peaks and 
peak frequency was calculated using PeakFit software (Systat Software Inc. CA, USA).  
 
Each wavelet transformation from LDF flux, O2 Sat and tHb measures was individually uploaded into 
PeakFit software on a linear scale and the best baseline for graph selected (Figure 2.4A). The linear 
data points were used to distinguish peaks in different frequency components. The highest peak in 
each region was determine and then referenced back to the corresponding frequency at which it 
occurred (Figure 2.4B). The AUC of peaks in each region were then determined by the software, if 
multiple peaks were present in frequency range the AUC of all peaks was summed (Figure 2.4C).  
 
LDF flux wavelet transformation measures adequately detected all five frequency components 
(endothelial, neurogenic, myogenic, respiratory and cardiac), but tissue oxygenation measures were 
only able to adequately detect the three lower frequency components (endothelial, neurogenic and 
myogenic). AUC and peak frequencies for O2 Sat and tHb were therefore only determined for lower 
frequency components.  
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Figure 2.4: Typical PeakFit analysis output. Wavelet transformation data is uploaded into PeakFit 
software on linear scale and the A) best baseline is selected B) peaks in each frequency region are 
identified by position and then C) AUC for each peak is determined by software and recorded.  
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2.2 Laboratory experiments  
 
2.2.1 Animal care 
Male Sprague Dawley rats (288g ± 8) reared and housed in the University of Tasmania animal facilities 
were used for all experiments. Animals were maintained at 21-22˚C and kept in a 12hr dark/light 
schedule. Animals were given access to water and commercial diet (4.8% lipid, 19.4 % protein, 70.7% 
carbohydrate, 5.1% crude fibre with added vitamins and minerals, Specialty Feeds, Glen Forest, WA, 
Australia) ad libitum up to the morning of experiments. All procedures and experiments were 
approved by the University of Tasmania Animal Ethics Committee in accordance with the 2013 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (#A13384). 
 
2.2.2 In vivo protocol 
 
2.2.2.1 Surgery 
On the morning of the experiment rats were anaesthetised with an intraperitoneal injection of sodium 
pentobarbital (50mg/100g body weight) prior to surgery. Once animals were non-responsive, a 
tracheotomy was performed to allow for spontaneous breathing throughout experiment. Both jugular 
veins and a carotid artery were cannulated with polyethylene tubing (Figure 2.5). The left jugular vein 
was cannulated (PE60 Intramedic®) to allow for continuous anaesthetic infusion (~0.6mg/min/kg 
sodium pentobarbital, maintaining anaesthesia) and delivery of intravenous solutions. The right 
jugular was cannulated (PE40 Intramedic®) to allow intravenous infusion of microbubbles (ultrasound 
contrast agent). Cannula inserted into the carotid artery (PE60 Intramedic®) was used to continuously 
determine animals mean arterial pressure (MAP) and heart rate (HR) via a pressure transducer 
(Transpac IV, Abbott Critical Systems, Morgan Hill, CA USA) and for arterial blood sampling. All 
cannulas were secured with size 3/0 waxed braided silk ligatures. Continuous monitoring of total blood 
flow to the rat hindlimb was achieved by an ultrasonic flow probe (Transonic Systems™, VB series 
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0.5mm, Ithaca, NY, USA) placed around the femoral artery in a position distal to the rectus abdominal 
muscle. To allow flow probe placement, ~1cm section of skin was removed from the region above the 
femoral artery and vein, the epididymal fat pad separated, epigastric artery ligated and artery 
separated from femoral vein and saphenous nerve. The flow probe and pressure transducer were 
interfaced with an IBM compatible PC computer. The computer acquired data at a sampling frequency 
of 100 Hz for femoral blood flow (FBF), HR and MAP using WINDAQ data acquisition software (DATAQ 
instruments, Akron, OH USA). 
 
 
Figure 2.5: Schematic diagram of the in vivo surgery. Surgery details are given in section 2.1.2.1. The 
above picture illustrates the ventral view of the rat after surgery. A tracheotomy tube was inserted to 
allow spontaneous breathing of room air. The cannulation of both jugular veins (used for intravenous 
infusion) and right carotid artery (used for continued measurement of MAP and HR as well as arterial 
blood sampling) is shown. Transonic™ flow probes which allow continual FBF measurements were 
placed around right femoral artery. Diagram adapted from Mahajan et al (228). 
 
Tracheotomy (spontaneous breathing) 
Jugular vein cannulated  
(microbubble infusion) 
Jugular vein cannulated (intravenous infusion)  
Carotid artery cannulated 
 (HR, MAP + arterial sampling) 
Transonic flow probe 
(femoral blood flow) 
femoral artery 
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2.2.2.2 Laser Doppler Flowmetry 
Microvascular blood flow of the rat tibialis anterior muscle was determined using LDF flux and tissue 
oxygenation measures. A small section of skin (~0.5cm) was removed from above the upper section 
of the left tibialis anterior muscle, exposing the muscle and a small layer of connective tissue. The CP3-
500 is a combined laser Doppler and tissue oxygenation probe (LDF + OXY, Moor Instruments, Devon, 
UK, tissues separation 0.5mm) was placed directly onto the surface of the exposed muscle (Figure 2.7) 
and data collected at a frequency of 40Hz using Moor Instruments recording software (moorVMS-PC 
V3.1, Devon, UK) as demonstrated in Figure 2.6.  
 
 
Figure 2.6: Typical CP3-500 probe output. LDF flux (perfusion units, upper panel), O2 Sat (percentage, 
middle panel), tHb (arbitrary units, lower panel) over time is demonstrated. 
 
 
2.2.2.3 Contrast enhanced ultrasound 
Microvascular blood flow in the rat calf (soleus, plantaris, and red, white and mixed gastrocnemius 
muscles) and upper thigh (biceps femoris anterior and posterior, adductor magnus and brevis, 
semimembranosus red and white, and semitendinosus) was assessed using the CEU technique. A 
50 
 
linear-array L9-3 ultrasound transducer was placed over the rat left calf or upper thigh, with 
ultrasound conductive gel (Conductive Gel, Medical Equipment Services Pty Ltd, Melbourne, AUS) 
between probe and hindlimb to allow for imaging (Figure 2.7). The transducer was interfaced with the 
iU22 ultrasound system on which CEU measures were taken (Figure 2.7).  
 
 
 
Figure 2.7: Schematic diagram of probe placements. As describe in sections 2.1.2.2 and 2.1.2.3, skin 
above left tibialis anterior muscle was removed and CP3-500 probe place directly onto muscle tissue. 
L9-3 ultrasound probe was placed over the rat left calf muscle to image soleus, plantaris and white, 
red and mixed gastrocnemius. 
 
 
The contrast agent, gas filled phospholipid microbubbles, were continuously infused intravenously via 
the right jugular vein (approximately 2.14x106 microbubbles/min), allowing steady state 
concentration to be reach in the blood. The mechanical index was set to 0.08 and the gain settings 
optimised for each individual experiment (2D 87-89%, C 30, P off). An example of ultrasound images 
on the rat calf with and without microbubbles, as well as an overlay of muscle positioning is 
demonstrated in Figure 2.8.  
 
Ultrasound probe (L9-3) 
CP3 LDF + OXY probe 
(Moor Instruments) 
Calf 
Tibialis anterior 
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Figure 2.8: CEU images of rat calf. A) Ultrasound image of the rat calf with B) an overlay of muscle 
positioning based upon R. Armstrong and M. Laughlin 1984 description (229). Abbreviations: s., soleus; 
pl., plantaris; gr., gastrocnemius red; gm., gastrocnemius mixed; gastrocnemius white. C) CEU image 
with contrast agent in rat calf muscle. 
 
 
CEU data were analysed using Qlab advanced quantification software, which allows for selection of 
many different regions of interest (ROI). CEU was used to asses both flowmotion changes and 
microvascular perfusion during different treatments. To assess changes in skeletal muscle flowmotion, 
recording of CEU images was triggered for ever 50ms (frequency of 20Hz) and continuously collected 
for 30min under the different treatment conditions. The sampling frequency of 20Hz is utilised in these 
experiments due to the limitations of the iU22 ultrasound system. A frequency of 20Hz allows 
sampling of data every 0.05 seconds. Sampling at 20Hz is therefore is considered appropriate for the 
collection of blood flow for the analysis of flowmotion via wavelet transformation as the highest 
frequency component (cardiac) occurs and a rate of 0.6-2.5 seconds. Microvascular perfusion was 
determined at the end of each treatment period using the same technique described in section 2.1.3. 
Microbubbles in the imaged region are destroyed and the replenishment over 45sec, which was 
recorded and fitted to an exponential rise to maximum plot, from which microvascular volume, filling 
rate and perfusion were determined.  
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2.2.3 Haemodynamic and LDF data analysis 
All data are expressed as mean ± SEM. Five second sub-sample of WINDAQ data were used to calculate 
MAP (mmHg), HR (bpm) and FBF (mL/min) at various time points. Over the course of the entire 
experiment, 5min averages of LDF flux, O2 Sat and tHb were determined using Moor Instruments 
software (moorVMS-PC V3.1, Devon, UK).  
 
2.2.4 CEU and LDF flowmotion analysis 
CEU (20Hz) and LDF + OXY (40Hz) data (30min, collected at the same time points) were exported from 
Qlab and Moor instruments software respectively. MATLAB program (MathWorks, Natick, MA, USA) 
was used to perform wavelet transformation. Prior to wavelet transformation, average value of data 
set was determined and then subtracted from each data point as a means of optimising the wavelet 
transformation analysis and removing edge effects. Different to the clinical data, a 2:1 cmor morlet 
wavelet was used in wavelet transformation analysis of animal data. The change from 8:1 to 2:1 cmor 
morlet in the analysis of animal blood flow data is due to the difference in quality of the data in each 
study. 8:1 cmor morlet was used to analyse the clinical data as a higher ratio produces more distinctive 
peaks, this was necessary for the clinical data as it was less controlled than in the laboratory setting 
and therefore contained greater random signal. In the laboratory experiments the animals were 
anesthetised and measures taken to minimise external influences on data collection, thereby there 
was no need to alter the morlet parameters as peaks in each region were already well defined at a 
lower ratio.  
 
As with clinical data (described in section 2.1.2.3) comparison of each frequency range contribution 
to flowmotion between treatment or control groups was determined by comparing the AUC of peaks 
in each frequency range. AUC of peaks and the frequency at which the highest peak in each frequency 
range was calculated using PeakFit software (Systat Software Inc. CA, USA). Analysis using PeakFit for 
animal data varied slightly from clinical (section 2.1.2.3) as respiratory and cardiac input occur at 
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higher frequency to humans and therefore data input to PeakFit program was on a different linear 
scale. Each wavelet transformation was individually loaded into PeakFit software and the best baseline 
for graph selected, AUC of peaks in each region were then determined by the software, if multiple 
peaks were present in frequency rage the AUC was summed.   
54 
 
2.3 Summary of blood flow measures  
 
 Table 2.1: Summary of blood flow measures and implications of this on flowmotion analysis. 
 
 
 
 
 
2.4 Statistical analysis 
All tests were performed using SigmaStat software (Systat Software Inc. CA, USA). The tests performed 
are outlined in each individual chapter. For each data set normality (Shapiro-Wilk) was assessed in 
SigmaPlot, and a suitable test selected if data was parametric or non- parametric. Significance was 
assumed at p < 0.05 and was assessed using Student’s t-test when there were two groups and Student-
Newman-Keuls post hoc test for multiple groups. 
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Chapter 3 - Microvascular flowmotion 
in the skin and subcutaneous tissue: 
healthy control versus T2D 
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3.1 Introduction 
The vascular system is an integral component of normal cellular function, providing a means of 
nutrient delivery and waste removal from the cells. It thereby allows the maintenance of homeostasis 
during rest and periods of increased metabolic demand (1). Disruption of normal vascular function can 
contribute to pathological disease states such as T2D (191). Insulin resistance alters vessel function 
and blood flow early on in T2D development, via the attenuation of endothelial derived insulin-
mediated vasodilation (endothelial insulin resistance). This aberrant change in insulin-mediated 
vasodilation is of particular importance in skeletal muscle (230) as it results in reduction in insulin-
mediated blood flow directly to the myocytes and thus an attenuation of skeletal muscle glucose 
uptake (168). Endothelial insulin resistance is therefore, in part, causative of the characteristic high 
blood glucose levels seen in T2D. As the disease progresses, T2D results in direct damage to the 
vasculature as glucose is a highly reactive molecule. Glucose binds to proteins on vessels to form 
advanced glycation end-product, which disrupts normal structure and therefore function (231, 232). 
The chronic pathological levels of blood glucose in T2D thus result in damage to both the 
macrovasculature and the microvasculature, and are causative of the long term adverse health 
outcomes of T2D such as cardiovascular disease, nephropathy, neuropathy and retinopathy (233). 
Disruption of normal microvascular function in T2D, through endothelial insulin resistance and glucose 
induced vessel damage, is therefore involved in both the early development of the disease and the 
development of the serious adverse health outcomes. To investigate the changes in blood flow that 
occur in T2D in both skin+SC and the more metabolically important tissue skeletal muscle, skin+SC LDF 
+ OXY and skeletal muscle CEU measures were taken. 
 
Pathological changes in vascular function could be mediated by changes in blood flow patterns and 
distribution. Investigating flowmotion and determining whether any or all of the controlling influences 
(endothelial, neurogenic, myogenic, respiratory and cardiac) are altered in T2D is important in 
understanding the pathogenesis of the disease (72, 217, 218). Developing our understanding of the 
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affected components may also provide potential treatment targets to improve the function of the 
microvascular blood flow, thereby improving the long-term health outcomes of patients.  
 
LDF is the most commonly used technique to measure flowmotion in humans. High power LDF probes 
are used to measure blood flow from the skin and underlying subcutaneous tissue (skin+SC). Tissue 
oxygenation measures are also becoming more frequently used to determine human skin+SC blood 
flow. Spectral analysis such as wavelet transformation can be applied to skin+SC LDF flux, O2 Sat and 
tHb data for the assessment of flowmotion. Determination of the contribution of each individual 
frequency component to flowmotion and the peak frequency at which the component is exerting 
influence, can give an extensive insight to blood flow patterns and help to identify areas of 
dysregulation.  
 
Wavelet transformation does however require larger data sampling times (a minimum of 20min) as 
the lower frequency components, such as the endothelial, occur at slower rates of one cycle every 50-
105sec (55, 56). Thus to ensure there are sufficient cycles measured, longer sample times are required. 
This imparts some practical limitations on data collection, which may be overcome by using complexity 
analysis, an assessment of the randomness of a signal, which only requires shorter sampling periods. 
While complexity analysis does not give a measure of the differing contribution of each frequency 
component within flowmotion, it will give an indication of how random the LDF signal is, with a more 
random signal indicating less regular control of blood flow, which is believed to be a healthy state. The 
more random the signal, the higher the complexity output. The use of complexity analysis on skin+SC 
LDF flux and tissue oxygenation measures could indicate if flowmotion dysfunction (i.e. decreased 
complexity) is occurring within an individual, giving an overall indication of vascular function. It has 
previously been shown in monkeys that the randomness of skin+SC LDF flux measures decreases with 
advancing insulin resistance and T2D (226). The use of this analysis technique may therefore offer a 
more practical means of assessing microvascular function in human participants.  
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The aim of this study was to determine if forearm blood flow distribution and microvascular 
flowmotion in skin+SC is altered in T2D participants. Forearm total blood flow, average skin+SC flux 
and skeletal muscle microvascular perfusion were measured to determine the distribution of blood 
flow within the forearm. Wavelet transformation of skin+SC LDF flux, O2 Sat and tHb measures were 
used to identify changes in any of the five controlling components of flowmotion, while complexity 
analysis was performed to determine if this more simplistic mathematical analysis could be used to 
detect microvascular dysfunction.  
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3.2 Methods 
This study was approved by the University of Tasmania Human Research Ethics Committee (#H14086) 
and conducted at the Menzies Institute for Medical Research. Through community advertisement, 23 
healthy controls and 18 sedentary (self-reported <30min of moderate exercise per week) clinically 
diagnosed type 2 diabetics were recruited for the study. Inclusion criteria for the study were 
participants aged between 18-60 years who were normal to overweight (BMI = 19 – 35 kg/m2). 
Exclusion criteria for study was a BMI>35 kg/m2, a history of smoking, cardiovascular disease, stroke, 
myocardial infarction, uncontrolled hypertension (resting brachial blood pressure >160/100mmHg), 
peripheral arterial disease, pulmonary disease, arthritis/muscular skeletal disease, malignancy within 
past 5 years or severe liver disease.  
 
3.2.1 Screening visit  
Eligibility for the study was determined at an onsite screening visit after first giving informed consent. 
Participants provided a detailed medical background. Anthropometric measures (height and weight) 
as well as resting blood pressure were taken on the day in the clinical setting. Body composition was 
determined using DEXA whole body scan as described in section 2.1.7. 
 
3.2.2 Clinic visit 
Participants presented to the clinic on the morning of testing overnight fasted and having refrained 
from alcohol and vigorous exercise for 48 hours prior. Type 2 diabetics ceased diabetes medications 
for 48 hrs prior to testing, which is standard practice and allows for accurate assessment of severity 
of insulin resistance. All other medication i.e. hypertension was taken as usual. Testing conditions 
were as described in section 2.1.1, with measures taken at ambient temperature (20-25°C) and 
participants laying semi-recumbent on a bed. The right arm was extended out from the body with the 
ventral side of forearm facing upward. All measures were taken under resting and fasted conditions, 
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after an initial period of equilibration (~20min).  Due to experimental issues and loss of data some 
data points are missing for various measure for some participants.  
 
 
Figure 3.1: Study protocol. All measures were taken under basal (resting) conditions. Skin+SC LDF flux 
and tissue oxygenation (LDF + OXY) was measured from 0 to 20mins. Resting BP was then repeatedly 
measured over 10min time period while brachial blood flow (BBF) was concurrently measured using 
ultrasound. The antecubital vein of the non-dominant arm was cannulated and a fasting blood sample 
was acquired at 40mins. Forearm skeletal muscle microvascular perfusion was then assessed from 30-
40mins using contrast enhanced ultrasound (CEU).  
 
 
3.2.2.1 Skin and subcutaneous tissue microvascular blood flow 
The LDF + OXY probe (described in section 2.1.2) was attached to the midsection of the ventral side of 
the right forearm. Skin+SC microvascular blood flow was assessed with LDF flux and tissue oxygenation 
measures over a 20min period (Figure 3.1).   
 
3.2.2.2 Total forearm blood flow 
Brachial artery blood flow at rest was determined as a measure of forearm total flow (figure 3.1). As 
describe in section 2.1.4, a L12-5 linear array ultrasound transducer was used to measure brachial 
artery diameter and then blood velocity. Brachial blood flow (BBF) is then calculated from velocity and 
diameter measures (BBF mL/min = π x (½ x diameter)2 x velocity x 60). Where diameter is in cm, and 
velocity is in cm/sec. 
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3.2.2.3 Forearm skeletal muscle microvascular perfusion 
Microvascular blood volume, filling rate and perfusion of forearm deep flexor muscle was determined 
as described in section 2.1.3. CEU measures of skeletal muscle microvascular blood flow were taken 
using a linear-array L9-3 ultrasound transducer while contrast agent (phospholipid microbubbles) 
were constantly infused. Microbubbles within the region under the ultrasound beam were destroyed 
and the replenishment of microbubbles back into the tissue was recorded over 45 seconds to 
determine microvascular perfusion measures (Figure 3.1). For a number of participants, CEU skeletal 
muscle microvascular perfusion measures were lost or not recorded correctly. As such participant 
numbers for forearm muscle blood flow are lower than other measures. 
 
3.2.2.4 Blood pressure and heart rate 
Resting systolic and diastolic blood pressure and heart rate measures were repeatedly taken over a 
10min time period with a Mobil-O-Graph monitor as described in section 2.1.5 (Figure 3.1). Vascular 
resistance was calculated from MAP and BBF to give an indication of vasodilatory state.  
Vascular resistance = MAP (mmHg)/BBF (min/mL)  
 
3.2.2.5 Blood analysis  
Fasting blood samples were taken from an antecubital vein of the non-dominant arm and analysed for 
fasting blood glucose, fasting plasma insulin, HbA1c and lipid profile as described in section 2.1.6. 
 
 
3.2.3 Data analysis 
  
3.2.3.1 Microvascular blood flow averages 
The mean LDF flux and tissue oxygenation measures were determined over a 10min period as 
described in section 2.1.8.1. 
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3.2.3.2 Complexity measures 
Mean complexity measures over the same 10min time period as average LDF flux and tissue 
oxygenation measures was calculated as described in section 2.1.8.2. 
 
3.2.3.3 Flowmotion measures 
Flowmotion analysis using wavelet transformation was performed on 20min of resting LDF flux and 
tissue oxygenation measures. Wavelet transformation data were then quantified by determining AUC 
of peaks within each flowmotion component and peak frequency, as described in section 2.1.8.3. 
 
3.2.4 Statistical analysis 
For all anthropometric, blood chemistry, blood flow and flowmotion measures, unpaired Student’s t-
tests were performed to determine differences between healthy controls and T2D, as described in 
section 2.1.9.  
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3.3 Results 
 
3.3.1 Participant characteristics  
Populations similar in age and gender were recruited to allow comparison between healthy controls 
and clinically diagnosed type 2 diabetics (Table 3.1). While on average the type 2 diabetics were five 
years older than healthy controls, this was not statistically different (p = 0.379). Likewise, the male to 
female ratio was similar between the two populations with 35% females in healthy controls and 33% 
in T2D group. 
 
Several anthropometric and blood chemistry analyses were performed (Table 3.1). Body weight (p = 
0.001), percentage body fat (p = 0.025) and BMI (p < 0.001) were all significantly higher in T2D group 
as compared to the healthy controls. Systolic blood pressure was significantly elevated (10.9mmHg 
difference) in type 2 diabetics (p = 0.018). There was no difference in the vascular resistance between 
healthy controls and T2D at rest.  T2D participants also displayed significantly higher fasting (p < 0.001) 
blood glucose, HbA1c (p < 0.001) and fasting plasma insulin (p < 0.001), as well as significantly lower 
HDL (p = 0.041) compared to healthy controls. The average duration of T2D was 7.08 ± 1.4 years within 
the T2D group (Table 3.2). The number of participants on different medications is indicated in Table 
3.2, all but two participants were taking metformin to control their diabetes, while two participants 
were taking insulin. 
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Table 3.1: Anthropometric and blood chemistry results of healthy controls and T2D participants. Data 
expressed as mean ± SE. 
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Table 3.2: Diabetes duration and medication taken by type 2 diabetics. Data expressed as mean ± SE. 
 
 
 
3.3.2 Forearm total flow  
Brachial artery blood flow was measured with 2D-ultrasound to determine the total amount of blood 
flow to the forearm. As shown in Figure 3.2, total forearm blood flow was significantly higher in the 
T2D group compared to the healthy controls at rest (p = 0.003). 
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Figure 3.2: Brachial artery blood flow. Brachial artery blood flow (mL/min) measured with 2D-
ultrasound for healthy control (HC; n=22) and T2D (n=12) groups. — indicates mean. * significant 
difference between healthy controls and T2D (p = 0.003). 
 
 
3.3.3 Skin and subcutaneous tissue microvascular blood flow and tissue oxygenation  
LDF flux measures red blood cell number and velocity in forearm skin+SC. A higher resting forearm 
skin+SC LDF flux (Figure 3.3A), and thus skin+SC microvascular blood flow, was seen in the T2D 
participants (p = 0.009). There were no significant differences in the tissue oxygenation measures 
(Figure 3.3B-C), which were measured at the same site as LDF flux. Skin temperature measured by the 
LDF + OXY probe showed no difference between healthy control (28.9 ± 0.2℃) and T2D (29.0 ± 0.2℃) 
groups. 
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Figure 3.3: LDF flux and tissue oxygenation measures. Average over 10mins for healthy control (○ HC; 
n=23) and T2D (□ n=18) groups of skin+SC A) LDF flux B) O2 Sat and C) tHb measures. — indicates 
mean. * indicates significant difference between healthy controls and T2D (p = 0.006). 
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3.3.4 Skin and subcutaneous tissue complexity measures  
Complexity analysis was performed on the same 10min LDF flux and tissue oxygenation data used to 
determine average flux (Figure 3.3). The complexity measures of LDF flux, which determines RBC 
number and velocity, are much higher than those of O2 Sat and tHb, indicating there is greater 
randomness in the LDF flux than the tissue oxygenation measures. No significant differences in 
complexity between healthy controls and type 2 diabetics were seen in any of the microvascular blood 
flow measures (Figure 3.4). 
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Figure 3.4: Complexity analysis. Complexity was calculated from 10min of skin+SC LDF flux and tissue 
oxygenation measures. A) LDF flux, B) O2 Sat and C) tHb, healthy control (○ HC; n=23) and T2D (□ 
n=18) groups. — indicates mean. 
 
 
3.3.5 Forearm skeletal muscle microvascular perfusion. 
CEU was used to determine forearm microvascular perfusion of skeletal muscle (deep flexor) to give 
an indication of the distribution of the blood flow within the forearm. No difference in the skeletal 
muscle microvascular blood volume, filling rate or overall perfusion measure were seen between 
healthy control and T2D groups at rest (Figure 3.5). 
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Figure 3.5: Microvascular blood perfusion as assessed by CEU in forearm skeletal muscle. Data were 
collected over 3 x 45sec loops using CEU to assess A) microvascular blood volume, B) microvascular 
filling rate and C) microvascular perfusion, healthy control (○ HC; n=20) and T2D (□ n=11) groups. — 
indicates mean. 
 
 
 
 
3.3.6 Skin and subcutaneous tissue flowmotion measures  
Figure 3.6 shows representative wavelet transformations traces of LDF flux, O2 Sat and tHb measures 
plotted on a log frequency scale. The average wavelet transformation plots demonstrate overall 
flowmotion patterns and the contribution of each frequency component for a healthy control and 
type 2 diabetic. 
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Figure 3.6: Wavelet transformation of skin and subcutaneous tissue blood flow measures. This figure 
shows wavelet transformations of skin+SC LDF flux (Panel A and B), O2 Sat (Panel C and D) and tHb 
(Panel E and F) in healthy control and T2D participants. These traces are representative of the data 
collected in each group. 
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In order to quantify each frequency component within the wavelet transformation, peak AUC for each 
frequency range and the frequency at which the highest peak occurs was quantified with PeakFit 
software. Flowmotion assessed by LDF flux showed significant differences between healthy control 
and T2D groups in peak AUC (Figure 3.7). In both the respiratory and cardiac frequency components 
peak AUC in T2D group was significantly increased as compared to healthy controls, p = 0.010 and 
0.028 respectively (Figure 3.7D and E). In addition, T2D participants tended to have a decreased input 
(assess by peak AUC) from the myogenic component (p = 0.072).  
 
LDF Flux Endothelial
HC T2D
P
e
ak
 A
U
C
 (
A
U
)
0
100
200
300
400
500
600
700
LDF Flux Neurogenic
HC T2D
P
e
ak
 A
U
C
 (
A
U
)
0
100
200
300
400
500
600
700
LDF Flux Myogenic
HC T2D
P
e
ak
 A
U
C
 (
A
U
)
0
50
100
150
200
250
LDF Flux Respiratory
HC T2D
P
e
ak
 A
U
C
 (
A
U
)
0
20
40
60
80
LDF Flux Cardiac
HC T2D
P
e
ak
 A
U
C
 (
A
U
)
0
50
100
150
200
**
A B C
D E
Figure 3.7: LDF flux wavelet transformation: peak area under the curve for each flowmotion 
component. The average peak AUC of wavelet transformed LDF flux measures for frequency regions 
A) endothelial B) neurogenic C) myogenic D) respiratory and E) cardiac. Healthy control (HC; n=23) 
and T2D (n=18). Data expressed as mean ± SE. * indicates significant difference between healthy 
control and T2D groups (p < 0.05). χ p = 0.072 between T2D compared to healthy control. 
 
 
In each wavelet transformation, the frequency at which the highest peak occurred within each 
flowmotion component measured by LDF flux was identified (Table 3.3). For the cardiac component 
frequency was significantly higher (p < 0.001) in T2D group, indicating a higher heart rate. Using the 
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wavelet transformation, average heart rate was calculated for each group. The resting heart rate was 
53.5 ± 1.7bpm for healthy controls compared to 67.6 ± 1.9bpm in T2D group. Peak frequency of the 
respiratory component was also significantly elevated in the T2D group (p = 0.007), indicating a higher 
average breathing rate, with rate 12.8 ± 1.0 breaths/min for healthy control and 15.4 ± 0.8 
breaths/min in T2D group. In the lower frequency components there was a tendency for T2D 
participants to have slightly elevated rate of input from the endothelial, neurogenic and myogenic 
components, but this did not reach significance.  
 
Table 3.3: LDF flux wavelet transformation: peak frequency for flowmotion components. 
 
Average peak frequency of each frequency region, expressed as frequency (Hz) and cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) groups. Data expressed as Mean ± SE. 
 
 
Wavelet transformation of tissue oxygenation measures are only able to adequately detect peaks in 
the three lower frequency, locally acting, flowmotion components (endothelial, neurogenic and 
myogenic). Quantification of O2 Sat flowmotion measures showed a significantly lower (p = 0.017) 
endothelial peak AUC in T2D group (Figure 3.8A). However, while there was a similar trend of lower 
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contribution in T2D group, there was no difference in peak AUC in the neurogenic and myogenic 
components (Figure 3.8B-C).  
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Figure 3.8: O2 Sat wavelet transformation: peak area under the curve for flowmotion components. 
Average peak AUC of wavelet transformed O2 Sat measures for frequency regions A) endothelial, B) 
neurogenic and C) myogenic. Healthy control (HC; n=23) and T2D (n=18) groups. Data expressed as 
mean ± SE. * indicates significant difference between healthy control and T2D groups (p = 0.017). 
 
Table 3.4 shows the peak frequency for each component, or rate of input, which were similar between 
the two groups. 
 
Table 3.4: O2 Sat wavelet transformation: peak frequency for flowmotion components. 
 
Average peak frequency of each frequency region, expressed as frequency (Hz) and cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) groups. Data expressed as mean ± SE. 
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For tHb measure, wavelet transformation peak AUC in endothelial and myogenic frequency 
components (Figure 3.9) was significantly lower in the T2D as compared to healthy control (p = 0.017 
and p = 0.047 respectively). In the neurogenic frequency component there was a trend of decreased 
T2D peak AUC compared to healthy controls (p= 0.101). 
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Figure 3.9: tHb wavelet transformation: peak area under the curve for flowmotion components. 
Average peak AUC of wavelet transformed tHb measures for frequency regions A) endothelial, B) 
neurogenic and C) myogenic. Healthy control (HC; n=23) and T2D (n=18) groups. Data expressed as 
mean ± SE. * indicates significant difference between healthy controls and T2D groups (p < 0.05). 
 
In the tHb measures, no significant difference in peak frequency between the two groups were seen 
(Table 3.5). 
 
Table 3.5: tHb wavelet transformation: peak frequency for flowmotion components. 
 
Average peak frequency of each frequency region, expressed as frequency (Hz) and cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) groups. Data expressed as Mean ± SE. 
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3.4 Discussion 
This study determined several differences in skin+SC microvascular flowmotion between healthy 
control and T2D groups at rest. An elevated rate and contribution to flowmotion was seen in the higher 
frequency components (cardiac and respiratory) in the T2D group (Figure 3.7 and Table 3.2). Whilst 
the lower frequency components (endothelial, neurogenic and myogenic) showed a lower 
contribution to flowmotion compared to healthy controls (Figure 3.8 and 3.9). There were also 
differences in total blood flow to the forearm and the distribution of that flow throughout, with 
elevated brachial blood flow and skin+SC perfusion in the T2D group (Figure 3.2 and 3.3). Complexity 
analysis of LDF + OXY data failed to show any differences in randomness of signal between the healthy 
control and T2D groups at rest (Figure 3.4). 
 
The anthropometric measures and clinical blood chemistries show a clear, expected difference in 
health parameters of healthy controls and the diagnosed type 2 diabetics (Table 3.1). Anthropometric 
measures in the T2D group show an overt disease state with increased body mass and BMI (30.9 ± 
1.5kg/m2, indicating obesity) compared to the healthy controls (25.3 ± 0.6kg/m2, on the upper end of 
normal) (234)), and significantly elevated fasting blood glucose, HbA1c and plasma insulin. T2D 
participants were hypertensive (systolic BP = 131.9 ± 3.9mmHg), indicating dysfunction in the 
cardiovascular system. All type 2 diabetes were on a form of antidiabetic medication, with the majority 
(92%) taking metformin, while only 15% were taking insulin. Additionally, 62% were taking 
antihypertensive medication and 77% on cholesterol lower medication. The need of the medications, 
again highlights an overt disease state in these individuals.  
 
The activity threshold of <30min of moderate exercise per week was only applied to the T2D group, 
activity level. As such, there is potentially varied level of activity within the healthy control group which 
is likely to result in difference in the cardiovascular health of the control group. This gives a more 
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accurate sample of the general healthy population and the variation within the healthy control group 
adds power to the study.  
 
Several different measures were used to assess blood flow distribution in the forearm. Brachial artery 
blood flow (total flow measured by 2D-ultrasound) was significantly elevated in the T2D group at rest 
(Figure 3.2). Likewise, skin+SC microvascular blood flow (assessed by LDF flux) was also elevated in the 
T2D group (Figure 3.3), indicating a greater amount of blood flow within the skin+SC microvasculature 
at rest. Importantly, there was no influence of skin temperature on perfusion. LDF flux is affected by 
temperature, with flux increasing as temperatures rise (235). It therefore appears that in response to 
the higher total blood flow to the forearm, there was a greater amount of blood flow to the skin+SC 
in these T2D participants. Tissue oxygenation measures in the skin+SC were no different between the 
two groups. Interestingly, there were no differences in skeletal muscle perfusion between the two 
groups (measured by CEU) at rest. The average duration of diabetes was 7.08 ± 1.4 years and as such 
the lack of difference in skeletal muscle perfusion is not all that surprising as capillary rarefaction in 
the skeletal muscle develops in T2D over prolonged periods of time (236, 237). Blood flow in the 
underlying skeletal muscle of the forearm at rest therefore appears to not be affected by T2D, whereas 
the skin+SC flux and total flow of the forearm does.  
 
The assessment of skin+SC flowmotion in healthy control and T2D participants showed a number of 
interesting results. Upon wavelet transformation of skin+SC LDF flux microvascular blood flow 
measures, it was found that the higher frequency components (respiratory and cardiac) are only 
adequately detected with the LDF flux measure, not the tissue oxygenation (section 3.3.6). This result 
is most like due to the ability of LDF to detect both RBC cell number (volume) as well as the velocity at 
which they travel, while it is thought that the tissue oxygenation measures mostly just RBC number 
(volume) (63). Therefore, based on the observations made with wavelet transformation of blood flow 
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data it is thought that the higher frequency components may exert their effect on flowmotion 
primarily by controlling velocity of blood flow.  
 
Both the rate and contribution to flowmotion of cardiac and respiratory components was elevated in 
the T2D group (Figure 3.7 and Table 3.2). Patients with T2D are known to have cardiovascular 
dysfunction that leads to increased heart rate and respiration (238-240). The elevated rate of cardiac 
and respiratory components to flowmotion is therefore consistent with the literature and the 
problems associated with the disease (72). The pathological changes to the cardiovascular system 
seen in T2D, such as arterial stiffening (200), may also account for the increased contribution of the 
cardiac and respiratory component of flowmotion. In these participants the greater stress placed upon 
the heart and larger blood vessels may have led to a pathological change in the contribution of the 
higher frequency components to flowmotion through such changes as the development of 
atherosclerosis and medial calcification (241). 
 
The contribution to flowmotion of the endothelial (detected by O2 Sat and tHb, Figure 3.8 and 3.9) 
and myogenic (detected by tHb, Figure 3.9) components was decreased in the T2D group. A reduced 
input in these lower frequency components have been seen previously. Stansberry et. al. (242) 
examined flowmotion patterns in the fingers of healthy and T2D participants, and found reduced input 
of the lower frequency components to flowmotion in T2D, as is also seen in the current study. 
Differences in the contribution to flowmotion in the lower frequency components were seen in the 
tissue oxygenation measures, but not the LDF flux. These differences in the flowmotion measures may 
relate to the differing penetration of each type of measure. It is thought that the white light 
spectroscopy (400-700nm) used to determine tissue oxygenation measures has less penetration into 
the skin+SC than the LDF flux (785 ± 10nm) (60, 61). As such, the two different microvascular blood 
flow measures may determine RBC movement in slightly different tissue volumes at the same skin 
site. Tissue oxygenation measures determine flow in more superficial layers of the skin+SC, whereas 
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LDF flux can measure flow in both the superficial skin layers and deeper into the subcutaneous tissue. 
Therefore, the difference in skin+SC flowmotion measures by LDF flux and tissue oxygenation at the 
same skin sight may be explained by the different volumes and combination of tissues each light 
source is able to illuminate.  
 
The reduction in lower frequency contribution to flowmotion in the T2D group is not surprising due to 
the pathological changes in microvascular function commonly seen in this disease. Endothelial 
dysfunction in insulin resistance leads to an attenuated response to insulin-mediated, NO-dependant 
vasodilation, while the concurrent ET-1 induced vasoconstriction activated by insulin (to maintain a 
balanced vascular tone) is not affected. The result is a pathological vasoconstriction in the 
microvasculature (191). Additionally, chronic elevation of blood glucose levels leads to pathological 
changes to endothelial proteins (due to glucose induced damage) and a dysregulation of endothelial 
cell function (233). The changes in endothelial signalling pathways and protein destruction result in 
dysfunction of normal endothelial activity, and thus may explain the reduction in endothelial 
contribution to flowmotion in T2D group.  
 
A reduction in the contribution of the myogenic component in T2D participants indicates an altered 
vasomotion or intrinsic contraction of vessel smooth muscle cells. The specific mechanism altering 
vasomotion in T2D is not clear, but it may be causing disruption to the intracellular synchronisation of 
Ca2+ release within the vessel smooth muscle cells, which is hypothesised to drive vasomotion activity 
(106, 109). Changes to the regulation of Ca2+ release within the smooth muscle cells results in changes 
to cellular contraction and thus could be altered in T2D, therefore changing the contribution of 
myogenic input to overall flowmotion patterns (10). 
 
It was surprising that no difference in the neurogenic component, either contribution to flowmotion 
or frequency of input, was seen in this study as T2D is known to involve autonomic dysfunction (198, 
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199). A number of previous studies looking at skin+SC flowmotion in obesity and T2D have reported 
changes in the neurogenic component at rest (95, 98, 215, 217). However, the participants in these 
studies were measured at different time points in disease progression to the current study. A number 
of the studies that describe changes in the neurogenic component measured skin+SC flowmotion in 
obese individuals who were not yet clinically diagnosed with T2D (95, 215, 243). These studies showed 
dysfunction in the neurogenic component, perhaps indicating that changes to this component of 
flowmotion may be involved in the early progression of the disease. Other studies reporting changes 
to the neurogenic component were performed on T2D participants with advanced disease who had 
developed neuropathy as a consequence of T2D (98, 217, 218). Again, neurogenic dysregulation may 
have been involved in the advancement of disease state either contributing to the development of 
neuropathy or resulting from the damage to the nervous system which occurs in this disease. In the 
current study where T2D participants are clinically diagnosed, but have no additional disease 
(including cardiovascular disease, neuropathy, retinopathy and nephropathy), the lack of difference 
to the healthy controls in the neurogenic component at rest may be attributed to the stage of disease 
progression of these participants. Changes in the neurogenic component of flowmotion in T2D may 
vary based on the duration of disease in an individual and the development of further complications 
such as neuropathy.  
 
Complexity measures have previously been used to show dysfunction in skin microvascular blood flow 
in type 2 diabetic monkeys (226), with disease progression associated with a reduction in skin+SC 
blood flow complexity. Analysis of flowmotion with wavelet transformation in this study showed 
differences between healthy control and T2D groups. It was therefore thought that transformation of 
human skin+SC LDF flux and tissue oxygenation measures with complexity analysis would show a 
difference in the randomness in T2D skin+SC blood flow and provide a means of quickly and easily 
determining the presence of skin+SC blood flow dysfunction in an individual. However, at rest no 
difference in complexity of LDF flux or tissue oxygenation measures were seen between healthy 
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control and T2D groups (Figure 3.6), indicating skin+SC complexity measures in humans may not be 
suitable for identifying blood flow dysfunction.  
 
An important factor when comparing the difference in flowmotion patterns between healthy controls 
and type 2 diabetics not taken into consideration here is the influence of insulin upon flowmotion 
measures. In order to fully understand the flowmotion dysregulation which occurs in T2D, an 
understanding of how insulin changes flowmotion in healthy controls and how this may be attenuated 
in T2D needs to be investigated. Due to the endothelial-dependent pathway through which insulin 
stimulates blood flow changes, and insulin stimulation of the SNS (157, 244), respiration and cardiac 
output (245, 246), it is thought that insulin alters flowmotion patterns. A number of studies examining 
skin+SC flowmotion in response to insulin stimulation (either a euglycemic hyperinsulinemic clamp 
(216) , consumption of a mixed meal (247) or direct delivery of insulin to the skin+SC via iontophoresis 
(215)) show changes to overall flowmotion and the contribution of lower frequency components. It 
was therefore expected that in the healthy control group of this study, insulin release would cause 
changes to skin+SC flowmotion patterns. While in the T2D group assessed in this study, where insulin 
resistance and pancreatic failure have led to glucoregulatory and cardiovascular dysfunction (elevated 
heart rate, respiration, systolic blood pressure, total flow and skin+SC microvascular perfusion), it is 
thought that insulin release will not result in a stimulation of flowmotion.   
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Chapter 4 - Microvascular flowmotion 
in the skin and subcutaneous tissue in 
healthy controls and type 2 diabetics: 
oral glucose challenge 
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4.1 Introduction  
Insulin modifies skeletal muscle blood flow by stimulating NO-dependent smooth muscle vasodilation, 
resulting in enhanced blood flow through the tissue and promoting glucose uptake (248). There is 
evidence to suggest that insulin induces a change in flowmotion (157, 244, 245), complementing the 
enhanced level of capillary perfusion and facilitating further delivery of insulin and glucose to the 
myocyte. However, there is significant variation in the literature in regards to which components of 
flowmotion insulin affects. Most of these discrepancies can be attributed to differences in study 
design and the characteristics of participants, which lead to inconsistent findings regarding the 
mechanism by which insulin may influence flowmotion. For example, de Jongh et. al. (249), using an 
LDF probe implanted directly into skeletal muscle tissue, showed increased activity in endothelial and 
neurogenic components of flowmotion in response to a euglycemic hyperinsulinemic clamp. In 
contrast, using a LDF probe on the skin, Rossi et. al. (250) used spectral analysis of skin+SC LDF flux to 
demonstrate an increased myogenic component of flowmotion upon local insulin stimulation, 
delivered by iontophoresis. Additionally, Jonk et. al. (247), also measuring skin+SC flowmotion with 
LDF, observed an increase in the contribution of all components of flowmotion in response to 
consumption of a mixed meal. These studies highlight the varied observations in insulin-mediated 
flowmotion changes, and thereby the need to further investigate the changes in flowmotion that 
occur in response to insulin.  
 
Aberrant changes in flowmotion have been observed during both acute and chronic insulin resistance. 
A study by Newman et. al. (57) performed in an anaesthetised rat model, showed an increase in the 
myogenic component of flowmotion with insulin infusion, which was then attenuated during an acute 
insulin-resistant state induced by the vasoconstrictor α-methylserotonin. Clough et. al. (215) observed 
an increased contribution to skin+SC flowmotion (LDF flux) in the endothelial component in response 
to insulin stimulation (iontophoresis) in healthy controls, which was significantly attenuated in 
participants with central obesity. Similarly, using skin+SC LDF flux measures, de Jongh et. al. (219) 
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showed an attenuated response to insulin stimulation (iontophoresis) in the skin+SC of obese women, 
with reduced endothelial and neurogenic contribution. These studies demonstrate an attenuation of 
insulin-mediated flowmotion in insulin resistance. Changes to skin+SC vasomotion have been 
observed in T2D (242, 251).  Using skin+SC LDF flux measures and Fast Fourier analyses, Stansberry et. 
al. (242) showed an impairment in lower-frequency vasomotion in 75% of type 2 diabetics compared 
to age matched healthy controls. Changes to flowmotion in key metabolic tissues such as skeletal 
muscle may reduce blood flow directly to myocytes, and thereby contribute to the reduced glucose 
disposal in insulin resistance and T2D. It is therefore important to understand the changes in 
flowmotion induced by insulin and how these may become dysfunctional in T2D.  
 
The primary aim of this study was to determine the difference in skin+SC flowmotion response to an 
endogenous release of insulin, via an oral glucose challenge (OGC), in healthy control and T2D 
participants. 
 
A limitation of most studies investigating changes in flowmotion in disease states such as obesity, 
insulin resistance and T2D is that blood flow measures are performed primarily on skin using LDF flux. 
Changes in flowmotion in more metabolically important tissues such as skeletal muscle are of greater 
interest in understanding the dysfunction and pathogenesis of these diseases. It is not clear if skin+SC 
measures of blood flow are an appropriate substitute for blood flow in deeper more metabolically 
relevant tissues such as skeletal muscle. Due to the different roles of skin+SC (protective and 
thermoregulation) and skeletal muscle (highly metabolic tissue) (252) in the body  it is unlikely that 
blood flow patterns would be similar between the two tissues. A secondary aim of this study was 
therefore to determine if there is a consistent response to OGC in measures of forearm total blood 
flow, skin+SC microvascular flux and skeletal muscle microvascular perfusion. This comparison was to 
determine whether skin+SC flowmotion measures are representative of skeletal muscle flowmotion, 
a more metabolically active tissue and target of insulin.   
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4.2 Methods 
The study outlined in this chapter was performed on the same day and same participants descried in 
chapter 3. After basal measures were taken, participants (characteristics reported in section 3.2) 
underwent an oral glucose challenge. While a 75g glucose load is used clinically for the diagnosis of 
T2D, this study used a 50g glucose load. Preliminary experiments showed that when administered in 
healthy participants, a 75g glucose load resulted in significantly reduced skeletal muscle blood flow 
response (when an increase was expected with endogenous insulin release (247)) and participants 
feeling ill (nauseous and/or light headed). This was thought to occur due to an excessive activation of 
the SNS in these insulin sensitive participants (253). Therefore, a modified 50g glucose load was used 
in the current study as it has previously been shown to be well tolerated in healthy participants, while 
still eliciting a significant change in blood glucose and plasma insulin levels in both healthy control and 
T2D participants (254).  
 
4.2.1 Protocol 
Before commencement of the OGC, a fasting blood glucose sample was obtained from the antecubital 
vein of the non-dominant arm. A 50g glucose drink (GLUCO SCAN, SteriHealth, Australia) was then 
consumed orally at t = 0 mins. Participants had 5mins to fully consume the drink. Blood glucose and 
plasma insulin levels were monitored over 120min after the consumption of glucose via venous 
samples from the antecubital vein at t = 15min, t = 30min and then every 30min up to the 120min 
time point (Figure 4.1). A time-course of blood glucose and plasma insulin was plotted and the AUC of 
each time course was determined to give an overall indication of glucoregulatory function in healthy 
control and T2D groups. 
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Figure 4.1: Oral glucose chanllenge (OGC) study protocol. Participants lay in a semi-recumbent 
possition thoughout testing. An initial basal period was observed and then 50g of liguid glucose was 
comsumed orally. Forearm skin+SC LDF + OXY measures where taken throughout basal and OGC. Total 
forearm blood flow was determined by measuring BBF during basal and at t = 45min into OGC. Skeletal 
muscle micorvascuar perfusion was determned using CEU at rest and at = 60min of OGC. Venous blood 
samples where taken before and then thoughout OGC (●). 
 
The blood flow measures taken previously at rest (described in section 3.2.2) were repeated during 
the OGC as described below. Timing of measurements was based on the peak glucose concentration 
in the blood, while trying to minimise the influence of other measurements occurring around the same 
time.  Vascular resistance was calculated from MAP and BBF to give an indication of vasodilatory state.  
Vascular resistance = MAP (mmHg)/BBF (min/mL)  
 
4.2.1.1 Skin and subcutaneous tissue microvascular blood flow 
The LDF + OXY probe (described in section 2.1.2) was attached to the midsection of the ventral side of 
the right forearm. Skin+SC LDF flux and tissue oxygenation measures were continuously recorded 
throughout basal and OGC (Figure 4.1). Skin+SC microvascular flowmotion was assessed with LDF flux 
and tissue oxygenation measures over two 20min time periods during basal (t = -30 to -10min) and 
then during OGC (t = 35-45min). 
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4.2.1.2 Total forearm blood flow 
Total flow into the forearm was determined by measuring the brachial artery blood flow with a L12-5 
linear array ultrasound transducer (describe in section 2.1.4). Brachial artery diameter and blood 
velocity were determined, and brachial blood flow (BBF) calculated as described previously in 2.1.4. 
BBF measures were taken at basal (t = -20min) and then at t = 45min into OGC (Figure 4.1). 
 
4.2.1.3 Forearm skeletal muscle microvascular perfusion 
Microvascular blood volume, filling rate and perfusion of forearm deep flexor muscle was determined 
with CEU as described in section 2.1.3. CEU measures were taken in triplicate during basal period (t = 
-10min) and then at t = 60min of OGC. 
 
4.2.1.4 Blood analysis  
Blood samples taken at fasting and throughout OGC (Figure 4.1) were analysed for blood glucose and 
plasma insulin as described in section 2.1.6. 
 
 
4.2.2 Data analysis 
  
4.2.2.1 Microvascular blood flow averages 
Mean LDF flux and tissue oxygenation measures over a 10min time period during basal (t = -30 to -
20min) and at t = 50 to 60min of OGC were determined as described in section 2.1.8.1. 
 
4.2.2.2 Complexity measures 
Mean complexity measures over the same 10min time period during basal (t = -30 to -20min) and OGC 
(t = 50 to 60min) as average LDF flux and tissue oxygenation measures was calculated as described in 
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section 2.1.8.2. The timing of measure is based on the peak glucose concentrating into the blood and 
ensuring clean data was analysed that had not been influenced by other measures.  
 
4.2.2.3 Flowmotion measures 
Flowmotion analysis using wavelet transformation was performed on 20min of basal (t = -30 to -
10min) and OGC (t = 35 to 55min) LDF flux and tissue oxygenation measures. Wavelet transformation 
data were then quantified by determining AUC of peaks within each flowmotion frequency component 
and peak frequency, as described in section 2.1.8.3. The timing of measure is based on the peak 
glucose concentrating into the blood and ensuring clean data was analysed that had not been 
influenced by other measures. 
 
 
4.3 Statistical analysis 
Two-way repeated measures ANOVA were performed to determine difference at basal and during 
OGC between healthy control and T2D groups with a Student-Newman-Keuls post hoc test, as 
described in section 2.4. An unpaired Student’s t-test was used to determine the difference in change 
during OGC from basal between healthy control and T2D groups. The correlation between change 
during OGC from basal in LDF flux and microvascular perfusion measures in all participants (healthy 
control and T2D groups were combined) was performed with a linear regression on parametric data 
and Spearman Correlation analysis on non-parametric, as described in section 2.4. 
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4.3 Results 
4.3.1 OGC blood glucose and plasma insulin 
After overnight fasting participants were given a 50g oral glucose load (OGC) to assess insulin 
sensitivity. Blood glucose and plasma insulin response to OGC was monitored throughout the protocol. 
Fasting blood glucose levels were significantly elevated (p < 0.001) in the T2D group, compared to 
healthy controls (10.2 ± 1.0 and 4.9 ± 0.0 mM respectively). Throughout the OGC the blood glucose 
concentrations were significantly higher (p < 0.001) in the T2D group (Figure 4.2A), resulting in a 
significantly larger (p < 0.001) AUC in the T2D group (Figure 4.2B). From t = 30min onwards the change 
from basal of blood glucose during OGC was significantly elevated (p < 0.002) in T2D group (Figure 
4.2C). While fasting plasma insulin was significantly elevated (p < 0.001) in T2D participants (97.3 ± 
17.8pM) compared to healthy controls (40.5 ±1.7pM), there was no difference between the two 
groups during the OGC (Figure 4.2D), and no difference in the calculated absolute AUC (Figure 4.2E). 
Despite the difference in fasting plasma insulin levels, there was no difference in the change from 
basal at any time point throughout OGC (Figure 4.2F). 
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Figure 4.2: Blood glucose and plasma insulin response to OGC. A) Blood glucose response to OGC, the 
B) calculated area under the curve (AUC) of OGC time course, and C) blood glucose during OGC 
represented as change from basal. D) Plasma insulin response to OGC, the E) calculated AUC of OGC 
time course and F) plasma insulin during OGC represented as change from basal. Healthy control (● 
HC; n=23) and T2D (  , n=18) groups. Data expressed as mean ± SE. * indicates significant difference 
between healthy control and T2D groups (p < 0.02). 
 
  
4.3.2 Forearm total flow  
Total blood flow to the arm was measured by determining brachial artery blood flow (BBF) using 2D-
ultrasound at basal (t = -20min) and at t = 45min of OGC (Figure 4.3). In the healthy control group 
there was no change in total flow to the forearm with the OGC. In the T2D group, BBF was significantly 
elevated (p = 0.006) 45mins post OGC from basal. Total flow to the arm in the T2D group was 
significantly higher than healthy controls both during basal and t = 45min into OGC (p = 0.039 and p < 
0.001 respectively). 
 
89 
 
Brachial Blood Flow
B G  B G 
B
ra
ch
ia
l 
B
lo
o
d
 F
lo
w
 (
m
L /
m
in
)
0
50
100
150
200
250
300
350
#*
*
Healthy Control T2D  
Figure 4.3: Brachial artery blood flow in response to OGC. Brachial artery blood flow (mL/min) 
measured during basal (B) and 45min after OGC (G). Healthy control (HC; n=23) and T2D (n=15) 
groups. Time points of each individual participant is represented by a different signal, — indicates 
mean. * indicates significant difference between healthy controls and T2D (p <0.05). # indicates 
significant difference from basal to OGC in T2D group (p = 0.006). 
 
 
4.3.3 Skin and subcutaneous tissue microvascular blood flow and tissue oxygenation  
LDF flux, O2 Sat and tHb data were determined by calculating a 10min average during basal (t = -30min) 
and 60min post OGC (Figure 4.4A-C). In the healthy control group, there were no changes in 
microvascular blood flow measures (LDF flux, O2 Sat and tHb) during OGC compared to basal. The T2D 
group, had significnatly higher basal (p = 0.027) and OGC (p = 0.004) LDF flux than healthy controls. 
Within the T2D group O2 Sat, but not tHb, was significantly elevated (p < 0.001) in OGC compared to 
basal. The change during OGC from basal was calculated for each blood flow measure to determine 
difference in response to OGC in each group (Figure 4.4D-E). The only difference in the change from 
basal was in the O2 Sat measure, where the increase from basal during OGC in T2D group was a 
significantly different to the decrease from basal during OGC in the healthy controls (p = 0.010). 
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Figure 4.4: LDF flux and tissue oxygenation response to OGC. A) LDF flux B) O2 Sat and C) tHb in the 
skin+SC were determined over a 10min time period at basal (B; open symbol) and 60min post OGC (G, 
filled symbol). Change during OGC from basal for each measure was determined to give D) ΔLDF flux 
E) ΔO2 Sat and F) ΔtHb. Healthy control (● HC; n=23) and T2D (  , n=18) groups. Data expressed as 
mean ± SE. * indicates significant difference between healthy controls and T2D (p < 0.05). # indicates 
significant difference from basal to OGC in T2D group (p = 0.027). 
 
 
4.3.4 Skin and subcutaneous complexity measures  
Complexity analysis was performed on the average LDF flux and tissue oxygenation measures using 
the same 10min time points used to calculate average flux (during basal, t = -30min and at t = 60min 
of OGC), to determine randomness of skin+SC blood flow (Figure 4.5). No significant changes from 
basal to OGC were seen in LDF flux or tHb measures. In the T2D group complexity calculated from the 
O2 Sat measures showed a significant increase from basal during OGC (p = 0.013). 
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Figure 4.5: Complexity analysis pre and post OGC. Complexity was calculated from 10min of LDF flux 
and tissue oxygenation measures during basal (B, open symbol) and OGC (G, filled symbol). A) LDF flux 
B) O2 Sat and C) tHb measures. (● HC; n=23) and T2D (  , n=18) groups. — indicates mean. # indicates 
significant difference from basal to OGC, p = 0.013. 
 
 
4.3.5 Forearm skeletal muscle microvascular perfusion 
Skeletal muscle microvascular perfusion in the forearm was measured to determine changes in blood 
flow distribution from basal to OGC (Figure 4.7). In the healthy controls microvascular blood volume 
and perfusion were significantly decreased during the OGC compared to basal (p = 0.024 and p = 0.001 
respectively). There was no change in microvascular blood volume, filling rate or perfusion between 
basal and at 50-60mins into the OGC in the T2D group (Figure 4.7A-C). The change during OGC from 
basal was calculated for each blood flow measure to determine difference in response to OGC in each 
group (Figure 4.7D-E). There was a trend (p = 0.099) for a greater decrease in microvascular volume 
during the OGC in healthy control compared to T2D group, but no significant difference in change 
during the OGC from basal in any of the skeletal muscle microvascular perfusion measures.  
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Figure 4.6: Response to OGC of microvascular blood perfusion as assessed by CEU in forearm skeletal 
muscle. Basal (B, open symbol) and OGC (G, filled symbol) data were collected over 3 x 45sec using 
CEU to assess A) microvascular blood volume, B) microvascular filling rate and C) microvascular 
perfusion. Change during OGC from basal for each measure was determined to give D) Δmicrovascular 
blood volume, E) Δmicrovascular filling rate and F) Δmicrovascular perfusion. Healthy control (● HC; 
n=23) and T2D (  , n=15) groups. Data expressed as mean ± SE. # indicates significant difference from 
basal to OGC (p < 0.01). 
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4.3.6 Correlation between skin and subcutaneous tissue flux and skeletal muscle perfusion 
To determine if skeletal muscle and skin+SC had a similar vascular response to the OGC, a correlation 
analysis was performed. The change in skin+SC LDF flux was compared to the change in skeletal muscle 
microvascular blood volume (Figure 4.7A) and perfusion (Figure 4.7B) in response to the OGC. Healthy 
control and T2D groups were combined in the analysis to give an n of 30. There was no significant 
correlation (R = 0.175, p = 0.809) between the change in skin+SC LDF flux and the change in skeletal 
muscle microvascular blood volume between basal and OGC (Figure 4.7A). Similarly, there was no 
significant correlation (R = 0.0477, p = 0.834) between the change in skin+SC LDF flux and the change 
in skeletal muscle microvascular perfusion (Figure 4.7B). 
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Figure 4.7: Correlation of skin and subcutaneous tissue with skeletal muscle blood flow. Panel A shows 
the correlation between the change in skin+SC LDF flux during OGC and the change in skeletal muscle 
microvascular blood volume during OGC. Panel B shows the correlation between the change in skin+SC 
LDF flux during OGC and the change in skeletal muscle microvascular perfusion during OGC. The two 
groups were combined for correlation analysis, healthy control (●) and T2D ( ) groups (n = 30). 
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4.3.7 Correlation between diabetes duration and blood flow measures 
To determine if diabetes duration influences a number of blood flow measures regression analysis 
was performed (Table 4.1). At both basal and during OGC there is a significant negative relationship 
between skin+SC LDF and T2D duration (p = 0.0087 R = -0.587 and p = 0.039 R = -0.577 respectively). 
There is a similar trend for skin+SC O2 Sat and brachial blood flow decreasing as duration of T2D 
increase. During basal state only, there is a significant positive relationship between skeletal muscle 
microvascular volume and T2D duration (p = 0.013 R = 0.748). 
 
 
Table 4.1: Correlation analysis of diabetes duration and blood flow measures. 
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4.3.8 Skin and subcutaneous tissue flowmotion measures  
Insulin release in response to an OGC induces changes in cardiac, respiratory, neurogenic and 
endothelial activity. As a result, skin+SC microvascular flowmotion patterns became altered in 
response to the OGC. Representative traces from individual participants during basal and the OGC are 
shown in Figure 4.8. 
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Figure 4.8: Response to OGC in wavelet transformation of skin and subcutaneous tissue blood flow 
measures. This figure shows wavelet transformation during basal (open symbol) and OGC (filled 
symbol) of skin+SC A) LDF flux B) O2 Sat and C) tHb measures for a healthy control and T2D 
participants. These traces are representative of the data collected in each group. 
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Quantification of the LDF flux wavelet transformation for each participant was done by calcualting the 
AUC of the peaks within each frequency range. Figure 4.9 shows a similar peak AUC in both groups in 
each of the frequency components. In the higher frequency components, compared to healthy 
controls there was an higher cardiac peak AUC in T2D group during OGC. 
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Figure 4.9: LDF flux wavelet transformation: peak area under the curve for each flowmotion 
components in response to OGC. Average peak AUC of wavelet transformed LDF flux measures during 
basal (B, open bar) and OGC (G, filled bar) for frequency regions A) endothelial B) neurogenic C) 
myogenic D) respiratory and E) cardiac. Healthy control (HC; n=23) and T2D (n=18). Data expressed 
as mean ± SE. * indicates significant difference between healthy control and T2D groups during OGC 
(p = 0.030). 
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In addition to AUC for each component, the peak frequency was also assessed (Table 4.2). In healthy 
controls, there was a significant increase in peak frequency during OGC compared to basal in the 
cardiac (p < 0.01), respiratory (p = 0.001) and myogenic (p = 0.019) components, with a near significant 
increase in neurogenic component (p = 0.078). Interestingly, in the T2D group, an increase was only 
observed in the peak frequency of the cardiac component of flowmotion (p < 0.001). 
 
Table 4.2: LDF flux wavelet transformation: response to OGC of peak frequency.
 
Average peak frequency of each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± 
SE. 
 
The change in peak frequency for both the healthy control and T2D groups is shown in Table 4.3. 
Cycle period of cardiac and respiratory components was decreased in response to the OGC in both 
groups, representing a faster rate of input in these components in response to the large glucose load. 
However, in the healthy control group the decrease in cycle period (and thus faster rate of input) in 
response to the OGC was significantly higher than in the T2D group in both the cardiac (p = 0.006) and 
respiratory (p = 0.017) components. This corresponds with the change in heart rate which was 
significantly elevated from basal during OGC in both healthy control (54.0 ± 0.4 bpm to 59.9 ± 0.4 bpm) 
and T2D (67.2 ± 0.5 bpm to 71.2 ± 0.5 bpm) groups. In the lower frequency components, the healthy 
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control group cycle period decreased in response to the OGC (faster rate of input), whereas in the T2D 
group the cycle period tended to increase. As such, a significant difference in the change in peak 
frequency during the OGC between healthy control and T2D groups was seen in the neurogenic (p = 
0.029) and myogenic (p = 0.011) components. 
 
 
 
Table 4.3: LDF flux wavelet transformation: change from basal in peak frequency. 
 
Average change from basal in peak frequency each frequency region, expressed as cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± SE. 
 
 
At basal, the O2 Sat wavelet tranformation measures show a significantly lower (p = 0.005) peak AUC 
in the endothelial region of the T2D group compared to healthy controls (Figure 4.10). In response to 
the OGC, the peak AUC in the endothelial region of healthy controls was significantly decreased from 
basal (p < 0.001).  
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Figure 4.10: O2 Sat wavelet transformation: peak area under the curve for flowmotion components in 
response to OGC. Average peak AUC of wavelet transformed O2 Sat measures during basal (B, open 
bar) and OGC (G, filled bar) for frequency regions A) endothelial B) neurogenic and C) myogenic. 
Healthy control (HC; n=23) and T2D (n=18). Data expressed as mean ± SE. # indicates significant 
difference from basal to OGC in healthy control group (p < 0.001) in endothelial component. * 
indicates significant difference between healthy controls and T2D (p = 0.005) in endothelial 
component.  
 
Unlike the LDF flux measures, there was no difference in peak frequency from basal to OGC seen in 
any frequency component measure by O2 Sat in either healthy control or T2D groups (Table 4.4). 
 
Table 4.4: O2 Sat wavelet transformation: response to OGC of peak frequency. 
 
Average peak frequency of each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± 
SE. 
 
 
The change in peak frequency during OGC measured by O2 Sat between healthy control and T2D 
groups is shown in Table 4.5. The change in peak frequency in response to the OGC measured by O2 
Sat was not significantly different between the two groups. 
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Table 4.5: O2 Sat wavelet transformation: change from basal in peak frequency. 
 
Average change from basal in peak frequency each frequency region, expressed as cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± SE. 
 
Figure 4.11 shows a number of changes in peak AUC in response to OGC measured by tHb. 
Quantification of wavelet transformation measures show a significantly lower peak AUC in T2D group 
at basal in endothelial (p = 0.011) and a near signficant decrease in neurogenic (p = 0.057) frequency 
components, compared to healthy controls. In response to OGC, the endothelial (p < 0.001) and 
neurogenic (p = 0.001) frequency components in healthy control group were significantly reduced 
from basal. In the T2D group, peak AUC of neurogenic component was also significantly reduced (p = 
0.022). 
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Figure 4.11: tHb wavelet transformation: peak area under the curve for flowmotion components in 
response to OGC. Average peak AUC of wavelet transformed tHb measures during basal (B, open bar) 
and OGC (G, filled bar) for frequency regions A) endothelial B) neurogenic and C) myogenic. Healthy 
control (HC; n=23) and T2D (n=18). Data expressed as mean ± SE. # indicates significant difference 
from basal to OGC in healthy control (p < 0.001) and T2D (p = 0.022) groups. * indicates significant 
difference between healthy controls and T2D in endothelial (p = 0.011) component. ω p = 0.057 
between healthy controls and T2D. 
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The rate of input for each component as measured by tHb is shown in Table 4.6. There was no 
difference seen in peak frequency from basal to OGC in any frequency component in either healthy 
control or T2D groups. 
 
Table 4.6: tHb wavelet transformation: response to OGC of peak frequency. 
 
Average peak frequency of each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± 
SE. 
 
Similarly, when the change in peak frequency in response to OGC was calculated, there was no 
discernible difference between the healthy control and T2D groups in the tHb measure of skin+SC 
flowmotion (Table 4.7).  
 
Table 4.7: tHb wavelet transformation: change from basal in peak frequency. 
 
Average change from basal in peak frequency each frequency region, expressed as cycle period 
(seconds). Healthy control (n=23) and T2D (n=18) group. Data expressed as mean ± SE. 
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4.4 Discussion 
A 50g OGC induced different blood glucose and blood flow responses in healthy controls compared to 
T2D participants. As expected, the T2D participants had higher blood glucose AUC in response to the 
OGC, indicating insulin resistance and glucoregulatory dysfunction (Figure 4.2). In response to the 
OGC, flowmotion measures in the healthy controls were expected to increase upon endogenous 
insulin secretion as insulin is known to stimulate endothelial and neurogenic components (6), but 
showed an unexpected decrease in contribution and increased rate of components, while in the T2D 
group flowmotion remained mostly unaltered in response to OGC (Figure 4.10, 4.11 and Table 4.1). 
There were also differences between forearm total and skin+SC blood flow response compared to 
skeletal muscle perfusion during the OGC in both groups (Figure 4.3, 4.4 and 4.6). 
 
As is characteristic of the disease, the T2D group showed poor blood glucose control over the course 
of the OGC (Figure 4.2). While fasting plasma insulin levels were elevated in the T2D group compared 
to healthy controls, plasma insulin concentrations throughout the OGC were similar between the two 
groups. The lack of difference between healthy control and T2D insulin concentrations throughout the 
OGC not unexpected. The average duration from diagnosis of type 2 diabetes is 7.08 ± 1.4 years and 
as such it is expected that the T2D group will have decreased capacity to secrete insulin from beta 
cells as well as insulin resistance in cells, leading to even poorer control of blood glucose (255).  Healthy 
controls showed normal glucoregulation, with a slower increase in blood glucose in response to the 
OGC and blood glucose concentrations returning to near basal levels at the 120min time point. The 
T2D group however, show dysfunction in glucoregulatory control with a faster increase in blood 
glucose levels after the 50g glucose load and blood glucose remaining significantly elevated at 120min. 
As T2D medication was withdrawn 48hrs prior to testing, the higher blood glucose concentration, 
despite similar plasma insulin levels between the two groups, suggests T2D participants had some 
beta cell dysfunction, which is characteristic of the disease. The difference in blood glucose response 
to OGC shows an overt disease state in the T2D participants, thereby providing suitable populations 
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to investigate blood flow and skin+SC flowmotion responses in both healthy control and T2D 
populations. 
 
In the healthy control group, total blood flow to the forearm (assessed with 2D-ultrasound, Figure 4.3) 
and skin+SC microvascular flux (LDF, Figure 4.4) were unaltered in response to OGC. In contrast, CEU 
measures of skeletal muscle microvascular blood volume and perfusion were significantly decreased 
in response to the OGC (Figure 4.6). This is a surprising result in the healthy participants as previous 
studies using either a mixed meal (65, 256, 257) to induce endogenous insulin release or a euglycemic 
hyperinsulinemic clamp (36, 37, 184, 248) have shown an increase in skeletal muscle microvascular 
perfusion. A possible explanation for the decrease in skeletal muscle microvascular perfusion during 
the OGC in healthy controls is an enhanced neurogenic input to the skeletal muscle vasculature, 
caused by an excessive activation of the SNS. Welle et. al. (258) observed a significant increase in 
plasma noradrenaline (NA) levels in response to a 100g oral glucose load in insulin sensitive 
participants. Increased circulating NA may result in augmented SNS (thereby neurogenic) activity, 
potentially causing increased contraction in vessel smooth muscle cells (vasoconstriction) and 
therefore a reduction in skeletal muscle capillary perfusion. Activation of the SNS in response to a 75g 
oral glucose load was also observed by Staznicky et. al. (253), where SNS output to muscle was 
increased in insulin-sensitive obese participants, but not in insulin resistant obese participants. This 
would suggest that in insulin sensitive participants, consumption of large oral glucose loads may result 
in increased SNS output. The data in this study, decreased skeletal muscle blood flow despite an 
endogenous release of insulin (Figure 4.6) and an increased rate of the neurogenic component in 
response to OGC in healthy controls but not T2D participants (Table 4.3), supports the idea that a large 
oral glucose load in an insulin sensitive individual induces an elevated SNS response. However, it 
should be noted that there was no significant change in mean arterial pressure from basal to OGC in 
either the control or T2D participants, which would have been expected to increase with an increased 
SNS output. It may still be a more local enhancement of neurogenic input is occurring to produce the 
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increased SNS with OGC. In contrast, this unexpected change in the vasculature has not been observed 
when increased insulin levels have been induced by a mixed meal (247, 256) or euglycemic 
hyperinsulinemic clamp (36, 37). 
 
In response to the OGC total flow to the forearm was unaltered in healthy controls while in contrast, 
the T2D group there was a significant increase from basal (Figure 4.3). While skin+SC LDF flux in the 
T2D group was elevated both at basal and during OGC (compared to healthy controls), the OGC did 
not induced a significant increase in skin+SC flux within the T2D group (Figure 4.4), which is not 
consistent with the increase in total flow. In contrast, skin+SC O2 Sat, as well as the resulting complexity 
of this measure, was increased during the OGC in T2D participants (Figure 4.4 and 4.5). This increase 
in the O2 Sat suggests an increased total flow, thereby decreased blood transit time through tissue, 
resulting in decreased extraction of oxygen. The increase in complexity value shows an increased 
randomness in O2 Sat signal, most likely brought about by a reduced control over blood flow in the 
skin+SC when bulk flow to the forearm is enhanced during the OGC.  
 
The different response to the OGC in skin+SC determined by LDF flux and O2 Sat measures in the T2D 
group could be explained by the penetration of the light used for each measure. O2 Sat, measured by 
white light spectroscopy, is thought to only measure flow from the most superficial layers of the 
subcutaneous tissue and skin (exact volume unknown), as the white light has limited penetration into 
the skin+SC (60). The LDF laser on the other hand is believed to have greater penetration into the 
skin+SC (~0.55-0.79mm2 volume of tissue measured), and thereby measures a different volume and 
tissue combination compared to O2 Sat, which could explain the difference in blood flow 
measurements at the same skin site (61).  
 
A significant negative correlation between duration of T2D and skin+SC perfusion was shown; with 
increasing years since T2D diagnosis linked to decreased skin+SC LDF flux at both basal and during 
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OGC. This is not surprising, as T2D progresses there is increasing damage to the microvasculature, 
through such mechanisms as glucose damage (241), which appears to have resulted in a reduced 
perfusion of skin capillaries. Additionally, changes in capillary density and morphology may have also 
resulted in this reduction in skin+SC perfusion (197). While not significant, there was a similar trend in 
the correlation of T2D duration with skin+SC O2 Sat and brachial blood flow, indicating damage to both 
large and small vessels, reducing bulk blood flow and skin+SC microvascular perfusion. Interestingly, 
skeletal muscle blood volume was positivity correlated with T2D duration at basal, but this was no 
longer present during the OGC. This is a very interesting observation which indicates that skeletal 
muscle blood volume at basal increases as dysfunction occurs and T2D progress, but the response to 
endogenous insulin is attenuated as the disease progresses. Even with increased basal perfusion in 
later stages of the disease, microvascular blood volume does not increase with insulin stimulation. 
 
As in chapter 3, the complexity measures of skin+SC blood flow showed very little difference between 
the healthy control and T2D groups (Figure 4.5). The only difference observed, an increased 
complexity of O2 Sat measures during the OGC in T2D group, was likely to be accounted for by the 
enhanced bulk blood flow which concurrently occurred. As changes in flowmotion were seen when 
the LDF flux and tissue oxygenation data were analysed using wavelet transformation measures, the 
complexity analysis does not appear to be sensitive enough to assess microvascular function in 
humans.  
 
As LDF flux was not significantly increased in response to the OGC in the T2D group (Figure 4.4), it 
appears that the majority of the increased flow to the forearm during OGC has not been diverted to 
the skin or underlying subcutaneous tissue. Interestingly, in the T2D group skeletal muscle 
microvascular perfusion was also not significantly altered in response to the OGC (Figure 4.6). CEU 
measures the perfusion of nutritive capillaries in skeletal muscle tissue, i.e. those that provide blood 
flow directly to the myocyte cells (259). The insulin-mediated increase in skeletal muscle nutritive 
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capillary recruitment is known to be attenuated in insulin resistance and T2D (6, 40, 193), and thus 
the lack of change in skeletal muscle microvascular perfusion in this study is not unexpected. It appears 
that the greater bulk blood flow to the forearm in the T2D group (Figure 4.3) is being diverted to the 
non-nutritive capillary pathway (which primarily services the connective tissue (28)) and thus blood 
flow is potentially being shunted through the muscle, resulting in decreased exposure of glucose and 
insulin to myocytes. Consequently, there is a decreased disposal of the glucose load into skeletal 
muscle, which may contribute to the prolonged elevation of blood glucose levels observed during the 
OGC in the T2D group (Figure 4.2) (236, 260, 261).  
 
Skin+SC flowmotion measures in the healthy control group showed a number of changes during the 
OGC. There was a decrease in the contribution of the lower frequency components of flowmotion 
(determined from tissue oxygenation measures, Figure 4.10 and 4.11) in response to the OGC. This is 
surprising as insulin release in response to an OGC would be expected to stimulate endothelial derived 
vasodilation (248), thereby increasing the endothelial contribution to flowmotion. Instead, a reduction 
in endothelial as well as neurogenic contribution was seen. As described above, an increased SNS input 
to the muscle has been observed in response to an OGC in insulin sensitive participants (253). In the 
current study, the decrease in the contribution of the neurogenic component to the skin+SC in healthy 
controls in response to the OGC may be a result of upregulation of SNS activity in the muscle and a 
subsequent down regulation in the skin+SC. Alternatively, the change to the neurogenic component 
may be a consequence of changes in other component inputs to the skin+SC (such as endothelial) 
interacting with the neurogenic input, causing a reduction in contribution. In addition to the reduced 
contribution in lower frequency components, the rate of input of the neurogenic, myogenic, 
respiratory and cardiac components of flowmotion (measured by LDF flux, Table 4.1) was increased in 
response to the OGC in healthy controls. These surprising responses to OGC in healthy control skin+SC 
flowmotion are likely, in part, due to an activation of the SNS, but may also be because flowmotion 
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was measured on the skin+SC of participants and not in the more metabolically relevant skeletal 
muscle tissue. 
 
In the type 2 diabetics the lower frequency component input to flowmotion (determined by tissue 
oxygenation measures, Figure 4.10 and 4.11) tended to decrease, but, with one exception (neurogenic 
input measured by tHb), there was no significant change. The rate of input of all but the cardiac 
component, which increased, also remained unchanged in response to the OGC (Table 4.1). A lack of 
insulin-mediated change in flowmotion in the T2D group was not unexpected as T2D commonly has 
both endothelial (188) and neurogenic (198) dysfunction. In T2D, insulin-mediated vasodilation in the 
vessel endothelial cells is attenuated and therefore no change or a decrease in the endothelial 
component of flowmotion was expected. Commonly in T2D there is an increase in autonomic activity 
(157), as such it may be that insulin-mediated increase in neurogenic input to flowmotion is not 
additive to basal levels, thereby the neurogenic component does not increase upon insulin 
stimulation. Despite the data showing unexpected changes in blood flow in healthy controls, the 
impaired contribution and rate of flowmotion components in response to the OGC indicates blood 
flow dysfunction is present within T2D participants. 
 
It is worth noting that high levels of glucose in circulation have been shown to independently influence 
blood flow, separate to insulin action. Williams et. al. (262) showed a reduction in endothelial-
dependent vasodilation of the brachial artery during acute hyperglycaemia induced through 
intraarterial infusion of a 50% dextrose solution. It may be that microvascular perfusion is also altered 
under acute hyperglycaemia. Therefore, it is possible that some of the OGC induced changes to blood 
flow seen in this study may be attributed to the effect of glucose itself, independent to insulin action. 
This may be an alternative explanation for the unexpected observations seen in measures such as OGC 
induced skeletal muscle microvascular blood volume changes in healthy control group. 
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An important observation in the current study is the different response to the OGC in skin+SC 
microvascular flux (Figure 4.4) and total forearm flow (Figure 4.3), compared to skeletal muscle 
microvascular perfusion (Figure 4.6). While total flow and skin+SC flux remained unaltered during the 
OGC, skeletal muscle perfusion was significantly decreased in the healthy controls. There was also no 
correlation between skin+SC and muscle blood flow in both groups. The differences in skin+SC and 
muscle response to the OGC indicates that the skin+SC flowmotion measured at basal and in response 
to the OGC may not represent the flowmotion occurring in the underlying, more metabolically 
relevant, skeletal muscle tissue. 
The data in the current study demonstrates a change in flowmotion at basal and in response to an 
OGC in the T2D participants, compared to healthy control. As such, the next question to be addressed 
in this thesis is how to improve flowmotion in T2D. A restoration of flowmotion may normalise blood 
delivery to important metabolic tissues such as skeletal muscle, thereby enhancing glucose uptake 
and thus improving long term outcomes for T2D participants. Previous studies have shown 
improvement in glucoregulatory and cardiovascular function of both healthy controls (263) and T2D 
(264, 265) participants with a resistance training intervention. It is not known if a similar exercise 
intervention can improve flowmotion in clinically diagnosed T2D participants.  
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Chapter 5 - Microvascular flowmotion 
in the skin and subcutaneous tissue in 
type 2 diabetics:                                    
the effect of resistance training 
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5.1 Introduction  
Treatment for T2D can involve lifestyle changes (including diet and exercise) and the use of drugs that 
either improve insulin sensitivity or enhance insulin production in the remaining β cells. In late stage 
T2D, insulin therapy also becomes necessary due to increased β cell destruction leading to decreased 
insulin production. Initially, the preferred intervention for treatment of T2D, and its precursor insulin 
resistance, is an exercise intervention which has been shown to improve glucose regulation, blood 
lipid profile and cardiovascular function in T2D (203).  
 
Both aerobic and resistance based exercise interventions have been shown to improve 
glucoregulatory function in T2D (264, 266). Tight control of blood glucose levels in T2D is extremely 
important for the long-term health outcomes of the disease. If blood glucose levels are not well 
controlled, but are instead constantly elevated, glycosylation damage of blood vessels results, leading 
to the development of adverse health outcomes such as retinopathy, nephropathy and neuropathy 
(165). A meta-analysis by Boule et. al. (267) and Snowling et. al. (268) looked at the effect of different 
types of training intervention on glucoregulatory function and found there was no difference in the 
improvement of glucose control between the two modes of exercise intervention. 
 
RT interventions in T2D show benefits in short time periods (6-8weeks) and are generally well 
tolerated by participants (224, 265, 269). Improvements in glucose control with a RT intervention have 
shown ameliorated HbA1c levels (264, 270), and enhanced insulin signalling, insulin mediated glucose 
uptake (224), and glycogen storage (264) in skeletal muscle. RT in obese and type 2 diabetic 
participants has also resulted in improvement of other health parameters such as weight loss (270) 
and cardiovascular function (271). For example, a study by Croymans et. al. (272) in obese young males 
showed a 12-week RT intervention improved a number of cardiovascular risk factors for CVD and T2D 
including central, systolic and diastolic blood pressure, percentage body fat, lean mass, and blood lipid 
profile. RT has repeatedly been shown to improve systemic cardiovascular function in T2D with 
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improvements in blood pressure and blood chemistry profiles (264, 270). In addition, endothelial 
function has also been shown to improve with RT, with studies in obese and T2D participants showing 
that an 8-week RT intervention improves endothelial function in conduit and resistance blood vessels 
(265, 269). Watts et. al. (269) showed that an 8-week RT intervention did not change in basal brachial 
artery diameter of T2D group, but there was a normalisation to the healthy control group in brachial 
artery flow mediated dilation (FMD) after training. FMD dilation is known to be a NO-dependant 
process, thereby the 8-week RT intervention improved endothelial-mediated vasodilation in a conduit 
blood vessel. RT therefore potentially improves the endothelial, cardiac and respiratory components 
that are known to influence flowmotion, yet there is little known about the changes in microvascular 
flowmotion that may occur after a RT intervention. Improvements to flowmotion with long-term 
lifestyle intervention have been reported in obese participants. Vinet et. al. (273) measured skin+SC 
flowmotion in response to insulin delivery via iontophoresis before and after a 6-month lifestyle 
intervention (dietary and exercise changes) and found at baseline the contribution of all (except 
respiratory) components of flowmotion during insulin delivery was decreased compared to healthy 
controls. After the lifestyle intervention participants had significant improvements in clinical 
parameters (decreased weight, BMI, fat mass and systolic blood pressure) and an improvement in 
skin+SC flowmotion response to insulin in the endothelial, neurogenic and cardiac components. Vinet 
et. al. (273) therefore showed an improvement in skin+SC flowmotion measures with a lifestyle 
intervention in obese individuals, but very little is known about whether a RT exercise intervention in 
clinically diagnosed T2D is able to improve flowmotion.  
 
The aim of this study was to undertake a 6-week RT intervention with the T2D group previously 
described in this thesis, to assess the impact on flowmotion. RT was chosen as previous studies have 
shown improvement in glucoregulatory function in a 6-week time period and because high intensity 
RT is reasonably well tolerated in sedentary type 2 diabetics (224). After completing the basal and 
OGC measures as described and reported in chapter 4, T2D participants undertook a 6-week RT 
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intervention. It was hypothesised that as long-term RT is known to improve cardiovascular function, 
flowmotion measures would be improved with training. Flowmotion was reassessed at basal and 
during OGC to determine if training resulted in any changes to this response. As data from the OGC 
(described in chapter 4) indicated that flowmotion measures in the skin+SC may not represent 
changes in the underlying skeletal muscle tissue, the changes in microvascular blood perfusion for 
Skin+SC and skeletal muscle were again assessed independently, with LDF + OXY and CEU respectively 
to determine the response to RT in each tissue bed.  
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5.2 Methods 
The characteristic of the T2D participants have been previously described in chapter 3 and 4. The T2D 
cohort underwent a 6-week RT intervention. Of the original 18 T2D participants who completed 
baseline measurements, 14 completed the RT intervention. Due to the budget of this study healthy 
controls were not exercise training and therefore a weakness of this study is a lack of control group to 
compare the changes in T2D group to. The interpretation of the results is therefore limited and 
conclusions can only be drawn about RT impact in T2D participants, and not compared to healthy 
controls.  
 
5.2.1 Resistance training intervention 
The RT program in the current study was based on a previous study by Russell et. al. (263) where a 6-
week RT program was shown to lower fasting blood glucose levels in healthy participants. The training 
intervention involved three sessions a week (Monday, Wednesday and Friday) at the same time each 
day (1830) at a local fitness centre in Hobart, Tasmania, Australia (All Aerobic Fitness). Sessions on 
Monday and Friday involved a mixture of free-weight and resistance machines. The exercises were, in 
order, leg press, lateral pull-down, chest press, weighted lunges, seated row, back fly, bicep curl, 
incline chest press, dumbbell shoulder press, leg extension, leg curl, dips, lateral shoulder raise, triceps 
extension, dumbbell deadlift, and push-ups. One set of each exercise was performed to complete task 
failure (6-15reps) and time to complete each session was limited to 60mins. Throughout the 
intervention, exercises were recorded and load incrementally increased (maintained between 65-85% 
of calculated 1 repetition maximum [1RM]) as greater strength was obtained by participants, to ensure 
progression. In the Wednesday session of each week core and stability exercises were performed. The 
type of exercise was continually modified to compensate for the increased strength and fitness of 
participants over the 6 weeks. Types of resistance-focused techniques performed on Wednesday 
included dumbbell sit-ups, medicine ball toss, leg-lifts, plank positions, burpees, and weighted 
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farmer’s walk. Ad libitum water consumption before, during and after training session was 
encouraged. 
 
5.2.1.1 Strength assessment  
To measure improvement in fitness from Pre-RT to Post-RT, relative strength of participants was 
determined via the Epley formula (274) as described by Russell et. al. (263). The 1RM for the exercises 
leg press, bench press and dead lift were calculated from weight (kg) lifted and repetitions performed: 
1RM = kg x (1 + [repetitions/30]) 
1RM of leg press, bench press and dead lift were then summed to give a total 1RM, which was then 
divided by participant weight to determine relative strength.  
 
5.2.2 Protocol 
Within two days of completing the 6-week RT intervention participants were reassessed using the 
same testing as at baseline, described in section 4.2.1. Briefly, participants were overnight fasted and 
stopped taking their diabetes medication for two days. A fasting blood sample was taken (t =0) and 
then the 50g OGC was repeated. Blood glucose and plasma insulin were determined throughout 
protocol (Figure 5.1) and blood flow measures were again taken at basal and in response to the OGC. 
Testing conditions were as described in section 2.1.1.  
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Figure 5.1: Study protocol. Participants lay in a semi-recumbent position throughout testing. An initial 
basal period was observed and then 50g of liquid glucose was orally consumed. Forearm skin+SC LDF 
+ OXY measures were taken throughout basal and oral glucose challenge (OGC). Total forearm blood 
flow was determined by measuring brachial blood flow (BBF) during basal and at t = 45min into OGC. 
Skeletal muscle microvascular perfusion was determined using contrast enhanced ultrasound (CEU) 
at rest and at = 60min of OGC. Venous blood samples were taken before and then throughout OGC 
(●). 
 
 
5.2.2.1 Skin and subcutaneous tissue microvascular blood flow 
The LDF + OXY probe (described in section 2.1.2) was attached to the midsection of the ventral side of 
the right forearm. Skin+SC LDF flux and tissue oxygenation measures were continuously recorded 
throughout basal and during the OGC (Figure 5.1). Skin+SC microvascular flowmotion was assessed 
with LDF flux and tissue oxygenation measures over two 20min time periods during basal (t = -30 to -
10min) and then during the OGC (t = 35 to 45min). 
 
5.2.2.2 Total forearm blood flow 
Total flow into the forearm was determined by measuring the brachial artery blood flow with 2D-
ultrasound (describe in section 2.1.4). Brachial artery diameter and blood velocity were measured, 
and brachial blood flow (BBF) calculated as described previously in 2.1.4. BBF measures were taken at 
basal (t = -20min) and then at t = 45min into OGC (Figure 5.1). 
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5.2.2.3 Forearm skeletal muscle microvascular perfusion 
Microvascular blood volume, filling rate and perfusion of forearm deep flexor muscle were 
determined as described in section 2.1.3. CEU measure were taken in triplicate during basal period (t 
= -10min) and then at t = 60min of OGC. 
 
5.2.2.4 Blood analysis  
Fasting blood samples were taken from antecubital vein of the non-dominant arm and analysed for 
HbA1c and lipid profile as described in section 2.1.6. Blood samples taken at fasting and then 
throughout the OGC (Figure 5.1) were analysed for blood glucose and plasma insulin as described in 
section 2.1.6. 
 
 
5.2.3 Data analysis 
  
5.2.3.1 Microvascular blood flow averages 
Mean LDF flux and tissue oxygenation measures over a 10min time period during basal (t = -30 to -
20min) and at t = 50 to 60min during the OGC were determined as described in section 2.1.8.1. 
 
5.2.3.2 Flowmotion measures 
Flowmotion analysis using wavelet transformation was performed on 20min of basal (t = -30 to -
10min) and OGC (t = 35 to 55min) LDF flux and tissue oxygenation measures. Wavelet transformation 
data were then quantified by determining AUC of peaks within each flowmotion frequency component 
and peak frequency, as described in section 2.1.8.3. 
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5.2.4 Statistical analysis 
Two-way repeated measures ANOVA were performed to determine difference at basal and during the 
OGC between Pre-RT and Post-RT groups, as described in section 2.4. Paired Student’s t-test was used 
to determine the difference in change during OGC from basal between Pre-RT and Post-RT groups. 
The correlation between change from basal during OGC (Δ) in LDF flux and microvascular perfusion 
measures in the Post-RT group was performed with a Spearman Correlation analysis, as described in 
section 2.4. 
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5.3 Results  
 
5.3.1 Participant characteristics  
Table 5.1 shows the difference in anthropometrics and blood chemistries Pre-RT (reported in chapter 
3) and Post-RT. RT resulted in a small but significant (p = 0.003) decrease in percentage body fat and 
a decrease in fasting blood glucose in these type 2 diabetic participants (p = 0.013). 
 
Table 5.1: Changes in participant anthropometrics and blood chemistries after 6 weeks of resistance 
training in type 2 diabetics. 
Anthropometric and blood chemistry differences between Pre-RT and Post-RT. Data expressed as 
mean ± SE. 
 
119 
 
5.3.1 Strength improvement with resistance training 
The strength of participants was improved over the 6-week training program. The calculated 1RM for 
bench press and leg press exercises, as well as total weight lifted was significantly (p < 0.01) increased 
with RT (Table 5.2). Relative strength (corrected for body weight) was also significantly improved from 
Pre-RT to Post-RT (p < 0.001). 
 
 
Table 5.2: Improvement in strength (1RM) after 6-week resistance training program in type 2 
diabetic participants.  
 
Average strength at baseline (Pre-RT) and after (Post-RT) resistance training (n = 14). 1RM calculated 
with Epley formula (274). Data expressed as mean ± SE. 
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5.3.2 OGC blood glucose and plasma insulin 
The results of a 50g OCG used to measure insulin sensitivity are shown in Figure 5.2. Fasting blood 
glucose was significantly decreased Post-RT (p = 0.019). Interestingly, there was no difference in the 
blood glucose levels before and after training at any time point during the OGC (Figure 5.2A), however, 
the blood glucose AUC was significantly decreased (p = 0.002) after RT (Figure 5.2B). Despite the 
significantly lower fasting blood glucose measures, there was no difference in the change from basal 
of blood glucose during between Pre and Post-RT. There was no difference in plasma insulin levels at 
fasting or throughout the OGC between Pre-RT and Post-RT (Figure 5.2D-F). 
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Figure 5.2: Blood glucose and plasma insulin pre and post 6-week resistance training program in type 
2 diabetic participants. A) Blood glucose response to OGC, the B) resulting AUC of time course and the 
C) blood glucose during OGC represented as change from basal. D) Plasma insulin response to OGC, 
the E) resulting AUC of time course and F) plasma insulin during OGC represented as change from 
basal. Pre-RT and Post-RT (n=12) groups. Data expressed as mean ± SE. * indicates significant 
difference between Pre-RT and Post-RT (p < 0.05). 
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5.3.2 Forearm total flow 
Total flow to the forearm determined by 2D-ultrasound at basal (t = -20min) and during OGC (t = 
45min) is shown in Figure 5.3. There is a significant increase in BBF in response to OGC, both Pre-RT 
and Post-RT (p = 0.007 and 0.037 respectively), however these responses were not significantly 
different Pre- versus Post-RT. 
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Figure 5.3: Brachial artery blood flow change with 6-week resistance training program in type 2 
diabetic participants. Brachial artery blood flow (mL/min) measured during basal (B) and 45min after 
OGC (G). Pre-RT and Post-RT (n=11) groups. Time points of each individual participant is represented 
by a different signal, — indicates mean. # indicates significant difference between healthy basal and 
OGC (p < 0.05). 
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5.3.3 Skin and subcutaneous tissue microvascular blood flow and tissue oxygenation  
The average skin+SC microvascular blood flow measures (LDF flux, O2 Sat and tHb) were assessed over 
a 10min period at basal (t = -30 to -20) and OGC (t = 50 to 60min) to determine blood flow changes 
resulting from 50g oral glucose load. There were no changes in LDF flux, O2 Sat or tHb in response to 
the OGC, and RT has no effect on these measures (Figure 5.4A-C). The change during the OGC from 
basal in LDF flux, O2 Sat and tHb measures was no different from Pre-RT to Post-RT (Figure 5.4D-F). 
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Figure 5.4: Skin and subcutaneous tissue LDF flux and tissue oxygenation change with 6-week 
resistance training program in type 2 diabetic participants. Average skin+SC A) LDF flux, B) O2 Sat, and 
C) tHb measures assessed over 10mins during basal (B, open symbol) and OGC (G, filled symbol). — 
indicates mean. Change from basal to OGC was calculated for LDF flux (D), O2 Sat (E) and tHb (F). Pre-
RT and Post-RT (n=14) groups. Data expressed as mean ± SE. 
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5.3.4 Forearm skeletal muscle microvascular perfusion 
Blood flow in the skeletal muscle of forearm was measured using CEU Pre-RT and Post-RT to determine 
if exercise training improved basal muscle microvascular perfusion and in response to OGC. No 
significant difference at basal or in response to the OGC, Pre or Post-RT was seen in the skeletal muscle 
microvascular perfusion measures (Figure 5.5A-B). However, training did result in a near significant (p 
= 0.052) reduction in microvascular filling rate at basal. Figure 5.5D-F shows the change in forearm 
skeletal muscle microvascular perfusion in response to OGC. Skeletal muscle microvascular perfusion 
measures tended to decrease in response to OGC Pre-RT, whereas Post-RT microvascular perfusion 
tended to increase during OGC. The change from basal was therefore significantly different between 
Pre and Post-RT for microvascular filling rate (p = 0.021) and perfusion (p = 0.002). 
Microvascular Filling Rate
B G  B G 
M
ic
ro
va
sc
u
la
r 
Fi
lli
n
g 
R
at
e
 (
1
/s
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Microvascular Volume
B G  B G 
M
ic
r o
va
s c
u
la
r  
V
o
l u
m
e
 (
A
I)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
A B C
Post-RTPre-RT Post-RTPre-RT Post-RTPre-RT
Microvascular Volume
Pre-RT Post-RT
M
ic
ro
va
sc
u
la
r 
V
o
lu
m
e
 (
A
I)
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
D E F
Microvascular Filling Rate
Pre-RT Post-RT
M
ic
ro
va
sc
u
la
r 
Fi
lli
n
g 
R
at
e
 (
1
/s
)
-0.10
-0.05
0.00
0.05
0.10
Microvascular Perfusion
Pre-RT Post-RT
M
ic
ro
va
sc
u
la
r 
P
e
rf
u
si
o
n
 (
A
U
/s
)
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
**
Microvascular Perfusion
B G  B G 
M
ic
ro
va
sc
u
la
r 
P
e
rf
u
si
o
n
 (
A
I/
s)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
 
Figure 5.5: Skeletal muscle microvascular blood perfusion change with 6-week resistance training 
program in type 2 diabetic participants. CEU was used to determine A) microvascular blood volume, 
B) microvascular filling rate and C) microvascular perfusion during basal (B, open symbol) and OGC (G, 
filled symbol). — indicates mean. Change from basal during OGC in forearm skeletal was calculated 
for D) Δmicrovascular blood volume, E) Δmicrovascular filling rate and F) Δmicrovascular perfusion. 
Pre-RT and Post-RT (n=10) groups. Data expressed as mean ± SE. χ indicates a near significant 
difference between Pre-RT and Post-RT groups (p = 0.052) at basal. * indicates significant difference 
between Pre-RT and Post-RT groups (p < 0.05). 
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5.3.5 Correlation between skin and subcutaneous tissue flux and skeletal muscle perfusion 
To determine if skeletal muscle and skin+SC had a similar vascular response to the OGC Post-RT, a 
correlation analysis was performed. The change in skin+SC LDF flux was compared to the change in 
skeletal muscle microvascular blood volume (Figure 5.6A) and perfusion (Figure 5.6B) in response to 
the OGC. There was no correlation between change in LDF flux in skin+SC and change in microvascular 
blood volume in skeletal muscle (Figure 5.6A), where R = 0.290 and p = 0.182. Similarly, there was no 
correlation between change in LDF flux in skin+SC and change in microvascular perfusion of skeletal 
muscle (Figure 5.6B), R = 0.109 and p = 0.885. 
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Figure 5.6: Correlation of skin and subcutaneous tissue with skeletal muscle blood flow after 6-week 
resistance training program in type 2 diabetic participants. The correlation between the change during 
OGC from basal of skin+SC LDF flux and skeletal muscle A) microvascular blood volume and B) 
microvascular perfusion was determined in Post-RT ( ) group (n = 8). 
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5.3.6 Skin and subcutaneous tissue flowmotion measures  
To determine of the effect of RT on flowmotion, representative traces from an individual Pre-RT and 
Post-RT participant during basal and the OGC are shown in Figure 5.7.  
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Figure 5.7: Wavelet transformation of skin and subcutaneous tissue blood flow measures before and 
after RT. This figure shows wavelet transformation during basal (open symbol) and OGC (filled symbol) 
of skin+SC A) LDF flux B) O2 Sat and C) tHb measures of one subject Pre-RT and Post-RT.  
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Wavelet transformations resulting from LDF flux skin+SC microvascular blood flow measures were not 
affected by 6-week resistance training as there was no difference in peak AUC from basal to OGC Pre 
or Post-RT (Figure 5.8).  
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Figure 5.8: LDF flux wavelet transformation: peak area under the curve for flowmotion component 
changes with 6-week resistance training program in type 2 diabetic participants. Average peak AUC of 
wavelet transformed LDF flux measures during basal (B, open bars) and OGC (G, filled bars) for 
frequency regions A) endothelial B) neurogenic C) myogenic D) respiratory and E) cardiac. Pre-RT and 
Post-RT (n=14) groups. Data expressed as mean ± SE. 
 
 
In both the Pre-RT and Post-RT measures, the OGC resulted in a significant elevation in the peak 
frequency of the cardiac input (p= 0.002 and p < 0.001 respectively, Table 5.3). No change in peak 
frequency in the lower frequency components of flowmotion were seen in the Pre-RT measurements. 
In the Post-RT group, the neurogenic and myogenic peak frequency were both significantly decreased 
during the OGC compared to basal (p = 0.027 and p = 0.016 respectively), which did not occur in the 
Pre-RT group, indicating a training effect. 
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Table 5.3: LDF flux wavelet transformation: peak frequency changes with 6-week resistance training 
program in type 2 diabetic participants. 
 
Average peak frequency in each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE. 
 
 
 
The cycles per second change from basal in the cardiac component was significantly different (p = 
0.003) from Pre-RT to Post-RT (Table 5.4). There were no other significant differences in cycle per 
second change from basal between the two groups, though the neurogenic component showed a 
trend (p = 0.055) of increased cycle period during OGC from basal in Post-RT compared to Pre-RT. 
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Table 5.4: LDF flux wavelet transformation: change from basal in peak frequency. 
 
Average change from basal the in peak frequency at each frequency region, expressed as cycle period 
(seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE. 
 
 
Quantification of the O2 Sat wavelet transformation data showed only one significant difference 
during the OGC compared to basal in the Pre-RT and Post-RT measures. Pre-RT there was a significant 
reduction in the endothelial peak AUC during the OGC as compared to basal (p = 0.006). This significant 
change was no longer present after RT intervention. While not significant, a similar trend in the 
neurogenic and myogenic components of decreased input during OGC Pre-RT, and an improvement 
Post-RT was also observed. 
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Figure 5.9: O2 Sat wavelet transformation: peak area under the curve for flowmotion component 
changes with 6-week resistance training program in type 2 diabetic participants. Average peak AUC of 
wavelet transformed O2 Sat measures during basal ((B, open bars) and OGC (G, filled bars) for 
frequency regions A) endothelial B) neurogenic and C) myogenic. Pre-RT and Post-RT (n=14) groups. 
Data expressed as mean ± SE. # indicates significant difference from basal to OGC in Pre-RT group (p 
= 0.012). 
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Pre-RT the myogenic component peak frequency significantly decreased (p = 0.026) in response to the 
OGC compared to basal (Table 5.5). This significant change was no longer present after RT 
intervention.  
 
Table 5.5: O2 Sat wavelet transformation peak: peak frequency changes with 6-week resistance 
training program in type 2 diabetic participants. 
Average peak frequency in each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE. 
 
 
 
There was no difference in the peak frequency change from basal to OGC between the Pre-RT and 
Post-RT groups (Table 5.6). 
 
Table 5.6: O2 Sat wavelet transformation: change from basal in peak frequency. 
 
Average change from basal the in peak frequency at each frequency region, expressed as cycle period 
(seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE. 
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Flowmotion measures determined from the tHb wavelet transformation showed no significant 
difference in peak AUC during the OGC compared to basal in Pre-RT or Post-RT. However, as with O2 
Sat measures, there was a trend for a decrease in the lower frequency components (endothelial, 
neurogenic and myogenic) input in the Pre-RT group, which appears to have been improved with RT. 
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Figure 5.10: tHb wavelet transformation: peak area under the curve for flowmotion component 
changes with 6-week resistance training program in type 2 diabetic participants. Average peak AUC of 
wavelet transformed tHb measures during basal (B, open bars) and OGC (G, filled bars) for frequency 
regions A) endothelial B) neurogenic and C) myogenic. Pre-RT and Post-RT (n=14) groups. Data 
expressed as mean ± SE.  
 
There was no difference in the peak frequency in Pre-RT or Post-RT during the OGC when compared 
to basal (Table 5.7). 
Table 5.7: tHb wavelet transformation peak: peak frequency changes with 6-week resistance training 
program in type 2 diabetic participants. 
 
Average peak frequency in each frequency region during basal and OGC, expressed as frequency (Hz) 
and cycle period (seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE. 
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The peak frequency changes from basal during OGC (Table 5.8) were not different between the Pre-
RT and Post-RT groups. 
 
Table 5.8: tHb wavelet transformation: change from basal in peak frequency. 
 
Average change from basal the in peak frequency at each frequency region, expressed as cycle period 
(seconds). Pre-RT and Post-RT (n=14) groups. Data expressed as Mean ± SE.  
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5.4 Discussion 
A 6-week RT intervention in T2D participants resulted in improvement in strength (Table 5.2), 
glucoregulatory function (Figure 5.2) and a small change in body composition (Table 5.1). While the 
total forearm blood flow (Figure 5.3) and average skin+SC microvascular flux (Figure 5.4) response to 
the OGC was unaltered with training, skeletal muscle perfusion (Figure 5.5) and skin+SC flowmotion 
(Table 5.3 and Figure 5.9) responses to the OGC were significantly alter from basaline Post-RT. 
 
The increase in relative strength (as measured by 1RM, Table 5.2) over the 6-week RT intervention 
showed participants successfully engaged in the exercise program, facilitating their progression. As a 
result of this training program, there was a small, but significant decrease in percentage body fat of 
participants, with no total body weight change (Table 5.1), suggesting a small improvement in body 
composition. The enhancement in physical strength and body composition was accompanied by an 
improvement in blood glucose levels, both fasting (Table 5.1) and in response to the OGC (Figure 5.2), 
while plasma insulin levels were unaltered. The exercise intervention therefore appears to have 
improved insulin-sensitivity of participants, as has been previously reported in T2D participants (224, 
275), resulting in increased glucose disposal in response to OGC and lower fasting blood glucose levels. 
While these measures improved with training, fasting blood glucose and blood glucose response to 
OGC were still elevated in comparison to the healthy controls (described in Table 3.1 and Figure 4.2), 
demonstrating that while there has been improvement in glucoregulation, participants still display an 
overt diabetic disease state. Additionally, while the improvements in fasting blood glucose and body 
composition are statistically significant, this may not translate into significant clinical improvements 
in the short term. Post-RT no change was made to the medication of any participants, indicating that 
the changes over the short RT intervention have not yet become clinically significant. However, with 
continued exercise in the T2D participant’s further improvements on health parameters are likely to 
occur and therefore have a greater long-term clinical significance and improvement.  
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Previously, RT interventions in T2D and insulin resistance have shown improvement in cardiovascular 
function in cardiac output, large vessel function (212, 272) and in NO-dependent flow mediated 
dilation of conduit and resistance vessels, indicating an improvement in endothelial function (213, 
265, 269). In the current study a short term 6-week exercise intervention did not improve blood 
pressure (Table 5.1), total forearm blood flow (Figure 5.3) or skin+SC microvascular flux (Figure 5.4), 
either at basal or in response to the OGC. Post-RT, bulk blood flow to the forearm was still significantly 
elevated in response to the OGC, as was skin+SC microvascular blood flow at basal and during the 
OGC, in comparison to healthy controls (as described in sections 4.3.2 and 4.3.3). The lack of 
improvement in blood pressure and macrovascular blood flow is perhaps due to the short duration of 
the exercise intervention as studies showing blood pressure changes with RT tend to occur over longer 
periods of time (12 weeks or more (270, 272)).  
 
While skin+SC flux and total blood flow, at basal or during OGC was not altered with RT, the response 
to OGC in the underlying skeletal muscle microvascular perfusion was improved (Figure 5.5). Prior to 
RT skeletal muscle microvascular perfusion decreased in response to the OGC (Figure 5.5). In contrast, 
Post-RT microvascular perfusion tended to increase in response to the OGC, indicating improved 
insulin-mediated vasodilation in the skeletal muscle. These improvements were primarily driven by an 
improvement in basal perfusion levels Post-RT (Figure 5.5). The RT intervention may have improved 
baseline skeletal muscle microvascular perfusion levels and insulin sensitivity of the endothelium, and 
thus augmented insulin-mediated vasodilation in the skeletal muscle. Improved insulin-mediated 
vasodilation enhances nutritive capillary recruitment, potentially then enabling a greater glucose 
disposal in skeletal muscle (41). While this change in response to the OGC Post-RT does differ from 
the decrease in skeletal muscle perfusion seen in the healthy control group (described in section 
4.3.5), it is important to note that the decrease seen in the healthy controls was surprising. An 
increased skeletal muscle microvascular perfusion in response to a mixed meal challenge (65) and 
euglycemic hyperinsulinemic clamp (37) has previously been seen in healthy populations. As discussed 
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in chapter 4, this surprising result in the healthy controls is possibly due to an increased activation of 
the SNS. (258). It appears that in the already insulin resistant T2D group, where blood glucose levels 
are chronically elevated, the OGC-mediated activation of SNS is blunted, as has previously been 
observed in an insulin resistant population (253). This blunted response may be due to an already 
elevated neurogenic activity, which is commonly associated with T2D (autonomic dysfunction) (199). 
Therefore, the increased perfusion in response to OGC Post-RT shows an improvement in vascular 
insulin sensitivity and increase in muscle perfusion.  
 
RT resulted in a significant decrease in the rate of the neurogenic and myogenic components of 
flowmotion in response to the OGC (measured by LDF, Figure 5.8). Pre-RT the contribution of the 
endothelial component was decreased during the OGC, while Post-RT there was no change observed 
in the endothelial component in response to the OGC (measured by O2 Sat, Figure 5.9), indicating a 
partial restoration of endothelial function. Based on the data from this study, the RT intervention has 
modified skin+SC flowmotion in the T2D group. Again, these findings differ from the skin+SC 
flowmotion changes seen in response to the OGC in the healthy control group (as described in section 
4.3.5), where lower frequency component contribution decreased and rate of components increased 
during the OGC. An increased activation of the SNS is likely to account for this observation in healthy 
controls (253). Previously, Jonk et.al. (247) observed an increase in all components of skin+SC 
flowmotion after endogenous release of insulin induced by a mixed meal in healthy controls. 
Flowmotion Post-RT, where the endothelial component was no longer decreased, does therefore 
appear to be improved, but not normalised in these T2D participants. 
 
An additional consideration for the current study may be that in the Post-RT group the measurement 
of flowmotion in the skin+SC, where RT did not alter average microvascular blood flow measured by 
LDF flux and tissue oxygenation (Figure 5.4), may not reflect the flowmotion occurring in the 
underlying skeletal muscle, which showed improved response to the OGC (Figure 5.5). It is possible 
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the minimal changes during the OGC in the lower frequency component contributions that occurred 
in the skin+SC (improvements seen in endothelial component only), does not reflect the skeletal 
muscle flowmotion changes, where insulin-mediated vasodilation seems to have improved with RT, 
and a greater change in flowmotion may occur.  
 
A further factor that needs consideration is the potential decrease in subcutaneous fat of T2D 
participants after RT intervention. RT caused a decrease in the percentage body fat of T2D participants 
(Table 5.1), therefore if there was a change in forearm subcutaneous fat content, it is likely that the 
skin+SC flowmotion measures are sampling different volumes of skin+SC after RT compared to 
baseline. The different blood volumes of the tissue potentially measured by the LDF + OXY probe may 
also explain the difference in skin+SC flowmotion measures before and after RT. Unfortunately, 
despite CEU imaging being performed on forearm muscle, any difference in subcutaneous fat from 
Pre-RT to Post-RT was not able to be determined as ultrasound images were focused on muscle tissue 
and adequate imaging of subcutaneous mass was not obtained for each subject. 
 
The results of this study, and those described in chapters 3 and 4 of this thesis, highlight an issue with 
the assessment of flowmotion in healthy and diseased populations, where, for primarily practical 
(non-invasive) reasons, flowmotion is assessed in skin+SC using LDF flux. The response to the OGC in 
healthy controls and in the T2D participants Pre and Post-RT, show a difference in skin+SC and muscle 
blood flow, indicating that skin+SC flowmotion measures may not reflect the flowmotion occurring in 
the underlying skeletal muscle tissue. Furthermore, there was no correlation in skin+SC and muscle 
blood flow in healthy controls and type 2 diabetics, Pre or Post RT (Figure 4.7 and 5.6 respectively). 
Understanding flowmotion in skeletal muscle and how it changes with metabolism, is of great 
importance in discerning the dysfunction that occurs in T2D given the critical role skeletal muscle 
blood flow plays in glucose disposal. Adaptation of the CEU technique, used to measures skeletal 
muscle microvascular perfusion in the clinical studies of this thesis, could potentially assess 
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flowmotion in skeletal muscle tissue in a non-invasive manner and allow assessment of flowmotion in 
large regions of tissue simultaneously. 
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Chapter 6 - Adaption of contrast 
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6.1 Introduction 
The ability to vary blood flow patterns and distribution in tissues is important for normal physiological 
function, optimising the delivery of nutrients and removal of wastes under different metabolic 
demands (80, 276, 277). Altering both total blood flow and flow distribution is believed to be of 
particular importance in tissues such as skeletal muscle. Nutrient requirement in skeletal muscle 
undergoes dramatic changes during different states of metabolic demand. During rest demand is low 
and therefore only about 1/3 of capillaries are perfused at any one time, allowing for greater blood 
flow distribution to other tissues in the body (reviewed in (6)). In contrast, during exercise demand for 
fuel significantly increases and (dependent upon level of intensity) many or all capillaries become 
perfused to meet heightened nutrient requirements of the myocytes (278). The mechanism by which 
changes in blood flow distribution occur is not well understood, however it is thought to be influenced 
by a number of factors, both centrally mediated and locally acting. 
Changes in blood flow distribution within skeletal muscle can be brought about by altering the vascular 
tone of 3rd-5th order arterioles which feed into the capillaries (16). Additionally, pre-capillary sphincters 
may contract or relax to allow or impede the passage of blood flow (35). Of particular interest in this 
thesis is the process of flowmotion as it is believed to be important for normal physiological function 
in skeletal muscle. However, the precise mechanisms which control this process and the influence of 
different metabolic states is still poorly understood.  
 
Elucidating the mechanisms which control skeletal muscle flowmotion is impeded by the technologies 
available to assess the phenomena. Intravital microscopy has been used to assess flowmotion in small 
specialised, surgically exposed animal muscle (279) or in the nailfold microvasculature of humans (92, 
100). However, this technique is limited in the study of flowmotion due to its inability to study larger 
sections of deeper more metabolically relevant tissues, without significant disruption to the blood 
flow. The primary technique used to assess flowmotion has been LDF. Due to its ability to non-
invasively assess skin+SC blood flow, LDF has been a useful tool in the discovery of flowmotion and 
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the categorisation of the different frequency components which influence blood flow distribution (56, 
90, 91, 96, 279). LDF does however have a number of limitations which prevent a complete 
understanding of flowmotion function. A major limitation with the LDF technique in the context of 
flowmotion is that it can only measure a small section of tissue at any one time. The LDF laser 
illuminates up to a volume of ~0.55-0.79mm2 section of tissue (61), thus assessing flowmotion in that 
area alone, giving no indications of possible differing flowmotion patterns occurring outside of this 
sample area. LDF is also limited in the types of tissues in which it can be used to assess flowmotion, 
especially in humans, as in deeper tissues such as skeletal muscle a LDF probe must be inserted into 
the tissues itself (or the skin above the muscle surgically removed). The need to implant the LDF probe 
presents a number of issues, such as the discomfort caused in participants, as well as the potential 
damage to the tissue and alteration of blood flow patterns. As such, the majority of flowmotion 
assessment using LDF has been in skin+SC, which is a non-invasive LDF measure where the probe is 
placed directly onto the skin surface. The previous chapters of this thesis have demonstrated a 
difference in microvascular perfusion between skin+SC and the underlying skeletal muscle as 
measured by LDF and CEU respectively. As such, it is unlikely skin+SC flowmotion measurements are 
representative of flowmotion in more metabolically active tissues such as skeletal muscle. LDF also 
measures both red blood cell number and velocity, meaning the influence of each of these 
components upon the overall measure of flowmotion cannot be separated. Thus, with LDF measures 
it is unclear if changes in flowmotion detected are a result of increased blood volume to a tissue 
(indicating greater capillary recruitment) or increased velocity (indicating an increase in total blood 
flow to the tissue), or a combination of the two. 
 
Originally developed to detect blood flow blockages in the heart (280, 281), the novel technique of 
CEU is a minimally invasive technique which has been adapted to measure skeletal muscle 
microvascular volume changes in humans and animals (282). The CEU technique allows continuous 
monitoring of blood volume in a section of skeletal muscle, and therefore any changes in 
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microvascular recruitment under different treatment conditions can be determined. The adaptation 
of the CEU technique for the measurement of skeletal muscle flowmotion would provide a means of 
overcoming a number of the limitations of LDF flowmotion measures. Unlike LDF, CEU is able to 
measure flowmotion across larger sections of skeletal muscle tissue, i.e. a 2D image of a whole rat calf 
muscle. CEU measurements are non-invasive in regards to the tissue being assessed (only requiring 
intravenous infusion of contrast agent), making the technique appropriate for human use, and limiting 
any experimental induced changes in skeletal muscle blood flow patterns. CEU is also a measure of 
blood volume alone and as such any changes observed can be directly related to blood volume 
changes within the tissue and not changes in RBC velocity like LDF. The adaptation of CEU to assess 
flowmotion therefore provides the opportunity to establish if flowmotion changes result purely from 
altered velocity of blood flow, or if blood volume also contributes.  
 
A novel idea is to not only measure skeletal muscle flowmotion with wavelet transformation of LDF 
flux and tissue oxygenation data, but to also apply the same processing principles to CEU data acquired 
during various treatment protocols. The use of CEU in the assessment of flowmotion gives a new 
approach to its study and can potentially improve the ability to evaluate different components of 
skeletal muscle flowmotion. Thus the aim of this study was to use CEU to assess skeletal muscle 
flowmotion with the wavelet transformation technique. The CEU measures were validated with a 
comparison to the well-established LDF technique. In order to validate the CEU technique, skeletal 
muscle flowmotion was altered with the infusion of phentolamine (PT). PT is an alpha-adrenoceptor 
antagonist known to cause vasodilation of arteries and arterioles via the inhibition of neurogenic-
mediated vasoconstriction (283). The systemic infusion of PT therefore results in an inhibition of the 
neurogenic component of flowmotion. LDF and CEU data were analysed by wavelet transformation to 
determine changes in skeletal muscle flowmotion.  
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6.2 Methods 
 
6.2.1 Animal care 
Male Sprague Dawley rats (288g ± 8) were used in these experiments. Animals were raised as 
described in 2.1.1.  
 
6.2.2 In vivo surgery 
The anaesthetised rat model was used for these experiments. Surgery was performed as described in 
section 2.1.2.  
 
6.2.3 Experimental procedure 
The systemic infusion of contrast agent during CEU measures causes an interference with the 
ultrasonic flow probe used to measure FBF, therefore, systemic and microvascular blood flow were 
measured in separate experiments (protocol A and protocol B, Figure 6.1). Protocol A allows the 
assessment of LDF flowmotion and FBF, while protocol B assesses flowmotion with LDF and CEU. These 
were performed on separate animals. 
 
6.2.3.1 Protocol A 
After post-surgery stabilisation, a 30min basal period was followed by a 60min systemic PT infusion 
(5mg/kg/min). Skeletal muscle microvascular blood flow in the tibialis anterior muscle was assessed 
with the LDF + OXY probe (LDF flux, O2 Sat and tHb measures). LDF flux, tissue oxygenation and FBF 
measures (as per section 2.1.2.1) were taken constantly throughout protocol (Figure 6.1). LDF + OXY 
flowmotion was assessed by wavelet transformation on data from the 30min basal period and last 
30min of PT infusion. Animals were euthanized at completion of experiment with an overdose of 
sodium pentobarbital. 
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6.2.3.2 Protocol B 
Protocol B also consisted of a 30min basal period followed by 60min of systemic PT infusion 
(5mg/kg/min). Tibialis anterior LDF + OXY flux was again measured throughout protocol. Calf or upper 
thigh CEU acoustic intensity (AI) measures were constantly recorded during 30min basal period, and 
for the last 30min of PT infusion (t=60-90min, Figure 6.1). Flowmotion measures from calf and upper 
thigh CEU and LDF + OXY data from 30min basal capture and last 30min of PT infusion was determined 
with wavelet transformation. Calf microvascular perfusion was determined at t=30min (basal) and 
t=90min (PT), as describe in section 2.1.2.3. Animals were euthanized at completion of experiment 
with an overdose of sodium pentobarbital. 
 
 
Figure 6.1: Microvascular experimental protocols. A) Protocol A: LDF flux, O2 Sat, tHb (LDF + OXY) and 
femoral blood flow (FBF) was recorded continuously throughout experiment. Following 30min basal 
recording phentolamine (PT) was systemically infused (5mg/kg/min) for remainder of experiment 
(60min). Wavelet transformation analysis was performed on 30min basal and last 30min of PT infusion 
LDF + OXY data. B) Protocol B: LDF + OXY was again recorded continuously throughout experiment. 
Contrast enhanced ultrasound (CEU) measures were taken on either calf or upper thigh skeletal 
muscle. A 30min basal CEU capture was taken. PT was then systemically infused (5mg/kg/min) for 
remainder of experiment. Continuous CEU capture was taken on the last 30min of PT infusion. CEU 
microvascular perfusion measures were taken at the end of basal and PT captures (*), t=30 and 90min. 
CEU and LDF + OXY data from the 30min basal and PT time points was used in the wavelet 
transformation analysis. 
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6.2.4 Data analysis  
 
6.2.4.1 Haemodynamic and LDF flux analysis 
Data were determined as described in section 2.2.3. MAP, HR and FBF were calculated every 5min 
over the course of experiment. LDF + OXY 5min LDF flux, O2 Sat and tHb averages were calculated 
throughout entire experiment. 
 
6.2.4.2 LDF + OXY flowmotion analysis 
Data from each 30min time period measured by LDF + OXY was exported from Moor instruments 
software and analysed as per section 2.2.4. To determine changes from basal to PT in lower frequency 
components of flowmotion in LDF + OXY measures, AUC of peaks in endothelial (0.095-0.02Hz), 
neurogenic (0.02-0.06Hz) and myogenic (0.06-0.15Hz) frequency ranges were determined using 
PeakFit as describe in section 2.1.8.3. As these experiments were performed on an animal model, but 
the frequency regions defined in the literature are based on human participants, less stringent 
parameters on frequencies rangers were applied when prudent. Where there were clear peaks for 
each component shown that were not necessarily within the defined frequency bands leniency was 
applied to allow for the potential difference between the animal model and human participants.  
 
6.2.4.3 CEU flowmotion analysis 
After extensive investigation, a region of 1mm2 was determined to be most appropriate for analysis. 
Qlab software allows for a maximum of 10 ROI to be used during any one analysis. A range of different 
ROI box sizes were analysed to determine the best means of assessing CEU data to then be compared 
to LDF + OXY. Figure 6.2 demonstrates the differences in wavelet transformation output at various 
box sizes. The decision was made to use ten x 1mm2 boxes as the data output was of a sufficient quality 
and comparable to the LDF + OXY measures as LDF has been shown to sample ~0.55-0.79mm2 volume 
of tissue (61).   
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Figure 6.2: Average wavelet transformation for different ROI sizes. As size of ROI measured decreases, 
the clarity of peaks in each frequency component becomes higher and more pronounced, without a 
significant change in frequency. Under 1mm2 decreasing ROI box size has less effect upon wavelet 
transformation. The 1mm2-sized ROI gives well defined peaks in the wavelet transformation output 
and is comparable to LDF measures, therefore was used in analysis.  
 
For calf and upper thigh CEU measures, both a predominantly white region and a mixed fibre region 
(Figure 6.3) in each muscle mass was assessed with ten 1mm2 regions of interest (ROI’s). Data for each 
ROI was exported and wavelet transformation per section 2.2.4 was performed. Analysis was 
performed this way to investigate if flowmotion varies in different sections with differing fibre types. 
It is not appropriate to use large ROI to assess flowmotion in skeletal muscle tissue as it is thought 
different sections of the muscle will have different flowmotion patterns. The output of large ROI 
analysis will thereby be an average of all the flowmotion patterns and not representative of the 
differing blood flow occurring across the tissue. Due to the observed highly variable nature of 
flowmotion across skeletal muscle, the basal wavelet transformation graph of each ROI for each 
experiment and each fibre type region was de-identified, randomised and given to informed, but 
impartial selectors. In duplicate, these selectors determined the three 1mm2 ROI’s of each experiment 
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and fibre type that displayed the strongest neurogenic peak in the basal recording. The experimental 
average was determined from these three ROI’s for both basal and PT treatment. As per LDF + OXY, 
to determine changes from basal to PT in lower frequency components of flowmotion in CEU 
measures PeakFit software was used to determine AUC of peaks in each frequency region as described 
in section 2.1.8.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Rat calf and upper thigh contrast enhanced ultrasound regions of interest. A) CEU image of 
rat calf with overlay of individual muscle positioning based upon R. Armstrong and O. Phelps 1982 
(229). Abbreviations: s., soleus; pl., plantaris; gr., gastrocnemius red; gm., gastrocnemius mixed; 
gastrocnemius white. B) Example of 10 regions of interest (ROI) placement in calf predominantly white 
fibre region. C) Example of 10 ROI placement in calf mixed fibre region. D) CEU image of rat upper 
thigh with overlay of individual muscle positioning based upon R. Armstrong and O. Phelps 1982 (229). 
Abbreviations: b.f.a., biceps femoris anterior; b.f.p., biceps femoris posterior; ad., adductor magnus 
and brevis; s.m.r., semimembranosus red; s.m.w., semimembranosus white; s.t. semitendinosus; gra., 
gracilis. E) Example of 10 ROI placement in thigh predominantly white fibre region. F) Example of 10 
ROI placement in thigh mixed fibre region. 
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6.2.5 Statistical analysis 
All tests were performed using SigmaStat software (Systat Software Inc. CA, USA) as described in 
section 2.4. Significant change in LDF flux, O2 Sat, tHb, MAP and FBF over time were determined using 
one-way repeated-measures ANOVA. Statistical difference between basal and PT was determined 
using a paired Student’s t-test.   
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6.3 Results  
6.3.1 Systemic haemodynamic changes 
PT inhibits the neurogenic input to the vascular system and thus causes haemodynamic changes 
systemically (Figure 6.4). HR was not significantly altered throughout experiment (Figure 6.4B). MAP 
remained steady at 113.6 ± 0.5mmHg throughout basal period and then significantly decreased (p < 
0.001) within 5min of PT infusion (Figure 6.4A). This drop in MAP plateaued at 45mins and remained 
at 79.2 ± 1.0mmHg for the rest of the experiment. FBF followed a similar pattern with an average of 
1.00 ± 0.01mL/min at basal becoming significantly increased upon PT infusion (p < 0.05) (Figure 6.4C). 
FBF however, continued to increase throughout experiment reaching 2.48 ± 0.19mL/min (2.5-fold 
increase from basal) at experiment end (t = 90min). 
 
Figure 6.4: Systemic hemodynamic changes with PT. Systemic PT induced changes in A) mean arterial 
pressure (n=14) and B) heart rate (n=14) C) total hindlimb blood flow (n=5). Data expressed as mean 
± SE. * significantly different from basal, p<0.05. 
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6.3.2 Microvascular haemodynamic changes 
Inhibition of neurogenic input to the vasculature resulted in altered microvascular blood flow in 
skeletal muscle. Change from basal in LDF + OXY measures (LDF flux, O2 Sat and tHb) for the tibialis 
anterior muscle are shown in Figure 6.5. LDF measures tended to increase from basal (173.4 ± 27.6PU) 
over course of experiment, becoming significant (p < 0.05) from t = 0 at t = 80 and 90min. O2 Sat 
remained steady throughout basal period (58.4 ± 0.1%) and then significantly increased at t = 40min, 
remaining elevated (70.6 ± 0.5%) for the rest of experiment. tHb was constant throughout basal (156.9 
± 16.1AU) and then continually increased upon PT infusion, reaching significantly different from basal 
(p < 0.05) at t = 60min. Peak increase of 24.4 ± 9.3AU was at achieved at t = 90min. 
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Figure 6.5: Microvascular blood flow changes from basal in tibialis anterior muscle. Systemic PT 
induced A) LDF flux change from basal B) O2 Sat change from basal C) tHb change from basal. Data 
expressed as mean ± SE, n=14. * Significantly different from t=0, p<0.05. 
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Infusion of PT resulted in increased capillary perfusion from basal (t=30min) to PT treatment (t=90min) 
in calf muscle as shown in Figure 6.6. Microvascular blood volume and microvascular filling rate of the 
calf muscle both significantly increased upon PT treatment (p = 0.002 and 0.004 respectively). When 
combined these two parameters give a measure of microvascular perfusion, which also increased 
significantly (p = 0.015) with PT infusion, indicating significant microvascular recruitment in the calf 
upon PT infusion.  
 
Figure 6.6: Microvascular perfusion in calf muscle as measure by contrast enhanced ultrasound. Calf 
microvascular perfusion pre (t = 30) and 60min (t = 90) into PT infusion. A) Microvascular volume (A) 
B) microvascular filling rate (β) C) Microvascular perfusion (Axβ) n=5. * Significantly increased from 
basal, p<0.05. 
 
 
 
6.3.3 Skeletal muscle flowmotion changes 
Data from wavelet transformation indicates the contribution of each frequency component to 
flowmotion and can be graphed on a log scale. Figure 6.7 shows typical wavelet transformations from 
each different microvascular blood flow measure. During basal capture a clear peak in the neurogenic 
frequency range (0.02-0.06Hz) is observed, upon PT infusion there is a prominent loss of the signal 
within the neurogenic frequency component. 
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Figure 6.7: Typical wavelet transformation of skeletal muscle blood flow measures Laser Doppler 
Flowmetry, oxygen saturation, total haemoglobin and contrast enhanced ultrasound. Typical wavelet 
transformations of basal and PT treatment over low frequency components endothelial (0.095-
0.02Hz), neurogenic (0.02-0.06Hz) and myogenic (0.06-0.15Hz) in tibialis anterior muscle measured by 
A) LDF flux B) O2 Sat C) tHb measures and calf muscle measured by D) CEU. 
 
The change in each of the flowmotion frequency components upon PT infusion can be quantified by 
determining the AUC of the peaks in each frequency range. Figure 6.8 shows the basal to PT changes 
in the lower frequency components of flowmotion (endothelial, neurogenic and myogenic) in the 
tibialis anterior muscle measured by the LDF + OXY probe. Flowmotion measures by LDF show a 
significant reduction (p < 0.001) in peak AUC from basal in both neurogenic and myogenic frequency 
ranges. Similarly, O2 Sat and tHb flowmotion measures show a significant reduction in both neurogenic 
(p < 0.001, p = 0.00125 respectively) and myogenic (p = 0.00088, p < 0.001 respectively) frequency 
ranges.  
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Figure 6.8: Phentolamine induced flowmotion changes in tibialis anterior muscle measured by Laser 
Doppler Flowmetry, oxygen saturation and total haemoglobin. Changes in flowmotion from basal (▫) 
with systemic PT (▪) infusion determined by area under the curve of the peaks in component 
frequencies endothelial (Endo, 0.095-0.02Hz), neurogenic (Neuro, 0.02-0.06Hz) and myogenic (Myo, 
0.06-0.15Hz). Data measured by A) LDF B) oxygen saturation C) total haemoglobin (n=14). Data 
expressed as mean ± SE. * significant decrease from basal p<0.05. 
 
Quantified data from the LDF + OXY probe was used for comparison (as this it is the standard technique 
for flowmotion measures) to determine if CEU can adequately measure skeletal microvascular 
flowmotion. Figure 6.9 shows the CEU flowmotion measures from different muscle types (calf and 
upper thigh), as well as different fibre type regions (predominantly white fibre and mixed fibre 
regions). There was a significant reduction (p = 0.050) in calf predominantly white fibre neurogenic 
component from basal to PT treatment. No significant change in contribution in any frequency 
component in the calf mixed fibre was observed. In the upper thigh predominantly white fibre region 
there was a significant decrease in both neurogenic (p = 0.00134) and endothelial (p = 0.016) 
frequency regions. Similarly, in the upper thigh mixed fibre region only the endothelial region was 
significantly decreased (p = 0.030) with PT infusion. 
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Figure 6.9: Phentolamine induced flowmotion changes in calf and upper thigh skeletal muscle 
measured by contrast enhanced ultrasound. Changes in flowmotion from basal (▫) with systemic PT (▪) 
infusion determined by area under the curve of peaks in component frequencies endothelial (Endo, 
0.095-0.02Hz), neurogenic (Neuro, 0.02-0.06Hz) and myogenic (Myo, 0.06-0.15Hz) as measured by 
CEU. A) calf predominantly white fibre region (n=5) B) calf mixed fibre region (n=5) C) upper thigh 
predominantly white fibre (n=9) D) upper thigh mixed fibre (n=9). Data expressed as mean ± SE. * 
significantly decreased from basal, p<0.05. 
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6.4 Discussion 
This study demonstrates for the first time that CEU can be adapted for the determination of skeletal 
muscle flowmotion. Assessment of skeletal muscle flowmotion using the CEU technique enables the 
study of blood flow patterns over large sections of muscle tissue, with the ability to identify different 
regional patterns of flowmotion. The infusion of PT allowed similar changes in flowmotion patterns to 
be identified by both the LDF + OXY (traditionally used for determination of flowmotion, Figure 6.8) 
and CEU data (Figure 6.9). The changes in flowmotion pattern identified with CEU show that 
microvascular flowmotion is in part brought about by changes in blood volume. Additionally, 
differences in fibre type flowmotion patterns within one muscle region were identified in this initial 
study, a further advantage of the CEU technique (Figure 6.9). 
 
A systemic dose of PT produced the expected changes in haemodynamic parameters, including a 
reduction in mean arterial pressure and increase in total hindlimb flow (Figure 6.4). These changes 
resulted from the inhibition of sympathetic-mediated vascular tone, thereby producing a dilation of 
blood vessels (283). These changes in systemic haemodynamics indicate an appropriate dose of PT 
was used to elicit change in microvascular flow and inhibit sympathetic nervous system-mediated 
neurogenic flowmotion contributions. 
 
PT infusion produced a significant change in all measures of blood flow in rat hindlimb. Total flow to 
hindlimb was shown to be increase with the FBF measures (Figure 6.4). Microvascular blood flow was 
shown to be greater with LDF flux (indicating an increase in RBC number and velocity in tibialis anterior 
muscle, Figure 6.5) and CEU (increased microvascular filling rate in the calf muscle, Figure 6.6). 
Changes in FBF, LDF flux and microvascular filling rate indicate an overall increase in the velocity of 
skeletal muscle total and microvascular blood flow during PT infusion. Tissue oxygenation was shown 
to be enhanced after PT infusion with the increase in O2 Sat measures in the tibialis anterior muscle 
(Figure 6.5). The increase in calf acoustic intensity (AI, measured by CEU) and tibialis anterior muscle 
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tHb measures show an increase in microvascular perfusion in response to PT (Figure 6.6), and thus 
indicates that PT has also increased microvascular blood volume. PT infusion is therefore producing 
both the expected systemic changes and a significant change in blood flow patterns and distribution 
in the microvasculature. 
 
Flowmotion measured by the LDF + OXY probe show a reduction in contribution to the neurogenic 
and myogenic components (Figure 6.8). Flowmotion measures by CEU show a similar reduction in the 
contribution of the neurogenic component, while also showing a reduction in the endothelial 
component (Figure 6.9). In addition to the expected reduction of the neurogenic flowmotion 
component induced by PT (an adrenoceptor antagonists) the LDF, O2 Sat and tHb measures show a 
concurrent decrease in the myogenic component of flowmotion. It appears that with the removal of 
neurogenic influence upon the vessel smooth muscle, there has been a subsequent change in the 
activity of vasomotion (the intrinsic contractility of the smooth muscle), thereby producing a change 
in the myogenic component of flowmotion as well as the neurogenic. What the specific changes that 
occur in the smooth muscle to produce an alteration in the myogenic component of flowmotion is not 
known. A possible explanation is the removal of neurogenic input altered the synchronised oscillation 
of Ca2+ in the smooth muscle cells, which is believed to be responsible for the generation of 
vasomotion (11). Similarly, the CEU measures in the upper thigh show an alteration in the endothelial 
component of flowmotion (Figure 6.9). The significant reduction in endothelial component was only 
seen in the CEU measures. This suggests that the removal of neurogenic input upon PT infusion is 
altering the endothelial component in some way to result in blood volume changes within the skeletal 
muscle tissue.  
 
Interestingly fibre type differences in flowmotion were revealed through the analysis of different 
regions of the calf and upper thigh muscles (as imaged by CEU, Figure 6.9). In the calf muscle significant 
changes in flowmotion from basal to PT were only observed in the predominantly white fibre region, 
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not the mixed fibre region. Changes to flowmotion measures in the upper thigh predominantly white 
fibre region occurred in both the neurogenic (as expected) and endothelial regions. Whereas only the 
endothelial region was significantly altered in the upper thigh mixed fibre region. Unfortunately due 
to the spatial resolution of the CEU technique, a predominantly red fibre region could not be analysed 
as these muscles tend to be small in size and deeper inside the tissue in rats (229). The flowmotion 
LDF + OXY measures on the tibialis anterior were taken via placing the probe on the surface of the 
outer muscle tissue. The tibialis anterior muscle is separated into two components, tibialis anterior 
white which is superficially located and tibialis anterior red which is located deeper in the hindlimb 
(229), therefore due to tissue penetration of the CP3 probe the LDF + OXY flowmotion measures are 
of a predominantly white fibre muscle region. The LDF + OXY measures of the tibialis anterior 
complement the predominantly white fibre calf and upper thigh CEU measures as a change in 
neurogenic component is seen in wavelet transformation of all measures. This data demonstrates the 
limitations of LDF. However, with the CEU technique allowing analysis of flowmotion across larger 
tissue regions, more intricate and subtle changes in flowmotion can be detected and analysed. It is 
thought that blood flow patterns are altered based on the specific needs of each different tissue 
region. As such, at any given time flowmotion patterns in different sections of a muscle may be not be 
acting in the same way. The CEU technique allows analysis of flowmotion across the whole tissue, 
which permits investigation of differing flowmotion patterns over a larger tissue region. Further 
development of the analysis of the CEU data may allow a pixel-by-pixel determination of flowmotion 
to highlight regional difference in flowmotion patterns across larger skeletal muscle sections. 
The difference in flowmotion fibre type changes observed in this study indicate an interesting 
observation about blood flow control over large regions of skeletal muscle tissue. It may be that 
flowmotion control differs over a tissue, and here in the rat hindlimb it appears that central nervous 
system control is more pronounced in predominantly white fibre regions, hence the greater change 
produced with PT infusion. Mixed and predominantly red fibre regions may have greater control 
exerted over flowmotion by a different mechanism, for example locally generated factors (myogenic 
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or endothelial). Further investigation of the differing influences over different skeletal muscle fibre 
types is required. 
 
The aim of this study was to determine if CEU could be used to assess flowmotion in skeletal muscle. 
By using LDF measures for comparison, it appears that the data generated by this CEU technique can 
indeed be analysed in a similar manner, with the resulting data providing a new comprehensive view 
of flowmotion changes in a large tissue region. Assessment of flowmotion by CEU in this anaesthetised 
rat model has also indicated that the frequency regions defined by Stefanovska et. al. (55) in humans 
may not be the same in this model. Leniency was shown in interpretation of results where clear peaks 
for each contribution were evident, but not necessarily exactly within predefined regions, indicating 
there may be variation in frequency regions in different species and under anaesthetic. Given this 
initial study, further research can now begin to assess how flowmotion is influenced by the metabolic 
state of the tissue and how the five components of flowmotion change in response to changes in 
substrate metabolism and oxygen uptake in the muscle. A previous study by Newman et al. (57) 
performed in a similar anaesthetised rat model, showed an increase in the contribution of the 
myogenic frequency component during insulin infusion (10mU/min/kg). Hindlimb glucose uptake was 
also increased during the insulin infusion, thereby linking changes in muscle metabolism with changes 
in flowmotion patterns. Flowmotion changes were measured in the tibialis anterior muscle using an 
implanted LDF probe. Further study with CEU technique is needed to further elucidate the interaction 
of flowmotion and metabolic state. 
 
In conclusion, the data in this thesis chapter indicates that the adaptation of the CEU technique, used 
in conjunction with the well-established LDF technique, provides a new way of assessing skeletal 
muscle flowmotion. Further investigation of the factors controlling flowmotion and differing 
flowmotion patterns with changes in muscle metabolic state can now be performed. A difference in 
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skeletal muscle fibre type flowmotion control was additionally demonstrated in this study and 
prompts further research into this area to establish if this interesting observation can be replicated. 
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Chapter 7 – Discussion 
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7.1 Summary of findings 
The aim of this thesis was to investigate the importance of flowmotion, with a particular focus on the 
dysfunction that occurs in T2D. A number of vascular processes become dysregulated in the disease 
(284), and thus it was thought that changes to flowmotion would be apparent. It is hypothesised that 
altered flowmotion contributes to pathological changes to metabolism, particularly decreased glucose 
uptake in the skeletal muscle, adding to the characteristic chronic elevation of blood glucose in T2D.  
 
The first aim of this thesis was to investigate flowmotion in healthy control and T2D participants at 
basal and in response to an OGC (which induces endogenous insulin release). Secondly, this thesis 
aimed to assess if a RT intervention, which has previously been shown to improve glucoregulatory 
control and cardiovascular function (266), could restore any flowmotion dysfunction in the T2D 
participants. Skin+SC flowmotion in the forearm was measured via LDF flux and tissue oxygenation. 
Wavelet transformation of these data measured the rate and contribution of each of the components 
that influence flowmotion (cardiac, respiratory, myogenic, neurogenic and endothelial). Differences 
between healthy control and T2D participants were seen at both basal and in response to the OGC, 
indicating dysfunction in flowmotion in T2D participants. The short-term RT intervention in these 
participants resulted in modest improvements in skin+SC flowmotion.  
 
While measures of skin+SC flowmotion are useful in investigating microvascular dysfunction in T2D, 
knowledge of changes to skeletal muscle flowmotion is of greater interest as this tissue plays a key 
role in whole body glucose disposal (162). Changes to blood flow and consequently glucose uptake in 
skeletal muscle in T2D is thought be an important process in the development of the disease (230, 
285). As such, a further aim of this thesis was to determine if the changes to blood flow in response 
to the OGC were similar in skin+SC and skeletal muscle. The forearm total blood flow, skin+SC 
microvascular flux and skeletal muscle perfusion in response to the OGC was therefore compared. 
There were clear differences in the response to the OGC in skin+SC and muscle blood flow measures, 
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indicating that the skin+SC flowmotion measures taken in this study are unlikely to represent the 
flowmotion occurring in the underlying skeletal muscle.  
 
The data in this thesis therefore highlight an issue in the current investigation of flowmotion, where 
predominantly skin+SC LDF flux measures are used. A non-invasive means of investigating skeletal 
muscle flowmotion is required to further knowledge of flowmotion changes in this tissue, which are 
of great importance in understanding the pathology of T2D. Thus, the final aim of this thesis was to 
adapt the CEU technique (currently used for the determination of skeletal muscle perfusion) to 
measure skeletal muscle flowmotion. An anaesthetised rat model was used to allow for invasive LDF 
blood flow measures in skeletal muscle and the pharmacological inhibition of the neurogenic 
component of flowmotion. To validate the CEU technique, results obtained from skeletal muscle 
flowmotion measured by LDF flux and tissue oxygenation (skin removed and LDF probe directly onto 
skeletal muscle) were compared to results obtained via CEU measures of flowmotion. The successful 
adaption of CEU to measure skeletal muscle flowmotion described in chapter 6 provides exciting 
opportunities to investigate flowmotion in this tissue during normal physiological function and in 
disease.  
  
 
7.2 Flowmotion in healthy controls 
The detection of skin+SC flowmotion during basal conditions in the healthy controls illustrates the 
occurrence of flowmotion at rest in this tissue. In this thesis, changes in flowmotion observed in the 
skin+SC were detected by both LDF flux and tissue oxygenation measures. The LDF technique 
determines both RBC number and velocity in the region of tissue illuminated by the laser (which 
cannot be separated, flux is a relative measure of the change in volume), whereas the tissue 
oxygenation measures (O2 Sat and tHb) are thought to determine only RBC number (with O2 Sat also 
being a measure of tissue oxygen use). The detection of flowmotion with these two different 
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measurement types indicates that flowmotion involves changes in both the velocity and volume of 
blood flow through tissue. In this thesis blood flow measured in the skin+SC was hypothesized to 
represent general flowmotion patterns in the body, but results presented in chapters 3, 4 and 5 
indicate that this may not be true for skeletal muscle and thereby potentially other tissues as well. 
 
It is thought that in skeletal muscle, blood flow distribution across the tissue is constantly changing, 
with only a portion of capillaries perfused at one time and constant variation in which capillaries are 
perfused (6). It is hypothesised that this constant variation in blood flow is, at least in part, controlled 
by flowmotion to produce optimal blood flow across the skeletal muscle tissue. Thereby, flowmotion 
at rest (in skeletal muscle) is thought to allow for adequate nutrient delivery to tissue to maintain 
basal metabolic activity, while supporting low total volumes of blood to a tissue. In response to 
changes in cellular metabolism, flowmotion is thought to alter to allow greater blood flow in support 
of enhanced metabolism (3).  
 
Previously, changes in skeletal muscle flowmotion have been observed during a hyperinsulinemic 
clamp (133), which is hypothesised to allow enhanced blood flow directly to cells, augmenting glucose 
uptake. Studies in skeletal muscle observed an increased microvascular capillary perfusion in response 
to endogenous insulin release, induced by consumption of a mixed meal (65) and during a euglycemic 
hyperinsulinemic clamp (37). This increased capillary perfusion was stimulated by insulin action on the 
vascular endothelium, resulting in vasodilation. Hyperinsulinemia has also been shown to activate the 
SNS (244) and increase cardiac output and respiratory rate (200). These changes induced by insulin in 
the components that may influence flowmotion are believed to enhance tissue metabolism (286). It 
was an aim of this thesis to investigate flowmotion changes in healthy controls in response to 
increased plasma insulin levels. However, the use of an OGC to induce endogenous insulin release 
produced unexpected decreases in skeletal muscle blood flow in the healthy controls. This surprising 
response during the OGC, where plasma insulin levels were shown to increase, may be due to a 
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concurrent excessive activation of the SNS resulting from acute high levels of glucose in the insulin 
sensitive population (253). Consumption of a large glucose load alone has been shown to increase 
noradrenaline (NA) plasma concentrations (258) and increase SNS activity in skeletal muscle (244) in 
insulin sensitive participants. Data in chapter 4 of this thesis, where the OGC induced an increased in 
the rate of neurogenic activity in healthy controls and a decrease in the T2D participants (Table 4.3), 
possibly indicates an increase of SNS activity in insulin sensitive participants, as has been previously 
described (253). This increased SNS response to ingested glucose appears to be absent in insulin 
resistant participants. It is thought in this population where autonomic dysfunction is common (199), 
neurogenic input is already increased at basal compared to healthy controls. As such, an increase in 
circulating NA does not induce a further activation of the SNS. The results of this thesis highlight an 
important implication for future studies looking at blood flow and flowmotion response to insulin. A 
study by Jonk et. al. (247), where skin+SC flowmotion in healthy controls was examined in response 
to a 75g oral glucose load and a 495-kcal liquid mixed meal (60% carbohydrate, 25% protein and 15% 
fat), highlights the difference between methods used to induced insulin release. In response to the 
two different meal types, all components of flowmotion were enhanced by consumption of the mixed 
meal, whereas only the endothelial component was increased with 75g glucose load. Based on the 
observations by Jonk et. al. (247) and the data in this thesis, it is recommended that in the study of 
insulin mediated changes in blood flow, elevated insulin should be induced via consumption of a mixed 
meal or with a euglycemic hyperinsulinemic clamp, which appear not to result in excessive SNS 
activation.  
 
 
7.3 Flowmotion in type 2 diabetes 
Data in this thesis highlight the general microvascular dysfunction that occurs in T2D, with changes in 
both the rate of input and contribution of the five components that influence flowmotion. A change 
in microvascular flowmotion, whether it be caused by insulin resistance or itself contributing to insulin 
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resistance, is believed to impact on the function of a tissue (80). Pathological changes to vascular 
function in metabolic tissues such as skeletal muscle attenuates glucose uptake, but changes in other 
tissues (e.g. skin+SC) are also important. Changes to skin+SC flowmotion caused by insulin resistance 
and as a result of direct glucose damage to vessels, may be used to identify early dysfunction in 
peripheral blood flow, which may indicate the potential occurrence of damage to other cell types such 
as nerves in T2D, which leads to the development of neuropathy. Further investigation into the 
dysfunction of flowmotion in insulin resistance and T2D is therefore potentially of great importance. 
It may lead to the identification of the mechanisms that become dysfunctional in the disease, 
providing drug targets for future treatment. However, the investigation of flowmotion in normal 
physiological function and T2D has so far shown inconsistent results.  
 
The primary means of investigating flowmotion has been through LDF measures of the skin+SC, due 
to its minimally invasive nature. These measures do provide valuable information about blood flow 
dysfunction occurring in insulin resistance and T2D, but the changes to flowmotion seen in different 
studies is highly variable. Changes in the five components that influence flowmotion at rest and in 
response to insulin are inconsistent between studies. A number of different factors may account for 
the variation of results, which need to be addressed before skin+SC LDF flowmotion measures could 
have diagnostic applications.  
 
Table 7.1 summarises a number of recent studies investigating skin+SC flowmotion in healthy, obese 
and T2D populations and highlights a number of variables (population studied, probe position, analysis 
technique, and treatment type) that may account for the inconsistency of the results between studies.  
 
 
 
 
164 
 
 
 
Table 7.1: Variations in skin and subcutaneous tissue flowmotion studies in healthy, obese and type 2 
diabetic populations 
 
 
 
One variable contributing to the inconsistent findings is the different populations of participants which 
have been assessed. It is likely that the level and type of dysfunction in flowmotion varies over the 
development and progression of T2D. Pathological changes to the five factors of flowmotion may 
possibly alter at different stages of the disease. Thereby, skin+SC flowmotion measures in clinically 
diagnosed T2D may vary significantly from those seen in early stages of disease development such as 
obesity. The age of the population may also influence skin+SC flowmotion. Changes to flowmotion 
have been reported with advancing age (287) and T2D populations tend to be older. The differences 
in subject populations are highlighted in studies by Montero et. al. (216) and de Jongh et. al. (219). 
Both studies investigated skin+SC flowmotion changes in obese populations during insulin 
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iontophoresis. However, participants in the Montero et. al. (216) study were adolescents of both sexes 
(aged between 12-17 years old), whereas the de Jongh et. al. (219) study population were obese 
women with a mean age of 40.1 ± 6.6 years. Montero et. al. (216) reported an impaired myogenic 
response to insulin, while de Jongh et. al. (219) reported blunted endothelial and neurogenic response 
to insulin. The studies by Montero et. al. (216) and de Jongh et. al. (219) also highlights the potential 
impact of gender in flowmotion studies, as flowmotion measures may differ between the sexes. Of 
particular note is the difference in subcutaneous adipose volume being assessed, as women tend to 
have a greater amount of subcutaneous adipose as compared to men (288). This has implications for 
LDF flux measures in the skin, where different combinations and volumes of tissue types may be 
measured, which may affect the flowmotion observed.  
 
Another important variable is the positioning of the probe on the body. Blood flow patterns in the 
forearm may vary significantly from those on the hand, foot or calf, yet each of these has been used 
in the investigation of skin+SC flowmotion. There are differences in skin+SC at these different sites, as 
well as differences in the underlying tissue. The forearm and calf have larger subcutaneous tissue 
content compared to the foot or hand, and the underlying tissue is predominantly muscle in the 
forearm and calf, as opposed to bone in the foot and hand (288). These differences have the potential 
to greatly impact LDF flux measures as the composition of tissue sampled at each site can vary 
considerably.  
 
The spectral analysis technique employed to analyses LDF data may also contribute to the 
inconsistency of the literature. Primarily, either Fourier analysis or wavelet transformation is used to 
determine flowmotion in skin+SC LDF flux measures. While both analysis techniques are able to detect 
the five frequency components of flowmotion, there are differences in the spectral analyses that may 
influence the results. For example, the wavelet transformation technique is thought to better 
elucidate the activity of the lower frequency components of flowmotion, compared to Fourier analysis 
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which is particularly adept at detecting higher frequency signals (55, 103). As such, the different 
flowmotion analysis techniques used in the literature may contribute to the observed variations in 
flowmotion response to insulin and changes in disease.  
 
An additional consideration in the investigation of skin+SC flowmotion changes in response to insulin, 
both in healthy and T2D participants, is the method used to elicit an insulin response. The gold 
standard technique in the investigation of insulin sensitivity and insulin-mediated responses is an 
euglycemic hyperinsulinemic clamp, where insulin is infused at a constant concentration and glucose 
at a variable rate to maintain a steady state blood glucose concentration during hyperinsulinemia. This 
technique produces a systemic response to insulin (138), therefore in the context of flowmotion it 
may activate both local and centrally acting components. The changes in skin+SC flowmotion in 
response to this systemic exogenous infusion of insulin may vary considerably to changes induced by 
another common technique, insulin iontophoresis where insulin is introduced locally in the skin+SC 
(250). Local insulin introduced through the skin will not activate the centrally mediated flowmotion 
components, while the forced introduction of insulin through the skin may cause changes in blood 
flow in itself. Additionally, issues associated with iontophoresis such as the indirect effects of the 
current used and the fact that the concentration of insulin is unknown with this technique (289), 
complicate flowmotion measures. Therefore, the method of insulin stimulation used could greatly 
effect which of the frequency components are alter by insulin.  
 
If these issues could be addressed and greater consistency in skin+SC flowmotion studies achieved, 
there is potential for this technique to be incorporated into clinical practice. Skin+SC flowmotion 
measures could perhaps be used to identify vascular dysfunction early on in disease pathology, and 
also be used to monitor disease progression and to identify early the development of secondary 
conditions such as neuropathy. The early detection of changes in flowmotion is potentially of great 
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importance as treatment programs such as exercise intervention or weight loss could be implemented 
to stop progression to clinically diagnosed T2D.  
 
Previous studies, particularly in early stages of disease progression (obesity) have identified changes 
in skin+SC flowmotion and then implemented a treatment to correct these changes. Rossi et. al. (243) 
identified changes to the endothelial, neurogenic and myogenic components in skin+SC flowmotion 
at rest, in morbidly obese participants (BMI 47.0 ± 8kg/m2), both with and without T2D. These 
participants then had gastric bypass surgery and subsequently, had significant weight loss (~40kg on 
average) 1-year post surgery when flowmotion was reassessed. As a consequence of the weight loss 
in these participants, the changes in skin+SC flowmotion seen at baseline were normalised. As such, 
it appears the weight loss is able to reverse flowmotion defects in obese participants. 
 
Exercise training interventions have enormous potential to improve health outcomes and quality of 
life in T2D patients as it promotes weight loss, increases insulin sensitivity and improves cardiovascular 
function. Importantly, in early stages of disease development (obesity and insulin resistance) an 
exercise intervention can normalise pathological changes in flowmotion. Vinet et. al. (273) showed a 
6-month exercise and dietary intervention in participants with metabolic syndrome (a precursor state 
for a number of different diseases including T2D) normalised the response to insulin of endothelial, 
neurogenic and cardiac components of flowmotion measured in the skin+SC. Identification of skin+SC 
flowmotion dysfunction at early stages of disease development could thus be used to prompt early 
pharmaceutical and exercise intervention in an attempt to stop progression towards T2D. Exercise 
intervention may also improve long-term health outcomes in participants already diagnosed with T2D. 
In this thesis a 6-week RT exercise intervention in clinically diagnosed type 2 diabetics improved a 
number of health parameters over the short intervention. Body composition and glucoregulatory 
control was improved, as has been previously shown with RT (271), as well as partial restoration of 
skin+SC flowmotion. Long-term exercise interventions in T2D has the potential to greatly improve 
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vascular function, and thereby flowmotion. With improvement in flowmotion in T2D, processes such 
as glucose disposal can potentially be improved and thus long-term outcomes and quality of life 
greatly enhanced. 
 
The studies describe this thesis highlights further considerations for the assessment of flowmotion in 
healthy control and T2D participants. Basal and OGC induced changes in skin+SC flowmotion give 
further evidence that flowmotion is altered in clinically diagnosed T2D participants. The next step is 
to understand how these changes develop in T2D, thereby potentially identifying drug targets for 
future pharmaceutical intervention. The data in chapter 5 indicates that long term RT intervention in 
type 2 diabetics may be a means of improving flowmotion, potentially in a number of tissues including 
skeletal muscle, which may lead to improved glucose disposal.  
 
To aid in the detection and treatment of microvascular dysfunction, this thesis hoped to develop 
complexity analysis of skin+SC LDF flux and tissue oxygenation measures as a means to easily identify 
microvascular dysfunction in a clinical setting. Previously, decreasing skin+SC LDF flux complexity was 
observed with increasing severity of insulin resistance and T2D in monkeys (226). Data in chapters 3 
and 4 of this thesis show differences in flowmotion between healthy control and T2D groups identified 
with spectral analysis of skin+SC blood flow data, but no differences between the two groups was 
identified with complexity analysis. Therefore, it appears that complexity analysis of skin+SC blood 
flow measures is not able to adequately detect skin+SC microvascular dysfunction in humans.  
 
Another outcome from the data in this thesis is the recommendation that investigation of insulin-
mediated changes in flowmotion in healthy and disease states should not use an oral glucose load, 
due to the unexpected decreased in blood flow it induced in the healthy controls. Instead consumption 
of a mixed meal or an euglycemic hyperinsulinemic clamp should be used, which have previously been 
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shown to increase blood flow in healthy controls (37, 65, 248, 256), as would be expected with an 
increase in insulin levels.  
 
The difference in skin+SC and skeletal muscle microvascular blood flow response to OGC observed in 
chapters 3, 4 and 5 have important implications for the future study of skeletal muscle flowmotion. 
This thesis highlights that skin+SC flowmotion measures may not be representative of skeletal muscle 
flowmotion, and thus to ascertain the changes in flowmotion that occur in response to stimuli such as 
insulin or during disease states like T2D, different techniques are required. While skin+SC flowmotion 
measures are still useful in the identification of microvascular dysfunction in T2D, these data suggest 
skin+SC flowmotion may not represent skeletal muscle flowmotion patterns. In T2D there are two 
important tissues in glucose metabolism that become dysfunctional, liver and skeletal muscle (290). 
Blood flow in the liver differs greatly from that in the skeletal muscle due to the both the structural 
and functional differences of the tissues (252). Changes in flowmotion in T2D are not likely to be 
important in the liver, but may have great importance in skeletal muscle tissue where 65-90% of 
glucose is stored after a meal (162-164). It is therefore of great interest to understand the normal 
physiological role of flowmotion at rest in skeletal muscle and the dysfunction which may occur in 
insulin resistance and T2D.  
 
Only a limited number of studies have directly investigated skeletal muscle flowmotion. Newman et. 
al. (57), using the anaesthetised rat model, measured flowmotion using a LDF probe invasively 
implanted directly into skeletal muscle tissue. This study showed an increase in the myogenic 
component of flowmotion during an euglycemic hyperinsulinemic clamp, which was then bunted 
during an acute insulin-resistant state induced by the vasoconstrictor α-methylserotonin. In healthy 
humans de Jongh et. al. (249) also used an invasively implanted LDF probe in the calf and showed an 
increase in the endothelial and neurogenic components of flowmotion during a euglycemic 
hyperinsulinemic clamp. While implanted LDF probes have allowed this investigation of skeletal 
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muscle flowmotion, there are a number of limitations that need to be considered with this technique. 
By inserting the LDF probe directly into the skeletal muscle tissue there is the potential for this invasion 
to alter blood flow patterns being investigated. Thereby the blood flow measures may not be a true 
representation of skeletal muscle flowmotion. Additionally, a considerable limitation of LDF is the 
relatively small amount of tissue (~0.55-0.79mm2 volume (61)) that can be sampled at any one time. 
Large tissue regions and differences in blood flow in different sections of muscle tissue therefore 
cannot be examined with this technique. There is potentially great variation in skeletal muscle blood 
flow across the tissue, particularly between different fibre types and between nutritive and non-
nutritive capillary networks (24). To overcome these limitations and greatly expand the potential for 
investigation of skeletal muscle flowmotion, the data in chapter 6 of this thesis shows the successful 
adaptation of the CEU technique in the assessment of skeletal muscle flowmotion. 
 
CEU is non-invasive to skeletal muscle, requiring only an intravenous infusion of the contrast agent 
(282). As such, it does not artificially alter the blood flow in skeletal muscle, thus flowmotion 
measurements are a true representation of blood flow patterns in the tissue. An exciting additional 
benefit of CEU flowmotion measures is the larger sections of tissue in which blood flow can be 
assessed by this technique, as the ultrasound technique is able to visualised large sections of skeletal 
muscle tissue. The data in chapter 6 demonstrates how the CEU technique allows analysis of differing 
flowmotion in different sections of the same tissue. In Figure 6.9 the differing flowmotion patterns in 
both a predominantly white fibre region and a mixed fibre region in the calf and upper thigh muscles 
upon inhibition of the neurogenic component are shown. These observations highlight the exciting 
potential for CEU to determine differences in flowmotion patterns across the same muscle section 
occurring at the same time. Also demonstrated by the successful measurement of flowmotion using 
CEU (which is a measure of blood volume alone), is that flowmotion changes are, in part, brought 
about but changes in blood volume, not just velocity. 
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The adaptation of CEU has great potential to investigate skeletal muscle flowmotion and significantly 
enhance knowledge of its physiological role and how flowmotion becomes altered in disease. The 
most exciting outcome of this thesis is the potential human application of CEU flowmotion measures, 
allowing for the first-time non-invasive measures of human skeletal muscle flowmotion. CEU could be 
used to assess skeletal muscle flowmotion in human participants to build our understanding of healthy 
patterns of flowmotion, as well as investigate how dysfunction develops in disease states. 
 
 
7.4 Limitations of study 
The data in this thesis allows a unique insight into microvascular blood flow patterns and distribution, 
however there are several limitations to consider in the interpretation of results. As shown in Table 
7.2, the size of the cohort in the clinical studies was under-powered for some measures and hence a 
limitation of this study. Underpowering of a study can lead to the occurrence of a type 2 statistical 
error. Potentially there are differences in blood flow and flowmotion measures between the T2D and 
healthy control groups that has not been identified in these studies due to insufficient numbers. Power 
calculations to determine the number of participants required to achieve a 60% change in the T2D 
group compared to the healthy controls were performed as this is the magnitude change previously 
seen in blood flow measures under different metabolic conditions (65, 282). The percentage change 
able to be detected with the actual number of participants in the study was also calculated. Power 
calculations were performed on skin+SC perfusion measures, total forearm blood flow and LDF flux 
flowmotion contribution of lower frequency components. Of the measures on which the power 
calculation was performed brachial blood flow, LDF flux, O2 Sat, and tHb were sufficiently powered, 
indicating no type 2 statistical error. However, the measures of skeletal muscle perfusion 
(microvascular volume, filling rate and perfusion) and LDF flux flowmotion appear to be 
underpowered in this study which leads to the possible occurrence of a type 2 statistical error.  
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Table 7.2: Size of cohorts and power calculations. 
 
 
The tissue oxygenation component of the LDF + OXY Moor Industries probe measures oxygenated and 
deoxygenated RBC in the section of tissue sampled. In this thesis O2 Sat and tHb, which are calculated 
from oxygenated and deoxygenated RBC measures, were chosen as determinates of microvascular 
blood flow. Each of these measures give further insight into metabolism occurring within the tissue 
site (O2 Sat) and a measure of microvascular blood volume (tHb), which can be compared to CEU 
measures. A limitation of this study is therefore the potential for error in the calculation of these 
measures from the raw oxygenated and deoxygenated RBC determined by the LDF + OXY Moor 
instruments probe. Kuliga et. al. (63) has previously shown that the relationship between blood flow 
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and O2 Sat measure in the LDF + OXY probe is best described by a one-phase association curve fit with 
a plateau in O2 Sat of 84%. As the O2 Sat measures in this thesis not exceed 80% at any point the 
impact of using the O2 Sat measure is considered negligible.  
 
A new technique, peak frequency analysis, was used in this study to better quantify the components 
of flowmotion. The use of this novel analysis technique allowed the determination of both the 
contribution through determination of peak AUC and peak frequency of each flowmotion component, 
giving novel insight into the control of microvascular blood flow patterns. However, validation studies 
to determine reproducibility and reliability are yet to be performed. Instead in this thesis, acceptable 
variation in the data was determined through observations made during analysis process. Official 
validation of this technique is still required.  
 
These limitations may have bearing on the mechanistic interpretation of the complex and unique data 
in this thesis. It is believed that the best analysis process (based on extensive investigation of various 
analysis techniques) was utilised. However, it may have influenced the interpretation of the results 
potentially selecting for the desired outcome. Bias may have been introduced through the manual 
selection of peak AUC and frequency in PeakFit. To overcome this limitation, analysis was completed 
by one person to ensure consistency, analysis was done in a random order and the parameters for the 
selection of peak area were set by the PeakFit program.  The under powering of the clinical studies 
may have masked potential differences between healthy control and T2D groups, but due to 
experimental and practical issues such as difficulty with participant recruitment and loss of data, this 
could not be avoided. The studies where significantly powered to determine expected difference 
between the two groups (skin perfusion, clinical chemistries and total limb flow) to then allow 
investigation into the unknown flowmotion changes.  
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7.5 Conclusion 
It is believed that flowmotion plays an important role in the optimisation of blood flow throughout 
different tissues, allowing for small volumes of blood to support basal metabolic rate, while maintain 
the ability to greatly enhanced blood flow directly to working cells when metabolic activity is 
increased. Due to the importance of flowmotion in normal physiological processes, it is believed that 
its dysregulation is involved in the development and progression of T2D. It is still unclear if changes to 
flowmotion occur in response to insulin resistance and vessel damage caused by high glucose 
concentrations, or if dysfunction develops in the disease through other mechanisms and itself 
contributes to insulin resistance. Nevertheless, the changes in flowmotion function are believed to be 
involved in the subsequence attenuation of glucose uptake that is characteristic of the disease. The 
data in this thesis demonstrate changes in skin+SC flowmotion that occur in T2D, both at rest and in 
response to OGC. It also addresses the potential for RT intervention to improve flowmotion in T2D. If 
flowmotion can be improved in T2D participants, potentially glucose uptake can be enhanced, leading 
to better glucoregulatory control and thereby better health outcomes and quality of life for patients. 
This thesis also addresses the current issues with measuring flowmotion in skin+SC. Skeletal muscle 
flowmotion is more relevant in the metabolic T2D disease. Therefore, this thesis also provides a new 
technique to non-invasively assess skeletal muscle flowmotion. There is great potential for this 
technique to overcome current limitations in the literature and investigate changes in flowmotion 
during different disease states, as well as regional variation of flowmotion across a large muscle mass. 
Using the new CEU technique to investigate skeletal muscle flowmotion can potentially expand 
knowledge of flowmotion function, to better help understand the changes that occur in disease 
progression and perhaps provide new drug targets for therapeutic intervention, particularly in early 
stages of disease development.  
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